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Introduction
In 1997 the author of the present thesis started studies relating to short children
born small for gestational age (SGA).The present chapter describes definitions of
SGA, prevalence and etiology of SGA, factors involving fetal growth and features of
short children born SGA.Also an overview of the literature is presented concerning
the effects of growth hormone (GH) treatment on growth in these children. Finally,
the aims of the study, study design and in- and exclusion criteria of this Dutch 
multicenter trial are described.
1. Small for gestational age (SGA)
Definitions of SGA
In literature, the term SGA has been applied to all newborns having a birth weight
and/or a birth length below the third or tenth percentile (or below –1.88 or 
–1.29 SDS) for the gestational age. Unfortunately, until recently there has not been
consensus among investigators whether birth weight or birth length should be used,
whether the cut-off point should be the 3rd or the 10th percentile and which 
references should be used.Therefore, it has been difficult to compare results between
different study groups. In all Dutch multicenter studies, however, SGA was defined as
a birth length below the –2.00 SDS using the curves of Usher and McLean (1).
Although the definition is somewhat arbitrary, the definition of SGA has been 
delineated as a birth length and/or birth weight < -2 SD for gestational age.
The term intra-uterine growth retardation (IUGR) has also been applied to
SGA infants. IUGR, however, refers to fetal growth retardation and can be observed
as a deviation of the intra-uterine growth chart.Therefore, IUGR can only be 
diagnosed when documented by two intrauterine growth assessments. SGA does 
not refer to fetal growth but refers to body size at birth. Not all SGA infants are 
intrauterine growth retarded.An SGA infant may have been small from the beginning
of fetal life.Also, growth retardation late in gestation does not need to result in an
SGA infant.
Different terms are used to subdivide SGA neonates.According to a frequently
used classification SGA infants can be divided into ‘symmetric’ versus ‘asymmetric’
SGA (2).The term ‘symmetric’ is applied to SGA neonates having a low birth weight,
a small birth length and a small birth head circumference. ‘Asymmetric’ SGA neonates
have a relatively large head since birth weight and birth length are low whereas head
circumference at birth is normal. Generally, growth retardation early in fetal life
results in symmetrically small neonates whereas growth retardation later in fetal life
results in asymmetrical SGA neonates.Another more often used classification divides
into ‘proportionate’ versus ‘disproportionate’ SGA (3).This subdivision uses birth
weight and birth length only.Those SGA neonates having both a low birth weight and
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a small birth length are referred to as ‘proportionate’ SGA neonates whereas those
only having a low birth weight are called ‘disproportionate’ SGA neonates. Infants can
also be classified into 4 categories according their birth weight (W) and birth length
(L) (4). Light and short SGA neonates are classified as SGAL+W, light neonates as
SGAW and short SGA neonates as SGAL (see Fig. 1). It is important to describe
these classifications since different SGA subsets may have different underlying 
mechanisms for SGA and may respond differently to therapy.
Fig. 1 
Classification of SGA infants  Adapted from Albertsson-Wikland K, Karlberg J. Acta Paediatr Suppl. 1994;399:64.
Prevalence and etiology of SGA
Depending on the definition of SGA, about 1.5 to 10 % of all live born neonates is
born SGA.The cause of SGA should be identified whenever possible as underlying
mechanisms are diverse and may influence prognosis and treatment effects. Impaired
fetal growth has multiple causes including a number of maternal, placental and fetal
factors (for a detailed list see Table 1) (5).
Fetal factors include chromosomal abnormalities, congenital defects, metabolic
diseases and genetic defects. Specialized genetic tests may be helpful to detect the
presently known genetic defects.
Normal
Low
NormalShort LENGTH
–2 SDS
SGAL
SGAL+W SGAW
normal
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Table 1
Factors associated with increased incidence of infants who are born SGA and selected examples
Fetal factors
Karyotypic abnormalities Trisomy 21 (Down syndrome)
Trisomy 18 (Edward syndrome)
Monosomy X (Turner syndrome)
Trisomy 13 (gonadal dysgenesis)
Other chromosomal abnormalities Autosomal deletions
Ring chromosomes
Genetic diseases Achondroplasia
Bloom syndrome
Congenital anomalies Potter syndrome
Cardiac abnormalities
Maternal factors
Medical conditions Hypertension
Renal disease
Diabetes mellitus (advanced stages)
Collagen vascular diseases (eg system
lupus erythematosis)
Maternal hypoxemia (cyanotic heart disease,
chronic anemia, chronic pulmonary disease)
Infection Toxoplasmosis
Rubella
Cytomegalovirus
Herpesvirus
Malaria
Trypanosomiasis
Human immunodeficiency virus
Nutritional status Low pregnancy weight
Low pregnancy weight with poor weight 
gain during pregnancy
Substance use / abuse Cigarette smoking
Alcohol
Illicit drugs
Uterine / placental factors
Gross structural placental factors Single umbilical artery
Velamentous umbilical cord insertion
Bilobate placenta
Placental hemangiomas
Infarcts, focal lesions
Insufficient uteroplacental perfusion Suboptimal implantation site
Placenta previa
Low-lying placenta
Placental abruption
Demographic factors
Maternal age Very young age
Older age
Maternal height
Maternal weight
Maternal and paternal race
Parity Nulliparity
Grand multiparity
Maternal history Previous delivery of SGA infants
Other
Multiple gestation Particularly severe in syndromes associated with shared fetal circulation
Adapted from Bernstein and Divon (58), Pollack and Divon (2),Wollmann (59) and Keller et al (60)
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Maternal factors include age, parity, medical conditions such as hypertension,
infections (particularly such as toxoplasmosis, rubella, cytomegalovirus and herpes
virus), malnutrition, alcohol abuse and cigarette smoking.
Placental factors involve problems in placental perfusion.As the placenta is
essential for nutrient and oxygen supply between mother and fetus, it is clear that any
placental dysfunction could result in fetal growth retardation. Examples of placental
insufficiency are abruption or infarction or other placental vascular abnormalities.
Examination of the placenta by a pathologist might discover specific causes.
Demographic factors such as maternal race, obstetric history, age of the 
mother, multiple gestation might be associated with SGA infants, particularly in case
of a shared fetal circulation.
Silver-Russell syndrome
A subgroup of children born SGA consists of children with Silver-Russell syndrome
(SRS).Typical features of children with SRS are a severely reduced birth weight and
–length, short stature during childhood and adulthood, typical craniofacial abnor-
malities with a relative large, prominent forehead (frontal bossing), a small, triangular
face, asymmetry of head and limbs, clinodactyly of the fifth finger and some other
minor abnormalities (6).A mean final height of 151.2 (cm) for boys and 139.7 (cm)
for girls has been reported in patients with SRS (6). Chromosome abnormalities (e.g.
maternal disomy of chromosome 7) have been reported in only a minority of children
(6).The reported genetic abnormalities comprise a heterogeneous group. Maternal
uniparental disomy of chromosome 7 is the most frequently observed abnormality
and has been described in 7 - 10 % of SRS children (7). Other less frequently ob-
served abnormalities include a ring chromosome 15, deletion of distal q15, translo-
cation of the distal part of chromosome 17q, trisomy 18 mosaicism and deletion of
the short arm of chromosome 8q11-13 (8). However many children with genetically
proven SRS do not present all characteristic features of SRS whereas on the other
hand some children have classical features without proven chromosomal abnor-
malities thus far.This means that the diagnosis of SRS is primarily based on clinical
features, only in few children supported by a chromosomal abnormality. Large 
varieties exist in the presence of Silver-Russell symptoms. Some children born SGA
show only minor features of SRS (e.g. only clinodactily) which makes it sometimes 
difficult to support the diagnosis of SRS. It seems a certain range exist varying from
Silver-Russell like (only one or two minor symptoms) to the classical SRS (all major
symptoms). Growth patterns of children with SRS do not differ from short children
born SGA (6).Therefore children with SRS were included in most trials investigating
growth aspects of short SGA children.
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2. Fetal growth
Fetal growth is the result of a very complex metabolic and endocrine process.
Several hormones play a role in fetal growth by influencing nutrient supply from 
mother to fetus and by affecting fetal organogenesis.
Growth hormone (GH)
The role of GH in fetal growth is rather controversial. Initially it was thought that GH
did not contribute to fetal growth, since neonates born with congenital GH deficiency
(GHD) generally do not have reduced birth weights and birth lengths. Growth 
retardation in GHD becomes evident only from 3 months after birth when a decline
in linear growth starts.
However, it was reported that birth length in these infants was on average 1
standard deviation (SD) lower compared to healthy neonates suggesting GH does
have an effect on linear growth in utero (9). GH receptors are already present in fetal
tissues although the numbers are lower compared to postnatal tissues (10,11). It has
been assumed that the reduced amount of GH receptors may play a role in the
moderate effect of GH on fetal growth.
Insulin-like growth factor-I and -II (IGF-I and -II)
IGF’s are very important determinants of fetal growth. Insulin-like growth factor-I
(IGF-I) plays an important role in both pre- and postnatal growth and its serum levels
are regulated by both metabolic and genetic factors. In fetuses and neonates born
SGA low circulating IGF-I levels have been observed suggesting a role for IGF-I in
fetal growth retardation (12-17). Gene deletion studies in mice clearly present the
role of IGF-I (Table 2). IGF-I knock-out mice had a birth weight which was about 60
% of normal (18). Postnatal growth in these mice decreased even further resulting in
adult weights of about 30 % of normal mice (19). However, these knock-out mice
behaved normally and appeared proportionate in size. In humans, only one homozy-
gous partial deletion of the IGF-I gene has been described in a 15-year old boy (20).
This child was born SGA and showed severe postnatal growth failure, sensorineural
deafness and mental retardation.
IGF-II plays predominantly a role in prenatal growth. Knockout studies in mice
clearly present the role of IGF-II in mice (18). IGF-II knockout mice showed a reduc-
tion in birth weight to 60 % of normal mice (Table 1).Also it is clear from these 
studies that the growth promoting effect of IGF-II acts through the IGF-I receptor.
IGF-II was also able to bind to another unidentified receptor. It was shown that IGF-II
stimulates growth early in gestation whereas IGF-I is an important growth factor later
in gestation.
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Insulin
Initially insulin was thought to be the major growth promoting hormone in fetal life.
More recently it is believed that insulin acts via stimulation of cellular nutrient 
(glucose) uptake and stimulation of IGF-I production (21). Glucose availability and the
subsequent increase in fetal insulin are the main regulators of fetal IGF-I production.
Fetal pancreatectomy in sheep resulted in low fetal IGF-I levels and caused severe
intra-uterine growth retardation (22). Intrafetal infusions of either insulin or glucose
increased fetal IGF-I levels. Insulin has also lipogenic effects which are well studied in
fetuses from mothers with diabetes gravidarum. Fetal hyperinsulinemia and hypergly-
cemia due to maternal diabetes results in stimulated fetal growth.The increase in
birth weight of these infants mainly consists of fat mass due to the lipogenic effects of
insulin. Birth length and lean body mass are only slightly increased which is in turn the
effect of IGF-I mediated through the high insulin levels (23).
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Table 2
Phenotype of mice mutants leading to growth retardation 
Genotype Birthweight Neonatal 
(% of nomal) lethality
IGF-I (-/-) 60 ±
IGF-II (p-) 60 -
IGF-IR (-/-) 45 +
IGF-I (-/-) / IGF-II (p-) 30 +
IGF-I (-/-) / IGF-IR (-/-) 45 +
IGF-II (p-) / IGF-IR (-/-) 30 +
IGF-I (-/-) = homozygous null mutation of the IGF-I gene
IGF-II (p-) = heterozygous null mutation of the paternal allele of the IGF-II gene
IGF-IR (-/-) = homozygous null mutation of the IGF-I receptor gene
IGF-I (-/-) / IGF-II (p-) = double mutant of IGF-I and -II
IGF-I (-/-) / IGF-IR (-/-) = double mutant of IGF-I and IGF-I receptor
IGF-II (p-) / IGF-IR (-/-) = double mutant of IGF-II and IGF-I receptor
Adapted from Liu et al, Cell 1993;75:59
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3. Consequences of being born SGA
Perinatal mortality and morbidity is greater in SGA babies compared to babies born
appropriate for gestational age (AGA). However, since perinatal care improved rapidly
during the last decade, most SGA infants now survive.This enables us to study the
consequences of being born SGA during childhood as well as during adulthood.
Postnatal growth
Most of the children born SGA show catch-up growth during the first 2 to 3 years of
life. If children have not shown catch-up growth during the first years of life they have
a greater risk of remaining short later in life. In a Swedish cohort of 123 infants born
SGA, which was defined as a birth weight below –2.0 SDS, 9 % still had a height
below –2.0 SDS at the age of 4 years (24). Hokken et al found that 15 % of a group
of 724 term and preterm SGA infants, which was defined as a birth length below
–1.88 SDS, still had a height below the third percentile at the age of two years (25).
Term SGA infants showed a more rapid increase in catch-up growth compared to
preterm infants. However, at the age of two years the percentage SGA infants without
catch-up growth was the same for term and preterm infants (Figure 2).
Longitudinal studies from birth to final height show that infants born SGA have an
increased risk of short stature in adult life. Chausssain et al reported that SGA child-
ren born with a birth length < -2 SD for gestational age who remained short during
childhood, reached an adult height of 161.9 +/- 8.0 cm (boys) and 147.6 +/- 7.2 cm
(girls).These adult heights were significantly lower than the target heights of these
patients (26).Also, Karlberg et al found a 7-fold increased risk for short stature at the
age of 18 years in those who had been born SGAL and a 5-fold increased risk in
those who had been born SGAW (27).
0
20
40
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80
3 6 12 24
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full-term
Fig. 2 
Percentage of SGA infants with postnatal catch-up growth to a height ≥ -1.88 SDS
Adapted from Hokken-Koelega et al. Pediatr Res 1995;38:267.
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Serum growth hormone (GH) and insulin-like 
growth factor-I (IGF-I) levels
The mechanism underlying persistent short stature in children born SGA is still not
fully understood. Disturbances in the growth hormone (GH)/insulin-like growth fac-
tor-I (IGF-I)-axis may play a role. Sixty percent of SGA children with insufficient catch-
up growth, defined as a height below –2 SDS, showed a decrease in physiologic 24-
hour GH secretion whereas 25 % showed low GH peaks during GH provocation
tests (28,29).Also, serum IGF-I levels were significantly lower in short children born
SGA compared to normal children (28,29).
Body composition
Short children born SGA have a lean appearance. However, limited data are available
on body composition during childhood in these short children. Most studies evalu-
ating body composition in short SGA children have used body mass index (BMI)
(30,31). BMI in short SGA children is significantly lower compared to healthy children
with the same age and sex. Leger et al measured body composition by magnetic reso-
nance imaging of the thigh and used this as an estimate of total body fat (32). In short
SGA children, they found a reduction of both muscle and subcutaneous fat mass
measured on cross sectional areas of the thigh. However, a more precise method to
investigate total body composition would be by Dual Energy X-ray Absorptiometry
(DXA). DXA uses a low radiation dose, is very accurate and is easily performed in
children (33,34). DXA measures lean body mass (LBM), fat mass and bone mineral
density (BMD).At the start of this study (1997), no data were available of body com-
position in short SGA children measured by DXA.
Spontaneous bone maturation
Data on bone maturation in short SGA children are very sparse.A French study
reported delayed bone ages until the age of 8 years in a group of short children born
SGA (35). However, after the age of 8 years bone age accelerated without a con-
comitant increase in height.This resulted in adult heights which were significantly
lower than the predicted adult heights at the age of 8 years. In 1975,Tanner et al 
already described in a group of short prepubertal children with Silver-Russell syn-
drome a similar pattern of acceleration of bone maturation from the age of 5 years
(36).This suggests that SGA children might experience a different bone maturation
over the years compared to their healthy peers. For that reason prediction of adult
height based on estimates of bone age are unreliable in these children.
Adult diseases associated with a low birth weight
Epidemiological studies have shown that type 2 diabetes mellitus (DM), hypertension
and cardiovascular diseases occur more frequently among individuals who were born
with a low birth weight (37,38).Also, the combination of type 2 DM, hypertension,
dyslipidemia and a high body mass index (BMI), called the Metabolic Syndrome, has
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been associated with a low birth weight (38,39). Most evidence is based on large 
epidemiologic, retrospective studies.The mechanisms underlying these associations
are still unknown. Insulin resistance and hyperinsulinism are thought to play a key role
in the pathogenesis of both type 2 diabetes mellitus and cardiovascular abnormalities
(39-41).Two main hypothesis exist.
Barker’s ‘fetal origins hypothesis’ postulates that these diseases are the result of
malnutrition during a critical period in fetal life (Figure 3) (42). Depending on the type
and time of poor fetal and early infant growth, a variety of long-term changes in organ
function may develop (43). It is not known whether this programming is at the level
of cell numbers or organ structure. Malnutrition early in gestation will result in fetal
growth retardation as well as growth retardation of several major organs including
the fetal pancreas.As one of the consequences the number of β-cells will be reduced
resulting in low fetal insulin levels. Since insulin is an important fetal growth factor,
low fetal insulin levels will result in a low birth weight and/or birth length.According
to this hypothesis, insulin resistance results from fetal malnutrition in order to divert
glucose resources to vital structures (brain and heart) at the expense of muscles and
other organs. In a post-natal environment of nutritional excess, this programmed insu-
lin resistance becomes permanent and insulin resistance becomes maladaptive which
contributes to the development of type 2 diabetes mellitus (44).
The second hypothesis is proposed by Hattersley and is called the ‘fetal insulin
hypothesis’ (45).The fetal insulin hypothesis, postulates that genes involving insulin
resistance could effect both birth weight and disease in later life (45-47) (Figure 4).
Fetal insulin related growth does not only reflect maternal glycemia but does also
reflect fetal genetic factors which regulate the secretion of insulin by the fetal pancre-
as and the sensitivity of fetal tissues for the effects of insulin.
Maternal
undernutrition
Other maternal or
placental abnormalities
Fetal
undernutrition
Other organ
malfunction,
eg, liver
Metabolic
syndrome
Decreased
β-cell mass
Type 2 diabetes
Insulin
resistance
Obesity
Age
Abnormal
vascular
development
Hyperlipidemia Hypertension
Fig 3
Representation of the fetal origins of syndrome X
Adapted from Barker DJP et al. Diabetologia. 1993;36:62. Barker DJP. BMJ. 1995;311:171
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An example of this hypothesis is the glucokinase gene (Table 3).The enzym glucokina-
se phosphorylates glucose to glucose-6-phosphate in the pancreas and liver where it
is the rate-deter-mining step for glucose metabolism.A heterozygous mutation in the
glucokinase gene leads to altered glucose sensing by the β-cells and results in hyper-
glycemia. If the mother has the mutation and the child has not, the fetal pancreas will
sense hyper-glycemia and secrete large amounts of insulin resulting in increased fetal
growth. Conversely, if the mother does not have the mutation whereas the child
does, the fetal pancreas will sense low serum glucose levels resulting in low insulin
levels and reduced fetal growth.
Fig. 4 
Simplified representation of fetal insulin hypothesis
Adapted from Hattersley et al. Lancet 1999;353:1789.
20
C
h
ap
ter 1  Introduction
Table 3 
Mutations in the glucokinase gene
Mother + Mother + Mother - Mother -
Fetus - Fetus + Fetus - Fetus + Sign.
N 21 19 8 10
Birth weight (g) 3957 ± 447 3378 ± 712 3321 ± 463 2889 ± 525 0.0001
Birth weight centile 86 ± 20 53 ± 33 49 ± 35 24 ± 28 <0.0001
Mother + = mutation present in the mother
Mother - = mutation absent in the mother
Fetus + = mutation present in the fetus
Fetus - = mutation absent in the fetus
Adapted from Hattersley et al. Nature Genetics 1998;19:268.
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4. Growth hormone (GH) treatment in SGA children
Efficacy
The first Dutch GH trial treating short children born SGA, which started in 1991, was
a randomised, double-blind, dose-response multicenter study.After two years of GH
treatment, with either a dose of 33 µg/kg/day or 66 µg/kg/day, height increased signifi-
cantly (30). However, bone maturation accelerated in both groups, especially during
the second year of treatment. Since both groups were treated with GH it was un-
known whether this acceleration in bone maturation was due to either an effect of
GH or an effect of ageing.Therefore the present study, a second multicenter trial with
a randomzied control group for 3-years was started.
At the time the present study was started (1997) several studies had shown
beneficial effects of GH treatment on linear growth in short children born SGA
(30,48-50).At that time however, all reports contained short-term results.All studies
showed a significant increase in height and in height velocity during 2 or 3 years of
GH treatment. Since studies evaluating the effects of GH-treatment on growth are
longitudinal studies and most patients started treatment at an age of about 6 years, it
is clear that it takes at least ten years before most children have reached their adult
height.Table 4 presents the summarized results of 4 different studies who were
published at the time we started our randomized, controlled GH trial in 1997.
Safety
Short-term studies of treatment with biosynthetic GH showed that major side-effects
were very uncommon.Adverse events which have been reported during GH treat-
ment in general were idiopathic intracranial hypertension, edema and lymphedema,
carpal tunnel syndrome, slipped capital femoral epiphysis, diabetes mellitus and carbo-
hydrate intolerance (51).
GH treatment is known to decrease insulin sensitivity in normal adults (52,53).
Since the known association between a low birth weight and a higher risk of develo-
ping type 2 diabetes mellitus in adult life, evaluation of glucose intolerance is recom-
mended during GH treatment in short children born SGA. However, not much is
known about possible side-effects of GH treatment on insulin sensitivity in short SGA 
children.The first Dutch multicenter trial showed that 4 % of the short prepubertal
SGA children already had an impaired glucose tolerance before the onset of GH 
treatment (54). During GH treatment serum glucose levels remained constant while 
fasting serum insulin levels increased.After 6 years of GH treatment impaired glucose
tolerance was found in 4 % of the children suggesting that 6-years of continuous GH
treatment has no adverse effects on glucose levels in short SGA children.
Since epidemiological studies also found a relation between low birth weight,
hypertension and dyslipidemia, blood pressure and serum lipids need to be monitored
during GH treatment of short SGA children. Until now no adverse effects has been
described of GH treatment on these parameters (55). During 6 years of continuous 
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GH treatment both serum lipids and diastolic blood pressure remained stable within
the normal range. In contrast, before GH treatment systolic blood pressure was hig-
her but decreased significantly after 6 years of GH treatment.Although these results
are reassuring, blood pressure and serum lipids need to be checked regularly during
GH treatment.
5.Aims of the study
Insulin sensitivity, blood pressure and serum lipids
To assess insulin sensitivity by the Frequently Sampled Intravenous Glucose Tolerance
(FSIGT) test, blood pressure and serum lipids in short SGA children. In addition, we
investigated the presence of clustering of insulin insensitivity with cardiovascular risk
factors in these prepubertal short SGA children since this phenomenon has been
described in epidemiological studies of adults born with a low birth weight.
IGF-I gene
To investigate 3 polymorphic markers, located in the IGF-I gene, in children and
parents participating in both the present and the first Dutch multicenter study.
As IGF-I plays an important role in both fetal and postnatal growth and serum IGF-I
levels are reduced in short SGA children we hypothesized that this gene might play a
role in the etiology of SGA.
Hypothalamus / pituitary
To study abnormalities in the pituitary region using magnetic resonance imaging (MRI)
in short SGA children.Abnormalities in the pituitary region are described in children
with either isolated GHD or multiple pituitary hormone deficiencies (MPHD). Since
disturbances in the GH/IGF-I axis have been reported in short children born SGA,
we hypothesized that these might be related to abnormalities in the pituitary region.
Efficacy and safety of GH treatment versus no treatment in short SGA children
The first Dutch GH trial treating short children born SGA showed a significant 
increase in height during 2 years of treatment with either a GH dose of 33 µg/kg/day
or 66 µg/kg/day.Also a significant acceleration in bone maturation was observed in
both groups.This finding was rather confusing since a continuation of this acceleration
in bone maturation could negatively influence final height.As both groups were 
treated with GH it was unknown whether the observed effect was either the result
of GH treatment or an effect of ageing. In view of the positive effects of GH treat-
ment on growth on one hand and the acceleration in bone maturation on the other
hand, we decided to evaluate the effects of GH treatment in a randomized, controlled
trial.The present multicenter study was started with a randomized control group for
3 years, investigating the effects of GH treatment (33 µg/kg/day) versus no treatment
during a period of 3 years.
nic_7.qxd  13-10-2003  13:38  Pagina 23
24
We evaluated the effects of GH treatment versus no treatment in short 
SGA children on
- Growth and bone maturation.
- Body composition and bone mineral density (BMD). Body composition was 
measured using DXA, BMI and skinfold thickness. DXA measures fat mass, lean body
mass (LBM) and BMD.
- Body proportions.
For the description of the randomized, controlled GH trial see Appendix A.
6. Outline of the thesis
Part I
Being born SGA has, besides an increased risk of being short as adult, also an in-
creased risk of developing type 2 diabetes mellitus (DM), hypertension and cardio-
vascular diseases later in life.Therefore we investigated insulin sensitivity, lipid 
metabolism and blood pressure in a group of short SGA children (Chapter 2).
Unfortunately, it is still not understood why a small percentage of children born SGA
remains short during child- and adulthood. Since IGF-I plays an important role in both
pre- and postnatal growth, we investigated the IGF-gene in a large cohort of short
SGA children and their parents (Chapter 3). In order to investigate the hypothalamic-
pituitary axis MRI’s were performed and results were compared to MRI results of
children with isolated GHD, multiple pituitary hormone deficiencies and children with
normal stature (Chapter 4).
Part II
This part shows results of the randomized, 3-year controlled GH trial. Changes in
height, bone age and bone mineral density (BMD) were evaluated, comparing SGA
children receiving GH treatment with those remaining untreated.We also investigated
the influence of the severity of short stature at start of the study on the gain in
height during treatment with different doses of GH (Chapter 5). Before and during
GH treatment DXA’s were performed in a subgroup of short SGA children and
results were compared to skinfold measurements and BMI (Chapter 6). Furthermore
head circumference and body proportions were studied at baseline and during 3
years of GH treatment in comparison with results of untreated short SGA children.
Also a differentiation was made between those who had been born with both a low
birth length and a low birth weight (SGAL+W) and those who had been born with a
low birth length only (SGAL) (Chapter 7).
In the general discussion the significance of the presented data and their relationship
with the present literature are discussed (Chapter 8).At the end of the thesis an
English and a Dutch summary of this thesis can be found (Chapter 9 and 10).
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Appendix A
Description of the randomized, 3-year controlled GH trial
Patients
Inclusion criteria:
1. Birth length standard deviation score (SDS) below – 1.88 (that is below 3rd
percentile) for gestational age (1)
2.An uncomplicated neonatal period, without signs of severe asphyxia 
(defined as Apgar score below 3 after 5 minutes), sepsis or long-term complications
of respiratory ventilation such as bronchopulmonary dysplasia
3. Chronological age (CA) between 3.00 and 7.99 years at start of the study;
4. Height SDS for age below –1.88 according to Dutch standards (56)
5. Height velocity SDS for age below zero to exclude children with spontaneous
catch-up growth (56)
6. Prepubertal, defined as Tanner stage 1 or a testicular volume < 4 (57)
7. Normal liver, kidney and thyroid functions.
Exclusion criteria:
1.Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus,
hypothyroidism, or inborn errors of metabolism, except of GHD
2. Disorders of major organs
3. Chromosomal abnormalities or signs of a syndrome, except of Silver-Russell
Syndrome (SRS)
4. Chondrodysplasia
5. Hydrocephalus
6.Active malignancy or increased risk of leukemia
7. Serious suspicion of psychosocial dwarfism (emotional deprivation)
8. Previous anabolic sex steroid or GH therapy
Study design 
The study design was an open-labelled multicenter study with a randomized control
group (Table 5). Before entering the study the GH status was evaluated in all children
using GH stimulation tests (arginine and/or clonidine). Children with GH deficiency
(GHD) which was defined as a GH peak < 10 µg/l during two GH stimulation tests,
were not randomized but started GH treatment at dose of 1 mg/m2 body surface
area/day (~33 µg/kg/day) (GHD-group).The non-GHD children were stratified accor-
ding to age (3.00-5.50 versus 5.50-7.99) and height of the parents (height of both
parents above –1.88 SDS versus height of at least one parent below –1.88 SDS).After
stratification the patients were randomly assigned to either the GH-group (2/3 of
children) or the control group (1/3 of children).The GH-group started immediately
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with GH treatment at a dose of 33 µg/kg/day (~1 mg/m2 body surface area/day).
The control group remained untreated for 3 years and received subsequently the
same GH treatment as the GH-group. Biosynthetic GH (r-hGH NorditropinR, Novo
Nordisk A/S, Denmark) was given subcutaneously once daily at bedtime.
Three-monthly, the GH dose was adjusted to the calculated body surface area.
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Study years n 1 2 3 further
Randomized study
GH-group 61
Control group 26
Comparison cohort
GHD-group 12
Table 5
Study design of the randomized, 3-year controlled GH study
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Abstract
Epidemiological studies have shown that the metabolic syndrome, a combination of
type 2 diabetes mellitus, hypertension, dyslipidemia and a high body mass index (BMI),
occurs more frequently among adults who were born with a low birth weight. Since
insulin is thought to play a key role in the pathogenesis of this 
syndrome we investigated insulin sensitivity and possible risk factors for cardio-
vascular disease in a group of short prepubertal children born small for gestational
age (SGA).
Frequently sampled intravenous glucose tolerance tests (FSIGT) were per-
formed in 28 short prepubertal children born SGA. Short stature was defined as a
height <-2 SD. SGA was defined as a birth length and/or a birth weight for gestational
age <-2 standard deviation (SD).Twelve short children born appropriate for 
gestational age (AGA) were used as controls for the FSIGT’s results only.AGA was
defined as a birth weight and/or birth length for gestational age >-2 SD. In short SGA 
children, blood pressure (BP), fasting levels of serum free fatty acids (FFA),
triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL) cholesterol
and low-density lipoprotein (LDL) cholesterol were measured and compared to 
reference values.
Mean insulin sensitivity (Si) level in short SGA children was significantly 
reduced to 38 % of the mean Si level measured in short AGA controls (p=0.004).
Mean acute insulin response (AIR) was significantly higher in SGA children compared
to short AGA controls (p<0.001). Differences in Si and AIR between the 2 groups
remained significant after adjusting for age and BMI (p<0.001 and p=0.003, resp.).The
mean systolic BP SDS was 1.3 (1.1), being significantly higher than zero. Mean fasting
serum levels of FFA,TC,TG, HDL and LDL were all within the normal range.
However, 6 of the 28 SGA children (21 %) had serum FFA levels above the normal
range. Clustering was found between insulin insensitivity (1/Si), blood pressure and
serum FFA levels.
Although the metabolic syndrome has been described in adulthood, our study
showed that risk factors for the development of type 2 diabetes mellitus and 
cardiovascular disease are already present during childhood in short prepubertal
children born SGA, suggesting a pre-type 2 diabetes mellitus phenotype.
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Introduction
Epidemiological studies in Europe and the USA have shown that type 2 diabetes 
mellitus (DM), hypertension and cardiovascular diseases occur more frequently
among individuals who were born with a low birth weight (1-3).The combination of
DM, hypertension, dyslipidemia and a high body mass index (BMI), called the 
metabolic syndrome, has also been associated with a low birth weight (4,5).The
mechanisms underlying these associations are still unknown. However, insulin 
resistance and hyperinsulinism are thought to play a key role in the pathogenesis of
both type 2 diabetes mellitus and cardiovascular abnormalities (4,6,7).That poor 
nutrition during a critical period in fetal life may result in later adult disease has lead
to the concept of fetal programming (8).According to the fetal programming
hypothesis, insulin resistance results from fetal malnutrition in order to divert 
inadequate glucose resources to vital structures (brain and heart) at the expense of
muscle. If insulin resistance becomes permanent (programmed), in a postnatal 
environment of nutritional excess, insulin resistance becomes mal-adaptive (9).The
fetal insulin hypothesis, postulates that genes involving insulin resistance could effect
both birth weight and disease in later life (10-12).
Studies in children have revealed that insulin sensitivity and fasting insulin levels
were related to blood pressure, serum lipids and obesity (13-15). Epidemiological 
studies have also shown that clustering of fasting insulin and risk factors for cardio-
vascular disease was already present during childhood and early adulthood (16,17).
Insulin insensitivity and glucose intolerance has been described in short prepubertal
children born small for gestational age (SGA) (9,18). However, there are no data on
clustering of insulin sensitivity and cardiovascular risk factors in short prepubertal
children born SGA. In the present study we investigated insulin sensitivity in a group
of prepubertal children born SGA using a frequently sampled intravenous glucose
tolerance test (FSIGT).Also, we studied risk factors for cardiovascular disease, i.e.
BMI, lipid metabolism and blood pressure and investigated if clustering of insulin 
sensitivity and cardiovascular risk factors was already present in these young SGA
children.
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Patients and methods
Patients
The study group comprised 28 prepubertal short children born SGA who were
recruited from Sophia Children’s Hospital in Rotterdam,The Netherlands.All children
fulfilled the same inclusion criteria: 1) birth length and/or birth weight standard devia-
tion score (SDS) below – 2 for gestational age (19), 2) height SDS for age below –2
according to Dutch standards (20), 3) height velocity SDS for age below zero to
exclude children with spontaneous catch-up growth (20), 4) prepubertal stage, defined
as Tanner breast stage I for girls and testicular volume less than 4 ml for boys (21), 5)
normal GH response to either arginine or clonidine stimulation (defined as GH level
≥ 10 µg/l), 6) an uncomplicated neonatal period, without signs of severe asphyxia
(defined as Apgar score below 3 after 5 minutes), sepsis or long-term complications
of respiratory ventilation such as bronchopulmonary dysplasia. Children with 
endocrine or metabolic disorders, chromosomal defects, syndromes and growth 
failure caused by other conditions (e.g. emotional deprivation, severe chronic illness,
chondrodysplasia) were excluded, with the exception of Silver-Russell syndrome.The
ethnicity was Caucasian for 25 children,Asian for 1 child and Indo-Mediterranean for
2 children.The study was approved by the Ethics Committee.Written informed 
consent was obtained from the parents or custodians of each child and from children
older than the age of 8 years.
Twelve short normal children born appropriate for gestational age (AGA) 
served as controls for glucose homeostasis data (FSIGT results) only.They fulfilled the
same in- and exclusion criteria as the short SGA children.The short AGA children
had a birth length and a birth weight for gestational age above -2 SD, a height below
–2 SDS (22), a prepubertal stage and a normal GH response to clonidine stimulation
(defined as GH level ≥ 10µg/l). Ethnicity was comparable with the SGA group:
Caucasian for 10 children,Asian for 1 child and Polynesian for 1 child.
Both SGA and AGA children were negative for both islet cell antibodies (≤10
Juvenile Diabetes Foundation units) and insulin autoantibodies to exclude type 1 
prediabetes. Children with a first degree relative who had type 2 diabetes mellitus,
were excluded.
Clinical measurements
In all subjects height and body mass index (BMI) were expressed as SDS adjusting for
sex and chronological age (20,22,23). Biceps, triceps, subscapular and suprailiacal 
skinfold thickness were measured using a Holtain skinfold caliper (24). For skinfold
thickness analysis the sum of four measurements, expressed as SDS using references
for healthy Dutch children, was used (25).To calculate SDS, data of the reference 
population were transformed using the LMS method (26).This method transforms 
the reference data at each age to a normal distribution.
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Systolic and diastolic blood pressure (BP) were measured using a Dynamap
Critikon 1846SX. BP was expressed as SDS adjusting for height, age and sex (27).
FSIGT
After an overnight fast, a modified frequently sampled iv glucose tolerance test
(FSIGT) was performed, as previously described (28).Two iv catheters were inserted,
one for sampling and one for drug administration.Three baseline samples were drawn
at -20, -10 and 0 min.At time zero, 25% dextrose (0.3 g/kg) was administered intra-
venously over 30 seconds. Blood samples were taken at 2, 3, 4, 5, 6, 8, 10, 12, 14, 16
and 19 min.At t=20 min., tolbutamide (5 mg/kg) was administered intravenously over
30 seconds. Further blood samples were taken at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60,
70, 80 and 90 min. Blood samples were centrifuged and plasma was frozen for later 
analysis. Glucose and insulin levels were measured in all samples.
Biochemical measurements
Serum lipids were determined in short SGA children.At start of the FSIGT test,
fasting levels of serum free fatty acids (FFA), triglycerides (TG), total cholesterol (TC),
high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) were
measured. For all serum lipids reference values were available for children of the
same age range as our study group (5 to 12 years) (29).
Assays
Glucose and insulin levels in both the SGA and the AGA group were all measured
using the same method. Plasma glucose levels were determined on a VITROS analyser
750 (Orthoclinical Diagnostics, Johnson & Johnson Company, Beerse, Belgium). Plasma
insulin levels were measured by the same IRMA (Medgenix, Biosource Europe).The
intra-assay coefficient of variation (CV) was 2 % to 4.7 % (19 – 405 pmol/l) and the
inter-assay CV was 4.2 % to 11.3 % (32 – 375 pmol/l).
TC and TG levels were measured using an automated enzymatic method with the
CHOD-PAP reagent kit and with the GPO-PAP reagent kit respectively (Roche
Diagnostics, Mannheim, Germany) . For HDL cholesterol a homogenous enzymatic
colorimetric assay was used (HDL-C, Roche Diagnostics Germany). LDL cholesterol
was measured enzymatically (Roche Diagnostics). Non-esterified fatty acids in serum
were measured using an enzymatic colorimetric method (WAKO Chemicals,
Germany).The total analytical imprecision of the measurements of TG,TC, HDL and
LDL cholesterol was 3.3, 2.9, 3.9 and 3.3 %, respectively.
Statistics
The insulin sensitivity index (Si) and glucose effectiveness (Sg) were calculated using
Bergman’s MINMOD software (30). In the abbreviated FSIGT protocol, the 180 min
value was replaced by the time zero value, as described for children by Cutfield et al.
(28). SI reflects the ability of insulin to increase net glucose disposal and Sg reflects
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glucose ability to increase its own uptake.The acute insulin response (AIR), an 
estimate of insulin secretory capacity, was measured as the area under the curve from
zero to 10 minutes corrected for baseline insulin levels.The glucose disappearance
coefficient (Kg) was calculated from the slope of the natural logarithm of glucose
concentration between 10 and 19 min (31).Analysis was performed using the 
statistical package SPSS (version 10.0). Differences between the groups were tested
using the independent sample t-test. Differences in time within the SGA group were
calculated using a paired t-test. Correlations were analysed using Spearman’s 
correlation coefficient. Level of significance was determined at p<0.05.
Since it is known that insulin sensitivity, BMI, serum lipids and blood pressure
are related to each other it is too simple to just investigate correlations between two
variables. In order to study the interrelationship between insulin insensitivity (1/Si),
BMI, blood pressure and serum lipids we performed a cluster analysis. One of the
most optimal methods to identify this real data structure is a non-metric principal
component analysis (NMPCA) which is an advanced method of clustering variables
on the basis of their mutual correlations (32,33).The objective of principal 
component analysis is to detect the underlying relation between variables in a low-
dimensional structure without substantial loss of information.The length and the
direction of the vectors (lines) represent the correlations between the variables in
two clusters (i.e. dimensions).
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Results
The clinical characteristics of the two groups are shown in Table 1. None of the 
children had Silver-Russell syndrome. FSIGT results of the SGA children were 
compared to the results of a group of short AGA controls since no other reference
data were available.All other measurements were compared with a reference 
population.
Insulin sensitivity (Si) was significantly lower in the SGA group compared to the
AGA control group (p=0.004) (Table 2). Mean Si levels in SGA children were 38 % of
mean Si levels measured in AGA controls.This difference remained significant after
adjusting for BMI and age (p<0.001).As expected, there was a compensatory increase
in mean acute insulin response (AIR) which was higher in the SGA children (p<0.001),
even after adjusting for age and BMI (p=0.003). Figure 1 shows the hyperbolic relation
between Si and AIR for both groups. Mean fasting serum insulin levels were 
significantly higher in the SGA group (p=0.01). However, this difference disappeared
after adjusting for BMI and age. Glucose effectiveness (Sg) and the mean fasting serum
glucose level were not significantly different between the two groups.Although the
glucose disappearance coefficient (Kg) did not differ between the 2 groups, Kg
showed a greater variation in the short SGA group. One short SGA child had a Kg in
the glucose intolerant range (<1.0).
The SGA group was very lean as indicated by the low BMI SDS and low 
skinfolds SDS. Both BMI SDS and the sum of skinfold SDS were significantly different
from zero (both p≤0.001). Neither BMI nor sum of skinfolds showed a significant 
correlation with fasting insulin levels or Si in the SGA group.
Systolic BP SDS was significantly higher than zero but values were within the
normal range (Table 3). Diastolic BP SDS was not elevated. No significant correlation
was found between blood pressure and fasting insulin levels or Si.
Mean fasting serum levels of TC,TG, HDL-cholesterol and LDL-cholesterol in
SGA children were all within the normal range (Table 3). Mean serum level of FFA
(1.0 mmol/l), however, was in the high-normal range (normal range 0.2 – 1.2) and 6 of
the 28 short SGA children (21 %) were above the normal range. None of the 
children had serum TC, HDL-, LDL-cholesterol and TG levels outside the normal
range. No correlations were found between serum lipids and fasting insulin levels or Si.
Cluster analysis was performed to investigate the relationship between insulin
insensitivity (1/Si) and cardiovascular risk factors, which were represented in the
model by BMI, various serum lipids and blood pressure. In this model two clusters of
variables emerged. Interestingly, the first cluster was dominated by insulin insensitivity
(1/Si), diastolic and systolic blood pressure and serum FFA (Figure 2).The second
cluster comprised TC, LDL,TG and BMI.This means that the variables within one
cluster are closely related to each other. However, variables of the first cluster do not
relate to the variables of the second cluster.These two clusters of variables explained
69 % of the total variance over all 9 variables, which is considered to be prominent.
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Table 1 
Baseline characteristics of the short SGA and the AGA controls
Short SGA AGA controls
n = 28 n = 12
Age (yrs) 9.2 (2.2)# 6.9 (1.5)
Boys / girls 17 / 11 8 / 4
Gestational age (weeks) 37.8 (3.0) 37.8 (4.0)
Birth weight SDS -2.2 (1.1)* -0.3 (0.7)
Birth length SDS -3.1 (1.2) -
Height SDS -2.8 (0.6) -2.6 (0.4)
BMI SDS -1.3 (0.8)† -0.6 (1.0)
All values are expressed as mean (SD)
* = significantly different between the groups (p ≤ 0.001)
# = significantly different between the groups (p = 0.002)
† = significantly different between the groups (p = 0.02)
SDS = standard deviation score
BMI SDS = body mass index SDS
Table 2 
FSIGT results of the short SGA and the AGA controls
Short SGA AGA controls
n = 28 n = 12
Fasting glucose (mmol/l) 4.8 (0.5) 4.5 (0.6)
Fasting insulin (mU/l) 6.0 (3.2)† 4.4 (0.4)
Si *10-4/min-1 (µU/ml) 15.2 (6.6)# 39.8 (23.0)
Sg *10-2 (mg/d) min-1 2.3 (1.3) 2.9 (1.1)
AIR (mU/l) 241 (116)* 90 (48)
All values are expressed as mean (SD)
# = significantly different between the groups (p = 0.004)
† = significantly different between the groups (p = 0.01)
* = significantly different between the groups (p < 0.001) 
Si = insulin sensitivity index
Sg = glucose effectiveness
AIR = acute insulin response
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Fig. 1.
The relationship between insulin sensitivity (Si) and the acute insulin response (AIR) in short children born SGA (black circles) and
in short children born AGA (open circles).
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Fig. 2.
Results of the non-metric principal component analysis (NMPCA).The variables consisted of two clusters. Magnitude and direction
of correlations are represented by the length and direction of the vectors (lines).
BMI = body mass index  BP dia = diastolic blood pressure  BP sys = systolic blood pressure
FFA = free fatty acids  TG = triglycerides  TC = total cholesterol  
HDL = high-density lipoprotein  LDL = low-density lipoprotein  1/Si = insulin insensitivity
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Table 3 
Body composition and cardiovascular parameters in short SGA children
Short SGA
Body composition
BMI SDS -1.3 (0.8)*
Skinfolds SDS -1.1 (0.8)*
Blood pressure
Systolic BP SDS 1.3 (1.1)*
Diastolic BP SDS 0.2 (0.6)
Serum lipids
FFA (mmol/l) [N: 0.2-1.2] 0.9 (0.4)
TG (mmol/l) [N: 0.3-1.1] 0.6 (0.2)
TC (mmol/l) [N: 2.8-5.4] 4.1 (0.6)
HDL-cholesterol (mmol/l) [N: 0.8-1.9] 1.5 (0.4)
LDL-cholesterol (mmol/l) [N: 1.3-3.4] 2.3 (0.6)
All values are expressed as mean (SD)
* significantly different from zero (p ≤ 0.001)
SDS = standard deviation score
BMI = body mass index
BP = blood pressure
FFA = free fatty acids
TG = triglycerides
TC = total cholesterol
HDL = high-density lipoprotein
LDL = low-density lipoprotein
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Discussion
The present study investigates insulin sensitivity in relation to cardiovascular risk
factors in a group of young children born SGA. Insulin sensitivity appeared 
significantly reduced in these SGA children, whereas systolic blood pressure was 
significantly increased compared to their peers.Although fasting serum lipids were in
the normal range, 21 % of the children showed FFA levels above the normal range.
In short SGA children insulin sensitivity (Si) was reduced to only 38 % of the
levels found in the short AGA controls.As expected to compensate for this reduction
in Si, the acute insulin response (AIR) was nearly three times higher in short SGA
children compared to the AGA controls. In normal subjects a reciprocal relationship
exists between insulin action and insulin secretion by the pancreatic β-cell (34).
If insulin sensitivity decreases, β-cells will secrete larger amounts of insulin in order to
maintain a normal glucose metabolism. If the beta-cells fail to adapt or fail to maintain
the secretion of large amounts of insulin, the risk of developing type 2 diabetes 
mellitus increases.A single reduction in either Si, Sg or β-cell function is not enough
to cause glucose intolerance.A decrease in two or three of these parameters will,
however, increase the risk dramatically (34). Our results show that short prepubertal
SGA children maintained a normal glucose tolerance due to a compensatory increase
in insulin secretion. Since these abnormalities are found in young children it can be
questioned how long it will take before type 2 diabetes will become overt.This
important question can only be answered during long-term follow-up. Glucose 
effectiveness, the ability of glucose to enhance its own peripheral uptake and reduce
its endogenous production in the liver independent of insulin, was not significantly 
different between the short SGA and AGA children. Our findings agree with results
described by Hofman et al., who also found a reduced insulin sensitivity in a group of
15 short prepubertal SGA children (9). Our results are also comparable to those
found in group of young adults who were born SGA.(35). In the present study,
glucose intolerance was already subclinically present in one SGA child (4 %).This 
finding is comparable to the results described by Sas et al, who found impaired 
glucose tolerance during an OGTT in 8 % of another group of 79 short prepubertal
SGA children (18).
BMI SDS and skinfolds SDS were significantly lower in our short SGA group
compared to the control group. Leanness is a typical feature of short prepubertal
SGA children (36). It is well known that increasing leanness is associated with a 
dramatic increase in insulin sensitivity (28). However, we did not find a relation
between BMI and insulin sensitivity in these short SGA children.This may be due to a
lack of variation in BMI among these children. In contrast to what is to be expected
in lean individuals, insulin sensitivity in prepubertal SGA children was significantly
reduced. Johnson et al investigated longitudinal (annual) changes in fat mass, measured
by Dual Energy X-ray Absorptiometry (DEXA), and insulin sensitivity in a cohort of
healthy children.They found that a low insulin sensitivity at a young age was followed
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by a higher increase in fat mass over years, independent of sex and pubertal stage
(37).This might implicate that lean and short SGA children with a low Si are at an
increased risk of becoming obese in early or later adulthood. Since a high BMI is one
of the features of the metabolic syndrome, the observed reduction in insulin 
sensitivity in SGA children may precede the changes in body composition occurring in
later life.When these children will develop overweight, it will worsen their underlying
reduced Si, thereby strongly increasing the risk of type 2 diabetes mellitus.
Our data showed a significantly higher systolic BP in short SGA children 
compared to age- and height-matched children (27). In contrast, diastolic BP was not
significantly different from age- and height-matched children.These data are consistent
with previous data in another group of short SGA children reported by Sas et al., in
which systolic blood pressure was elevated to levels in the high-normal range (38).
Hypertension in adult life has been associated with a low birth weight (5,39).Also,
studies investigating blood pressure during childhood and early adulthood  have
shown a significant inverse relationship between systolic blood pressure and birth
weight (40) (41). Since there is evidence that blood pressure is tracking from 
childhood to adulthood (42), our results might indicate that short children born SGA
are at increased risk of becoming hypertensive in later life. It has been reported that a
high systolic BP is more important in the pathogenesis of cardiovascular disease than
a high diastolic BP (43).Therefore, short children born SGA need regular evaluation
of their blood pressure during childhood and adulthood.
Fasting serum levels of total cholesterol, triglycerides, LDL and HDL-
cholesterol were all within the normal range.These findings are in agreement with
previous reports (38,44). Our study is the first one investigating serum FFA levels in
SGA children.We found that fasting serum FFA levels were in the high-normal range,
with 6 children (21 %) having levels above the normal range. Recently, an important
role was attributed to FFA in the pathogenesis of type 2 diabetes (45).Two peptides
play an important role in the FFA metabolism.Acylation stimulating protein (ASP) 
stimulates FFA uptake by peripheral cells and esterification into TG (46). If ASP 
activity is low, serum FFA level will increase. Sniderman et al. found a defect in the
ASP pathway leading to an ineffective FFA storage which in turn will result in insulin
resistance and obesity (47).Thus, a reduction in ASP activity might play a role in the
increased serum FFA levels in these children.Another possibility is an increased 
activity of hormone sensitive lipase (HSL). HSL is responsible for hydrolysis of TG, the
rate limiting step in the breakdown of TG in adipocytes (48).A raised activity of HSL
will result in an increased breakdown of TG followed by an increase in serum FFA
levels. In normal subjects HSL is deactivated by insulin when energy supply is suffi-
cient (49). If suppression by insulin fails, HSL activity increases which in turn may
result in a rise in serum FFA levels. Several studies postulated that the HSL gene is
involved in type 2 diabetes (50-52). Further research is required to study FFA 
metabolism in larger groups of SGA children.
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Cluster analysis was used to investigate whether a number of features (i.e. BMI,
blood pressure and serum lipids) was related to the insulin insensitivity (1/Si) in these
SGA children.We found two important clusters.The first cluster clearly showed that
insulin insensitivity (1/Si) was related to higher systolic and diastolic blood pressure
and higher serum FFA levels.This is in concordance with previous epidemiological
studies in children and adults reporting an association between low insulin sensitivity
and cardiovascular risk factors (7,16,53,54). In contrast to previous reports, we found
a second cluster, consisting of BMI, total cholesterol, LDL-cholesterol and triglycerides.
This second cluster comprised parameters which are known to be closely related to
obesity. Since our study group was far from obese it is not surprising that we did not
find clustering of BMI with insulin insensitivity (1/Si). Our findings may imply that a
reduction in insulin sensitivity together with a slight increase in serum FFA levels and
systolic blood pressure are the first abnormalities in the development of the meta-
bolic syndrome. Lean SGA children may be considered as having a pre-type 2 diabetes
mellitus which may become overt when they become overweighed. For that reason it
seems particularly important to prevent the overweight in children born SGA
In conclusion, low reduced insulin sensitivity is already asymptomatically 
present in short prepubertal children born SGA. Furthermore, these children had an
increased systolic blood pressure whereas 21 % of the children had FFA levels above
the normal range.Thus, although the metabolic syndrome is an adult disease, this
study shows that risk factors for the development of type 2 diabetes mellitus and 
cardiovascular diseases are already present during childhood in these lean and short
children born SGA.
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Abstract
Low birth weight is associated with an increased risk in adult life of type 2 diabetes,
hypertension and cardiovascular disease (CVD).The fetal insulin hypothesis postulates
that genes involving insulin resistance could effect birth weight and disease in later life
(Hattersley, 1999). Besides insulin, there is extensive evidence that insulin-like growth
factor-I and –II (IGF-I, IGF-II) play an important role in fetal growth.We hypothesized
that minor genetic variation in the IGF-I gene could influence pre- and postnatal
growth.
Three microsatellite markers located in the IGF-I gene in 124 short children
(height <-1.88 SDS) who were born small for gestational age (SGA) and their parents
were studied. SGA was defined as both a birth weight and birth length below –1.88
SDS for gestational age.
Two polymorphic markers showed transmission disequili-brium.Allele 191 of
the IGF1.PCR1 marker was transmitted more frequently from parent to child 
(χ2 = 4.8 and p=0.02) and allele 198 of the 737/738 marker was transmitted less fre-
quently from parent to child (χ2 = 4.5 and p=0.03) . Children carrying the 191-allele
had significantly lower IGF-I levels than children not carrying this allele (-1.1 SDS vs.
–0.50 SDS; p=0.03).Also, head circumference SDS remained smaller in children with
allele 191 compared to children without allele 191 (-2.1 SDS vs. –0.9 SDS; p=0.003).
Our results show that genetically determined low IGF-I levels may lead to a
reduction in birth weight, length and head circumference and to persistent short 
stature and small head circumference in later life (proportionate small). Since low
IGF-I levels are associated with type 2 diabetes and CVD, we propose that the IGF-I
gene may provide a link between low birth weight and such diseases in later life.
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Introduction
About 10-15 % of children born small for gestational age (SGA) have an increased
risk of being short as adults (1, 2).The mechanism underlying persistent short stature
in these children is not fully understood. Insulin-like growth factor-I (IGF-I) plays an
important role in both pre- and postnatal growth and its serum levels are regulated
by both metabolic and genetic factors.
In fetuses and neonates born SGA low circulating IGF-I levels have been 
observed suggesting a role for IGF-I in fetal growth retardation (3-5). More direct 
evidence for a role of IGF-I in fetal and postnatal growth comes from gene deletion
studies in mice (6).Weight and length at birth were significantly reduced in IGF-I
knock-out mice (birth weight about 60% of normal) (6), and postnatally they showed
a further deterioration of growth resulting in adult weights of about 30 % of normal
mice (7, 8). Until now only one human homozygous partial deletion of the IGF-I gene
has been described in a 15-year old boy (9).This child was born SGA and showed
severe postnatal growth failure, sensorineural deafness and mental retardation.
Low serum IGF-I levels have been reported in short children born SGA (10,
11).We hypothesized that minor genetic variation in the IGF-I gene might cause a
change in serum IGF-I levels resulting in altered fetal and postnatal growth.We 
therefore investigated the IGF-I gene in a large group of short children born SGA and
their parents.Three polymorphic dinucleotide repeat markers were studied and the
results were analysed using the transmission disequilibrium test (TDT) (12).
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Methods
Subjects
This study included 124 children (66 boys and 58 girls) with short stature born SGA
and their parents.All children fulfilled the same inclusion criteria: 1) birth length and
birth weight standard deviation score (SDS) below – 1.88 for gestational age (13); 2)
height SDS for age below –1.88 according to Dutch standards (14); 3) height velocity
SDS for age below zero to exclude children with spontaneous catch-up growth; 4) an
uncomplicated neonatal period, without signs of severe asphyxia (defined as Apgar
score below 3 after 5 minutes), sepsis or long-term complications of respiratory 
ventilation such as bronchopulmonary dysplasia. Children with endocrine or 
metabolic disorders, chromosomal defects, syndromes and growth failure caused by
other conditions (e.g. emotional deprivation, severe chronic illness, chondrodysplasia)
were excluded, with the exception of Silver-Russell syndrome.The ethnicity was
Caucasian for 113 families,Asian for 1 family, Indo-Mediterranean for 4 families and
mixed ethnicity for 6 families.The study was approved by the Ethics Committee.
Written informed consent was obtained from the parents or custodians of each child
and from children older than the age of 8 years.
Clinical and biochemical measurements
In children and parents standing height was measured and expressed as SDS adjusting
for sex and chronological age using Dutch standards (14). Body mass index (BMI) 
was calculated as weight (in kilogram) divided by square of height (in meters) and
expressed as SDS for sex and age (15). Serum IGF-I levels were measured in children
using a specific RIA (16) and values were transformed into SDS adjusting for sex and
age (16).
IGF-I gene
The polymerase chain reaction (PCR) was used to amplify three dinucleotide repeat
markers located in the IGF-I gene (Fig. 1)(17).The three markers were 737/738, a
cytosine-adenine (CA) repeat in the promoter region of the gene (18), IGF1.PCR1, an
intronic cytosine-thymine (CT) repeat lying between exon 2 and 3 (19) and D12S318,
a microsatellite marker (CA repeat) lying 3’ to the gene (20) (21).All reactions were
carried out in a volume of 10 µl in the presence of 0.1 mM dNTP, 1.5 mM MgCl2 and
0.25 units Taq DNA polymerase (Sigma, Poole, UK).
For the IGF1.PCR1 and 737/738markers 100 ng of peripheral leucocyte geno-
mic DNA was amplified using 0.5 nmol/l forward primer (IGF1.PCR1: 5’-TTGTGT-
CAACTGCTGATATG-3’; 737/738: 5’-GCTAGCCAGCTGGTGTTATT-3’) and 0.5
nmol/l reverse primer (IGF1.PCR1: 5’-AACCAAAACATCATTCC-3’; 737/738: 5’-
ACCACTCTGGGAGAAGG-3’).Amplification was for 37 cycles of 30 s at 94 ºC, 30 s
at 58 ºC and 30 s at 72 ºC. For D12S318 50 ng of genomic DNA was amplified using
0.3 nmol/l forward primer (5’-TGCTTGGGTCATCAATCTGC-3’) and 0.3 nmol/l
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reverse primer (5’-GGTTATAGACATATAAA-3’) for 35 cycles of 30 s at 94 ºC, 30 s
at 58 ºC and 30 s at 72 ºC.
Forward primers were labelled with either HEX or FAM.The sizes of PCR 
products were determined by the ABI 377 DNA Analyser using ROX 500 as a 
fluorescent size marker.The results were analysed using GENESCAN and 
GENOTYPER software (Applied Biosystems, UK).
Statistical analysis
The transmission disequilibrium test (TDT) was performed using the TDT/S-TDT
program 1.1 of Spielman (12, 22).The TDT test is a valid test for linkage and 
association, even when the population under study consists of subjects of different
ethnic origin.The TDT method evaluates whether the frequency of transmission of
alleles from heterozygote parents to their affected children deviates from 50%, the
expected Mendelian frequency when there is no linkage.
Statistical tests to analyse genotype-phenotype relationships were performed
with use of SPSS package (version 10.0). Independent sample t-testing was used to
analyse differences in phenotype between different genotypes.To investigate the
possible influence of allele 191 on birth size and growth, a repeated measurement
analysis (SAS Proc Mixed) was performed with all length and weight measurements,
converted to their SD-score, from birth to the age of 4.0 years. Head circumference
measurements were available from birth until the age of 1.5 years in 83 children.As
random covariables were used the intercept, age and age-squared, as fixed covariables
age, age-squared (if significant), presence of allele 191 and its interaction with age
(unadjusted model). If significant, the model was adjusted for sex, gestational age,
multiple birth and their interaction with age (adjusted model). Statistical significance
was defined as p < 0.05.
737/738
Exon
IGF1.PCR1 D12S318
5’ 3’
1 2 3 4 5 6
Fig. 1 
Schematic organization of the IGF-I gene.
Exons 1 to 6 are indicated by boxes, with coding regions in black and non-coding regions in white. Promoter regions are indicated
by a dashed line. Dinucleotide markers are indicated by arrows.
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Results
Baseline characteristics are shown in Table 1. Birth length SDS , birth weight SDS,
head circumference SDS and height SDS were all significantly lower compared to
–1.88 SDS. BMI SDS, IGF-I SDS, fathers height SDS and mothers height SDS were all
significantly lower compared to zero, i.e. compared to the median for normals.
TDT results and allele frequencies of the 3 markers are shown in Table 2. Significant
evidence of transmission disequilibrium was found in the IGF1.PCR1 and the 737/738
markers.
The wildtype allele of the IGF1.PCR1 marker was allele 189. Significant 
transmission disequilibrium was found with allele 191 (χ2 = 4.8 and p=0.02).This
allele was transmitted more frequently from parents to children. Interestingly, the
mean serum IGF-I level was significantly lower in children carrying allele 191 com-
pared to children without allele 191 (-1.1 SDS vs. –0.50 SDS; p=0.03) suggesting a
functional relationship between this polymorphism and the IGF-I gene (Table 3). No
significant difference in height SDS was found between children with and without
allele 191. Both in the unadjusted and adjusted model, no significant relation was
found between the changes in height and weight SDS from birth until 4.0 years and
allele 191. However, changes in head circumference SDS during the first 1.5 years
were significantly associated with allele 191.At the age of 1.5 years children carrying
allele 191 had a significant smaller head circumference SDS than children without
allele 191 (p=0.003) (Table 3). Head circumference SDS of the 191-carriers did not
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Table 1
Baseline characteristics of 124 short children born SGA
Gestational age (weeks)1 37.0 (32.8 – 39)
Birth length SDS1 -3.3 (-4.7 - -2.5)*
Birth weight SDS -3.0 (0.8)*
Birth head circumference SDS -2.5 (1.1)*
Age (years) 6.7 (2.4)
Height SDS -3.0 (0.7)*
BMI SDS -1.4 (1.3)†
IGF-I SDS -0.6 (1.1)†
Fathers height SDS -1.1 (1.1)†
Mothers height SDS -1.3 (1.0)†
Values expressed as mean (SD) unless stated otherwise
BMI SDS = body mass index SDS
1 = Median (interquartile range)
* = significantly lower compared to –1.88 (p<0.001)
† = significantly lower compared to zero (p<0.001)
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change during the first 1.5 years of life whereas the non-carriers showed a significant
increase in head circumference SDS during that period (p<0.001). BMI SDS and
parental height SDS did not differ significantly between 191-carriers and 191-non-
carriers.
Allele 192 of the 737/738 marker was the most common allele and therefore
likely to be the wildtype allele.Transmission disequilibrium was found with allele 198
(χ2 = 4.5 and p=0.03).This allele was less likely to be transmitted from parents to
children. Since only one child was carrier of the 198 allele it was not possible to ana-
lyse phenotypic 
differences between the 198-carriers and non-carriers. None of the alleles of the
D12S318 marker was in transmission disequilibrium.
Table 3
HC SDS and serum IGF-I SDS in carriers versus non-carriers of allele 191
Carriers allele 191 Non-carriers allele 191 p-value
HC SDS
- at birth -2.0 (0.3) -2.3 (0.2) ns
- after 1.3 years -2.1 (0.4) -0.9 (0.2) 0.003
IGF-I SDS -1.1 (0.2) -0.5 (0.1) 0.03
Values are expressed as mean (SE)
HC SDS = head circumference SDS
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Table 2
Allele frequencies of 124 short children born SGA
Allele1 Frequency (%) Transmitted Non-transmitted p-value
IGF1.PCR1 
marker 
185 0.8 2 0
187 0.4 1 1
189 65.3 61 61
191 8.5 21 9 0.02
193 0.8 2 6
195 2.4 6 10
197 4.0 10 14
199 4.0 8 7
201 6.5 14 20
203 1.6 4 3
205 1.6 3 1
207 3.6 9 9
209 0.4 1 0
211 - 0 1
737/738 
marker
176 0.4 1 1
186 - 0 1
188 1.2 3 1
190 4.0 11 7
192 71.8 62 54
194 16.5 39 39
196 5.6 12 19
198 0.4 1 7 0.03
D12S318 
marker
239 - - -
241 - 0 1
243 - 0 1
247 6.0 16 11
249 10.1 24 22
251 6.5 17 16
253 52.0 63 60
255 8.5 18 25
257 6.9 15 15
259 5.2 14 8
261 4.0 10 17
263 0.8 2 1
265 - 0 2
1 = allele in number of base pairs
Italics = wildtype allele
Bold = allele with significant transmission disequilibrium
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Discussion
Our study provides evidence for an important role of the IGF-I gene in short children
born SGA.Allele 191 of the IGF1.PCR1 marker was transmitted more frequently
from parent to child suggesting this is a ‘causal allele’.The association between head
circumference and allele 191 indicates this allele might play a role in SGA children
with persistent short stature and small head circumference (proportionate small) . It
was to be expected that we could not detect significant differences in changes in
height between different genotypes since our study population is a very homogenous
group where all children are short (height <-1.88 SDS).Also, children with allele 191
had significantly lower serum IGF-I levels than those without allele 191 suggesting a
functional relationship.
Our results are suggestive of the existence of a functional variant of the IGF-I
gene located between the promoter region and exon 3 which results in significantly
lower serum IGF-I levels. Further research is needed to unravel the exact location
and function of this mutation.
The 198 allele of the 737/738 marker was less frequently transmitted from
parent to child. Since the frequency of this allele was very low it is difficult to draw
conclusions regarding its relation to serum IGF-I levels.An unexpected finding is that
parents carrying the 198 allele (n = 8) were significantly shorter than parents without
this allele (n = 240) (-2.0 SDS vs. –1.1 SDS; p=0.03).This suggests the allele itself is
associated with short stature. Since this allele is less likely to be transmitted to
offspring it is unlikely that a causal relation exists between this polymorphism and
SGA.
Johnston et al. could not find an association between the IGF-I gene and the
SGA phenotype in a cohort of French term singleton SGA subjects and a cohort of
adults born appropriate for gestational age (AGA)(23).Although the mean adult
height of the SGA cohort was significantly lower compared to the AGA cohort, no
distinction was made between the SGA adults who had attained normal height and
those who remained short.This might explain why no significant association was
found.
Insulin resistance has been reported in short children born SGA (24) and
impaired glucose tolerance was described in 8% of our study population (25). Severe
insulin resistance has been reported in a child with a homozygous IGF-I gene defect
(26). Besides being an important contributor to fetal growth, IGF-I has a stimulatory
effect on growth and development of pancreatic beta-cells.A lifetime exposure to
low-normal serum IGF-I levels has been reported as a risk factor for developing 
cardiovascular disease and type 2 diabetes (27-29).Thus, polymorphisms in the IGF-I
gene resulting in low serum IGF-I levels may increase the risk of cardiovascular 
disease and type 2 diabetes.We found an association between a polymorphism of the
IGF-I gene and low serum IGF-I levels in a specific group of short children born SGA
who remained proportionate small. Since low IGF-I levels increase the risk of 
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developing adult disease we suggest that this IGF-I polymorphism may be a link
between a low birth weight and an increased risk of adult disease.This would be 
consistent with the ‘fetal insulin hypothesis’ (30). Besides the glucokinase gene (31),
the IGF-I gene might not only be involved in fetal growth but also in the pathogenesis
of diabetes and cardiovascular disease. Further research is needed to confirm our 
findings and to explore if other genetic and environmental factors may also 
contribute to this phenotype.
This is the first study showing an association between a polymorphism of the
IGF-I gene and low serum IGF-I levels in a group of short children born SGA. Our
results suggest that genetically determined low serum IGF-I  levels may lead not only
to a reduction in birth length, weight and head circumference but also to persistent
short stature and small head circumference during childhood and adulthood (propor-
tionate small).As low serum IGF-I levels are associated with adult disease, the IGF-I
gene may provide a link between the association of low birth weight and disease in
later life in this specific group of small SGA children.
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MRI findings of the pituitary gland in short children born small for 
gestational age (SGA) in comparison with growth hormone-deficient
(GHD) children and children with normal stature.
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Abstract
Disturbances in the GH / IGF-I axis are reported in 25 – 60 % of short children born
small for gestational age (SGA).We hypothesized that these abnormalities might be
related to abnormalities in the pituitary region.Therefore, the results of magnetic 
resonance imaging (MRI) of short SGA children were compared to MRI results of
other groups of short children and to normal controls.
MRI was performed in four groups of short children: SGA children without GH
deficiency (SGA group; n=17), SGA children with isolated GH deficiency (SGA +
IGHD group; n=10), non-SGA children with isolated GH deficiency (IGHD group;
n=24) and non-SGA children with multiple pituitary hormone deficiencies (MPHD
group; n=15). MRI was also performed in children with normal stature (control group;
n=13). Pituitary height (PH) and thickness of the pituitary stalk (PS) were measured
and the relationship with the maximum GH peak during a GH stimulation test, serum
IGF-I and IGFBP-3 levels was evaluated.
Short SGA children either with or without IGHD did not show major 
anatomic abnormalities in the hypothalamic-pituitary region in contrast to 58 % of
the non-SGA IGHD children and 87 % of the MPHD children who had anatomic
abnormalities. PH in SGA children without GHD was normal whereas it was signifi-
cantly lower in SGA children with IGHD.The lowest PHs were measured in non-SGA
children with MPHD.A moderate decrease in PH was associated with significantly
lower maximum serum GH peaks and lower serum IGF-I and IGFBP-3 levels.
Measuring PHs in children with less severe GHD, who underwent MRI as part
of the diagnostic process, might support the diagnosis of GHD even in the absence of
anatomical abnormalities. Our study demonstrates that there is no indication to 
perform MRI of the pituitary region in short children born SGA without GHD.
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Introduction
Short children born small for gestational age (SGA) constitute a specific group.About
15 % of them fail to show catch-up growth during the first 2 years of life (1-3). If they
are still short at the age of 2 or 3 years they have a greater risk of being short as
adults (1-3). It is still unknown why a small percentage of SGA children remains short.
Disturbances in the growth hormone (GH)-insulin-like growth factor-I (IGF-I)-axis
may play a role. Sixty percent of children with insufficient catch-up growth showed a
decrease in GH secretion during 24 hours whereas 25 % showed low GH peaks
during GH provocation tests (4,5).Also serum IGF-I levels were significantly lower in
short children born SGA compared to normal children (4,5).
Several studies in patients with hypopituitarism revealed abnormalities in the
pituitary region using magnetic resonance imaging (MRI) (6-8).These abnormalities
included ectopia of the neurohypophysis (NH), hypoplasia or interruption of the 
pituitary stalk (PS) and hypoplasia of the adenohypophysis (AH).Abnormalities were
more frequently observed in patients with multiple pituitary hormone deficiency
(MPHD) than in patients with isolated GH deficiency (IGHD) (9-11).
No data were available on MRI findings of the pituitary region in short children
born SGA.We hypothesized that disturbances in the GH/IGF-I axis, as had been
reported in these children, might be related to abnormalities in the pituitary region.
Therefore MRI’s were performed in short SGA children with and without GHD. Since
MRI abnormalities are well described in children with IGHD and MPHD, we used
these groups as references. Results were also compared to MRI findings in a group of 
children with normal stature. In addition, pituitary height (PH) and thickness of the
pituitary stalk (PS) were measured and the relationship with different growth 
parameters was evaluated.
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Patients and methods
Patients and controls
The study was performed in 66 children with short stature and in 13 children with
normal stature (controls). Short stature was defined as a height for chronological age
< –2 SDS according to Dutch references (12). Small for gestational age (SGA) was
defined as a birth length for gestational age < – 2 SDS (4,13). GH status was 
evaluated in all short children using GH stimulation tests (arginine, clonidine or pro-
panolol). Growth hormone deficiency (GHD) was defined as a GH peak < 10 ng/ml
during two GH stimulation tests, according to the Dutch Consensus guidelines (14).
Multiple pituitary hormone deficiency (MPHD) was defined as GHD associated with
at least one deficiency of the other anterior pituitary hormones. Birth data were
obtained from all children. Normal controls for this study were children with a height
>-2 SDS who underwent an MRI for reasons not related to GHD. Children with 
evidence of hypothalamo-pituitary disease, neurological disorders and syndromal
abnormalities were excluded from the control group. Based on birth length, actual
height and GH-status, children were divided into 5 groups:
I  a: - SGA without GHD (SGA group; n = 17)
b: - SGA with isolated GHD (SGA+IGHD group; n = 10)
II a: - non-SGA with IGHD (IGHD group; n = 24)
b: - non-SGA with MPHD (MPHD group; n = 15)
III - Controls (control group; n=13)
SGA children with and without GHD participated in a Dutch multicenter study 
studying the effects of GH treatment. Data of non-SGA children with IGHD and
MPHD were evaluated retrospectively.All children, except for the control group,
received GH treatment.
The study was approved by the Medical Ethics Committee of the Academic Hospital
Rotterdam and the Erasmus University Rotterdam. In the SGA group without GHD
written informed consent was obtained from the parents or custodians of each child.
In the SGA+IGHD, IGHD and MPHD group an MRI was performed as part of the
diagnostic process.All MRI’s were performed during adequate hormonal suppletion.
Hormone measurements
Plasma GH was measured by a double antibody RIA using a rabbit anti-GH serum as
the first and a goat antirabbit globulin as the second antibody (15).A specific RIA
measured IGF-I after acid chromatography, as described previously (15). IGF-I was
expressed as SD-scores using reference data from a healthy Dutch population of 600
children (15). IGFBP-3 was isolated from human plasma (16) and determined by a
specific RIA using a polyclonal antiserum derived from New Zealand White rabbits.
IGFBP-3 levels were expressed as SD-scores using reference data from a healthy
Dutch population of 286 children aged 0-14 years provided by the laboratory (17).
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Because data from non-SGA children with IGHD and MPHD were collected retro-
spectively, some serum IGF-I and IGFBP-3 levels were missing.
MRI evaluation
Patients were examined on a 0.5 T Philips Gyroscan (Philips Medical Systems, Best,
The Netherlands). Scan sequences included T1 weighted (SE 450-600/TE 21-30) 
sagittal and coronal 3 mm slices of the hypothalamo-pituitary area and T2 weighted
(SE 2000-2500/TE 100) axial 0.5 cm slices of the total brain. Interslice gap was 10 %
of slice thickness.The matrix was 205x256, the field of view was 18 cm.
The height of the pituitary gland (PH) was determined by measuring the 
greatest distance between the base and the top of the gland on a midsagittal image
using a slide-rule.The thickness of the PS was measured in the middle on a midsagittal
image and both proximal (PS-proximal) and distal (PS-distal) on a coronal image.All
measurements were performed blinded to subject classification by the same investiga-
tors (N.A. and W.v.d.L.). Since PH is dependent on age and sex, values are expressed
in SD scores (18). Pituitary hypoplasia was defined as a PH below –2 SDS.
Statistics
Data are expressed as the mean plus or minus the standard deviation (SD).
Differences between groups were tested using independent Student's t-tests.
Pearson’s correlation coefficient was used for correlations. Statistical significance was
defined as p < 0.05. Statistical tests were performed with use of SPSS package 
(version 8.0).
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Results
Characteristics of the various groups are shown in Table 1.The mean maximum GH
peak was significantly different between groups.Also, the mean IGF-I SDS differed 
significantly between the groups with the highest values measured in the SGA group
and the lowest values in the MPHD group.
Only one out of 17 children of the SGA group (6 %) showed a hypoplastic AH.
No other pituitary abnormalities were found in this group. None of these children
had a breech delivery, vacuum or forceps extraction.
In the SGA+IGHD group only one out of 10 children (10 %) had a hypoplastic
AH. One child was born by breech delivery, but this child did not show MRI 
abnormalities.
In the IGHD group 58 % of the children showed pituitary abnormalities: 38 %
(9/24) had a hypoplastic AH, 42 % (10/24) an ectopic NH and 17 % (4/24) a 
disrupted/absent PS. One child born by breech delivery had an ectopic NH, a 
disrupted PS and a normal AH.The children born by vacuum or forceps extraction
did not show pituitary abnormalities.Ten out of 24 (42 %) children did not show
abnormalities in the pituitary region.
Most severe abnormalities were found in the children with MPHD: 87 %
(13/15) had a hypoplastic or absent AH, 87 % (13/15) an ectopic or absent NH and
67 % (10/15) a disrupted/absent PS. Four children were born by breech delivery and
one was born with vacuum extraction.All 5 children showed severe abnormalities in
the pituitary region. Only 2 children (13 %) had a normal adeno- and neurohypophysis
with a normal stalk.
Midline-defects were found in two patients. One non-SGA child with IGHD
showed bilateral optic hypoplasia and one non-SGA child with MPHD had bilateral
optic hypoplasia and a hypoplastic optic chiasm. No abnormalities were found in the
normal controls. None were born by breech delivery, one was delivered by vacuum
extraction.
Mean (SD) pituitary height (PH) and pituitary stalk thickness (PS) for the
various groups are shown in Table 2. PH SDS was not significantly different between
the SGA group and the control group. In the SGA+IGHD group PH SDS was 
significantly lower compared to the SGA group and the control group (p=0.003 and
p=0.004 respectively).Also, children with IGHD and MPHD showed significantly lower
PH SDS compared to the SGA and the control group (all p<0.001). Children with
MPHD had lower PH SDS than children with IGHD but this difference did not reach
the level of significance (p=0.064).
PS thickness in SGA and SGA+IGHD children was significantly lower compared
to controls (p=0.037 and p=0.046). PS thickness in children with IGHD did not differ
significantly from the controls. Since PS could only be measured in 5 children with
MPHD due to an absent or disrupted PS in the remaining 10 children, we could not
analyse these data. In all groups, even in the control group, we found the proximal PS 
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Table 1 
Characteristics of the various groups
G
roups
n
Sex M
/F
G
A
 (w
ks) 
BW
 SD
S
BL SD
S
A
ge (yrs)
H
eight SD
S
BM
I SD
S
M
ax.G
H
 (ng/m
l)      IG
F-I SD
S
IG
FBP3 SD
S
I
SG
A
17
10/7
36.5 (2.6) 1
-2.6 (1.1) 2
-3.1 (1.3) 3
6.7 (1.3)
-3.1 (0.6)
-1.0 (1.1)
24.2 (12.1) 5
-0.3 (1.5) 6
-1.1 (1.4) 7
SG
A
+
IG
H
D
10
6/4
36.5 (2.9) 1
-2.4 (1.1) 2
-3.8 (1.4) 3
6.1 (1.8)
-3.2 (0.7)
-0.9 (1.3)
8.5 (2.9) 8
-2.1 (1.0) 9
-2.6 (1.3)
II
IG
H
D
24
13/11
39.4 (2.2)
-0.3 (1.1)
-0.7 (0.9)
8.3 (3.5)
-3.1 (0.6)
0.1 (1.3)
5.8 (2.6) 10
-2.7 (1.8) 10
-2.7 (1.0)
M
PH
D
15
11/4
38.7 (3.7)
-0.1 (1.2)
-0.7 (1.1)
5.3 (3.4)
-3.7 (0.9)
-0.1 (1.5)
2.2 (2.5)
-4.9 (1.2)
-3.9 (3.4)
III
C
ontrols
13
7/6
40 (1.8)
0.1 (1.4)
N
D
5.6 (5.0)
0.4 (0.9) 4
-0.1 (1.4)
N
D
N
D
N
D
All values are expressed in m
ean (SD
)
G
A =
 gestational age;BW
 SD
S =
 birth w
eight SD
-score;BL SD
S =
 birth length SD
-score
N
D
 =
 not done;for controls no baseline data concerning BL,G
H
,IG
F-I and IG
FBP-3 w
ere available
1
=
 P<
0.01 vs.IG
H
D
 and controls
2
=
 P<
0.001 vs.IG
H
D
,M
PH
D
 and controls 
3
=
 P<
0.001 vs.IG
H
D
 and M
PH
D
4
=
 P<
0.001 vs.other groups
5
=
 P<
0.001 vs.SG
A+
IG
H
D
,IG
H
D
 and M
PH
D
6
=
 P<
0.005 vs.SG
A+
IG
H
D
,IG
H
D
 and M
PH
D
7
=
 P<
0.05 vs.SG
A+
IG
H
D
 and IG
H
D
8
=
 P=
0.01 vs.IG
H
D
;P<
0.001 vs.M
PH
D
9
=
 P<
0.001 vs.M
PH
D
10
=
 P≤0.001 vs.M
PH
D
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to be significantly thicker than the distal PS (p<0.001). No significant correlation was
found between the PH and the PS thickness.
PH SDS showed significant positive correlations with the maximum GH peak
(r=0.52; p<0.001), IGF-I SDS (r=0.36; p=0.006) and IGFBP-3 SDS (r=0.56; p<0.001).
PH SDS did not show a correlation with height or body mass index. PS thickness did
not correlate with the maximum GH peak, IGF-I SDS or IGFBP-3 SDS.
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Table 2 
M
ean (SD
) pituitary height (PH
) and pituitary stalk (PS) thickness on M
RI
G
roups
n
A
ge (yrs)
PH
 (m
m
)
PH
 SD
S
PS (m
m
)
PS-prox (m
m
) PS-distal (m
m
)
I
SG
A
17
8.1 (1.2)
4.9 (0.8) 2
0.6 (1.4) 1
1.6 (0.2)
1.9 (0.5)
1.5 (0.2)
SG
A
+
IG
H
D
10
7.4 (2.8)
3.7 (0.7) 4
-1.1 (1.1) 3
1.6 (0.3)
2.1 (0.4)
1.5 (0.2)
II
IG
H
D
24
10.5 (4.2)
3.8 (1.0) 6
-2.5 (2.5) 5
1.7 (0.8)
2.8 (0.8) 9
1.6 (0.9)
M
PH
D
15
10.6 (4.7)
2.9 (1.0) 7
-4.4 (3.8) 7
*
*
*
III
C
ontrols
13
6.3 (4.6)
4.8 (1.0)
0.5 (1.3)
1.8 (0.2) 8
2.0 (0.6)
1.5 (0.2)
* 10 patients m
issing data due to absent or disrupted PS
1
=
 P<
0.005 vs.SG
A+
IG
H
D
,IG
H
D
 and M
PH
D
2
=
 P ≤0.001 vs.SG
A+
IG
H
D
,IG
H
D
 and M
PH
D
3
=
 P=
0.099 vs.IG
H
D
;P<
0.01 vs.M
PH
D
 and controls
4 =
 P<
0.05 vs.M
PH
D
 and controls
5 =
 P=
0.064 vs.M
PH
D
;P<
0.001 vs.controls
6
=
 P<
0.01 vs.M
PH
D
 and controls
7
=
 P<
0.001 vs.controls
8 =
 P<
0.05 vs.SG
A and SG
A+
IG
H
D
9
=
 P<
0.001 vs.SG
A;P<
0.01 vs.SG
A+
IG
H
D
 and controls
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Discussion
This is the first report describing MRI results in a cohort of short children born SGA
with and without IGHD.We found that short children born SGA without GHD (SGA
group) did not have lower pituitary heights (PHs) compared to controls with normal
stature, except for one child who showed hypoplasia of the AH. None of them had an
ectopic NH or a disrupted or an absent PS. Nagel et al. described similar findings in 3
children with short stature after intrauterine growth retardation (IUGR) and found
no abnormalities in their pituitary gland (19). Only one out of 10 SGA children with
IGHD (SGA+IGHD group) showed a hypoplastic AH (10 %).We did not observe any
other anatomical abnormalities in the pituitary region of these children.
Our MRI findings in the non-SGA group with IGHD (IGHD group) were com-
parable with findings in IGHD children described by others.About 40 % of these
children showed a hypoplastic AH and an ectopic NH (38 % and 42 %, respectively)
and 4 out of 24 showed PS abnormalities.The observed difference in abnormalities
between the SGA+IGHD group and the IGHD group might explain the difference in
severity of GHD.The IGHD group had significantly lower maximum GH peaks com-
pared to the SGA+IGHD group.This is in agreement with reports showing that 
children with severe IGHD had more pituitary abnormalities than children with 
partial IGHD (10,19).
Most pituitary abnormalities were found in non-SGA children with multiple
pituitary hormone deficiencies (MPHD group). In our study 87 % of these children
showed a hypoplastic AH and an ectopic NH and 67 % showed PS abnormalities.
Children with MPHD showed the lowest maximum GH peaks and serum IGF-I and
IGFBP-3 levels.Thus, children with the most severe form of GHD showed the most
severe pituitary abnormalities.These findings agree with observations described in
previous reports (9-11,19,20).
Evaluating all children we found a significant positive correlation between 
pituitary height SDS (PH SDS) and the severity of GHD (maximum GH peak, IGF-I
and IGFBP-3 levels).This indicates that a child with a low maximum GH peak, low
serum IGF-I and low IGFBP-3 levels has a greater risk of having a small pituitary
gland. Our results agree with Nagel et al who investigated 91 children with different
causes of short stature (19).They also measured PH and found a significant corre-
lation between PH and GH secretion, serum IGF-I and IGFBP-3 levels.We found no 
difference in PH SDS between the SGA group and the control group. PH SDS in the
SGA+IGHD group, however, was significantly lower compared to the SGA group and
the control group.This study shows that even a moderate decrease in PH (with PH
remaining within the normal range) was associated with significantly lower maximum
GH peaks during provocation tests and to significantly lower serum IGF-I and 
IGFBP-3 levels.Therefore, assessment of PH in children with partial IGHD without
MRI abnormalities in the pituitary region, may support the diagnosis of GHD. Our
data indicate that MRI is not likely to show anatomic abnormalities of the pituitary in
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short children born SGA without GHD.Therefore, in these children, there is no need
to perform MRI’s as part of a diagnostic process.
Pituitary abnormalities are related to perinatal events such as breech delivery,
vacuum or forceps extraction and perinatal asphyxia (7).These pituitary abnormalities
may either be caused by birth trauma or may exist before birth and cause a higher
risk of complications during delivery (21).As in other reports, we found relatively
more breech deliveries in the children with MPHD (7,10,22).
We hypothesized that disturbances in the GH/IGF-I axis in short children born
SGA, might be related to abnormalities in the pituitary region. Our findings, however,
did not confirm this hypothesis. Subnormal GH secretion and subnormal serum IGF-I
and IGFBP-3 levels in these children can not be explained by anatomic abnormalities
in the pituitary region. In the SGA+IGHD group pituitary height was significantly
lower compared to the SGA group and controls.This suggests that the size of the
pituitary plays a role in the GH secretion in SGA children with IGHD. It is not known
whether a reduced number or a reduced volume of somatotrophic cells may lead to
a smaller pituitary causing a reduction in GH secretion. One report (23) showed that
the somatotrophic cells of a patient with IGHD were morphologically identical to
normal somatotrophic cells. However, further research is required to answer this
question.
In conclusion, short SGA children either with or without IGHD did not show
major anatomic abnormalities in the hypothalamic-pituitary region. Pituitary height
(PH) in SGA children without GHD was normal whereas it was significantly lower in
SGA children with IGHD.This study showed that even a moderate decrease in PH
was associated with significantly lower maximum serum GH peaks, serum IGF-I and
IGFBP-3 levels.
Therefore, in children with less severe GHD who underwent MRI as part of
the diagnostic process, measuring PHs may support the diagnosis of GHD even in the
absence of anatomical abnormalities. Our study shows that there is no indication to
perform an MRI in short children born SGA without GHD.
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Abstract
To investigate in a group of short children born small for gestational age (SGA), the
effects of 3 years of GH treatment versus no treatment on bone age (BA), height and
bone mineral density (BMD).Also, to evaluate the influence of the severity of growth
retardation at start and the GH dose on the gain in height.
The study design was an open-labelled, controlled multicenter GH study for 3
years. Non-growth hormone deficient (GHD) children (n=87) were randomized to
either a GH-group (n=61) or an untreated control group (n=26). In addition, 12 SGA
children had GHD (GHD-group) and were treated in parallel. Both the GH- and the
GHD-group were treated with a GH dose of 33 µg/kg/day. BMD was evaluated using
Dual Energy X-ray Absorptiometry (DXA). In addition, data of our first GH trial in
which short SGA children were treated with a GH dose of 66 µg/kg/day (n=24) were
used for comparison of height gain.
In contrast to the control group, the GH-group showed a significant increase in
height (p<0.001), as did the parallel GHD-group. Bone maturation (∆ bone age (BA)/
∆ calendar age(CA)) increased significantly during the first two years of GH treat-
ment but slowed-down thereafter.The 3-year ∆BA/∆CA ratio correlated significantly
with the gain in height (r=0.6, p<0.001).At start, mean BMD SDS and mean BMAD
SDS were significantly lower than zero. During GH treatment both increased impres-
sively (p<0.001).The gain in height of children with severe short stature at start 
(≤ -3.00 SDS), did not differ between those receiving either a GH dose of 33 or 66
µg/kg/day.
Three years of GH treatment in short children born SGA results in a 
normalisation of height during childhood.Also, bone maturation increased proportio-
nately to the height gain.At start, mean values of BMD and BMAD were significantly
reduced but normalised during GH treatment.We did not find an indication to treat
very short SGA children (H SDS ≤ -3.00) with a higher GH dose.We rather suggest
to start GH treatment at an early age in order to achieve a normal height before
puberty starts.
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Introduction
Short stature is one of the risks of being born small for gestational age (SGA).About
10-15 % of children born SGA fail to show catch-up growth in height above the third
percentile during the first years of life and have an increased risk of being short in
adult life (1-3).The mechanisms underlying this lack of catch-up growth are still unk-
nown. Disturbances in the growth hormone (GH) / insulin-like growth factor-I (IGF-I)
axis have been described (4,5). Sixty percent of these children had abnormalities in
GH secretion and/or reduced serum IGF-I levels (4,5).
Several studies have shown beneficial effects of either continuous or disconti-
nuous GH treatment on linear growth in short children born SGA (6-8). In the first
Dutch trial, a randomized, double-blind, dose-response multicenter study, normalisa-
tion of height during childhood was obtained during 5 years of continuous treatment
with either a GH dose of 33 µg/kg/day or 66 µg/kg/day (7).This study showed an
acceleration of bone maturation in both groups, which was most pronounced during
the first 2 years of treatment. Since both groups were treated with GH it was un-
known whether this acceleration in bone maturation was due to either an effect of
GH or an effect of ageing.Therefore, the present multicenter study was started with
a randomized control group for 3 years, investigating the effects of GH treatment (33
µg/kg/day) versus no treatment on bone maturation and its relation to changes in
height during a period of 3 years.We also evaluated the GH-induced growth response
in relation to the severity of growth retardation at start of the study. In order to
investigate if children with severe short stature would benefit more from treatment
with a higher dose of GH, we compared present data with data of our previously 
performed randomized GH-dose-response trial (33 versus 66 µg/kg/day).
In short children born SGA bone mineral density (BMD) has never been 
studied in a randomized controlled trial. Low BMD could lead to osteoporosis and
would increase the risk of bone fractures in both children and adults (9,10). BMD in
adulthood is mainly determined by the peak bone mass achieved during adolescence
or early adulthood and by bone resorption during adult life (11). Peak bone mass is
the highest level of bone mass achieved as a result of normal growth.Thus, obtaining a
high peak bone mass early in life, provides a larger bone reserve later in life (12).
Therefore, BMD was studied in a subgroup of short children born SGA using Dual
Energy X-ray Absorptiometry (DXA) during this 3-year randomized, controlled GH
trial.
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Patients and methods
Patients
The study comprised 104 Dutch children (48 boys and 56 girls) with short stature
born SGA.All children fulfilled the same inclusion criteria: 1) birth length standard
deviation score (SDS) below – 2.00 SDS for gestational age (13); 2) an uncomplicated
neonatal period, without signs of severe asphyxia (defined as Apgar score below 3
after 5 minutes), sepsis or long-term complications of respiratory ventilation such as
bronchopulmonary dysplasia; 3) chronological age (CA) between 3.00 and 7.99 years
at start of the study; 4) height SDS for age below –2.00 according to Dutch standards
(14); 5) height velocity SDS for age below zero to exclude children with spontaneous
catch-up growth (14); 6) prepubertal, defined as Tanner stage 1 or a testicular volume
< 4 (15); 7) normal liver, kidney and thyroid functions. Children with endocrine or
metabolic disorders, chromosomal defects and growth failure caused by other syn-
dromes (e.g. emotional deprivation,Turner syndrome, severe chronic illness, chondro-
dysplasia), with the exception of Silver-Russell syndrome were excluded.The diagnosis
Silver-Russell was based on clinical characteristics (16).The study was approved by the
Ethics Committees of all nine participating centers.Written informed consent was
obtained from the parents or custodians of each child.
Study design
The study design was a multicenter GH trial with a randomized control group for 3
years. Before entering the study the GH status was evaluated in all children using GH
stimulation tests. Children with growth hormone deficiency (GHD), which was 
defined as a GH peak < 10 µg/l during two GH stimulation tests, were not randomi-
zed but started GH treatment at dose of 33 µg/kg/day (~1 mg/m2 body surface
area/day) (GHD-group; n=12; 5 boys and 7 girls).The non-GHD children (n=87) were
stratified according to age (3.00-5.50 versus 5.50-7.99) and height of the parents
(height of both parents above –2.00 SDS versus height of at least one parent below
–2.00 SDS).After stratification the patients were randomly assigned to either the 
GH-group (2/3 of children) or the control group (1/3 of children).The GH-group
(n=61; 25 boys and 36 girls) started with GH treatment at a dose of 33 µg/kg/day.
The control group (n=26; 16 boys and 10 girls) remained untreated for 3 years and
subsequently received the same GH treatment as the GH-group.
Biosynthetic GH (r-hGH NorditropinR, Novo Nordisk A/S, Denmark) was
given subcutaneously once daily at bedtime.Three-monthly, the GH dose was adjusted
to the calculated body surface area.
In order to evaluate the GH-induced effect on growth in relation to the 
severity of growth retardation at start, we compared the results of the present study
with those of children receiving GH at a dose of 66 µg/kg/day in our first randomized
GH-dose-response trial (7).These children fulfilled exactly the same in- and exclusion
criteria as described above.
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Anthropometric measurements
Standing height (H) was measured 3-monthly by two trained investigators (NA and
later on VB) using a Harpenden stadiometer.The mean of 4 measurements was used
for analysis. Height was expressed as SD-score for sex and chronological age (HSDS-
CA) using Dutch references (14).Target height was calculated using Dutch reference
data according to the formula: 1/2 * (Hfather + Hmother + 13) + 4.5 for boys and
1/2 * (Hfather + Hmother - 13) + 4.5 for girls, where the addition of 4.5 cm re-
presents the secular trend.TH was expressed as SD-score using Dutch references
(14). Bone age (BA) was determined blindly by one investigator (NA) according to
the Tanner & Whitehouse method (17). Bone maturation was expressed as the ratio
between the change in BA and the change in CA (∆BA/∆CA).
Bone mineral density measured by DXA
In a subgroup of 38 SGA children (20 of the GH group, 10 of the control group and 8
of the GHD group), bone mineral density (BMD) was measured in one center by
Dual Energy X-ray Absorptiometry (DXA) type Lunar DPX-L PED using the pediatric
medium scan mode. Since both BMD at start and during GH treatment did not differ
between the GH- and the GHD group, these results were analysed together. BMD of
the total body (BMDTB in gram/cm
2) and of the lumbar spine (BMDLS in gram/cm2)
was measured.The coefficients of variation for BMDTB and BMDLS have been repor-
ted to be 0.64 % and 1.04 %, respectively (18).To adjust for differences in bone size,
bone mineral apparent density (BMAD) was calculated according to the formula:
BMDLS*[4/(π*width)] (19).Width stands for the mean width of the second to fourth
lumbar vertebral body. Since all parameters of BMD were dependent on age and sex,
the values were transformed into SD-scores using Dutch reference values for 
children older than 4 years (20,21).
Biochemical measurements
Blood samples were taken at the start of the study from all children and subsequently
every 6 months from GH-treated children (GH-group) and every 12 months from
non-treated children (control group) for determination of serum levels of IGF-I and
IGFBP-3.After centrifugation, all samples were frozen (-20 C) until assayed.
Hormone assays
A specific RIA measured IGF-I and IGF-II after acid chromatography as described pre-
viously (22). Both growth factors were expressed as SD-scores using reference data
from a healthy Dutch population of 600 children (22).
IGFBP-3 was isolated from human plasma according to the method developed
by Martin and Baxter (23) and determined by a specific RIA using a polyclonal antise-
rum derived from New Zealand White rabbits. IGFBP-3 levels were expressed as SD-
scores using reference data from a healthy Dutch population of 286 children aged
0-14 years provided by the laboratory (24).
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Statistics
Of 104 children 5 children dropped out of the study for the following reasons: one
child was very disappointed she was randomized into the control group, 3 children
had psychological problems with the daily GH injections and in 1 child coeliac disease
was diagnosed. Since these children dropped out either at start or during the first
year of the study, these children were excluded from baseline and 3-year analysis.
Therefore, 99 children (46 boys and 53 girls) were eligible for statistical analysis. Data
are expressed as the mean plus or minus the standard deviation (SD). SD-scores
were compared with zero using Student's one sample t-test. Differences between
groups were tested using independent Student's t-tests. Differences in 1-year changes
between the groups were tested using analysis of covariance and differences between
points in time within the groups were tested by paired Student's t-tests. Pearson’s
correlation coefficient was used for correlations. Stepwise multiple regression analysis
was used to assess multivariate relationships. Factors showing a linear correlation
with the 3-year change in H SDS were entered into the model. Only results of the
most significant model are shown. Statistical significance was defined as p < 0.05.
Statistical tests were performed with use of SPSS package (version 10.0).
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Results
At baseline
The baseline characteristics of the 3 groups, GH-, control- and GHD group, are
shown in Table 1.Thirteen children had Silver-Russell syndrome.At the start of the
study no significant differences were found between the 3 groups. During the 3-year
study period, puberty started in 4 children of the GH-group, in 2 children of the 
control group and in 2 children of the GHD group. Since most children remained pre-
pubertal during the study period, analysis was performed in prepubertal children only.
As soon as a child entered puberty he or she was excluded from further analysis.
Results did not change when data of these children were excluded from the start of
the study (data not shown). Results of children with SRS did not differ from results of
children without signs of SRS (data not shown).
Changes in height
In the GH-group H SDS increased significantly from –3.0 SDS at start to –1.3 SDS
after 3 years of GH treatment (p<0.001) (Figure 1).The GHD-group showed similar
growth as height increased significantly from –3.4 SDS to –1.2 SDS after 3 years
(p<0.001).The control group, however, showed a very small increase in H SDS from
–3.2 to –2.9 SDS (p<0.001).
Table 1 
Baseline characteristics
SGA
Randomized controlled trial GHD group
GH group Control group
n=61 n=26 n=12
Boys / girls 25 / 36 16 / 10 5 / 7
Gestational age (wks) 36.1 (3.9) 36.0 (3.6) 35.9 (3.6)
Birth length SDS -3.4 (1.5) -3.1 (1.3) -3.5 (2.0)
Birth weight SDS -2.3 (1.2) -2.7 (1.0) -2.5 (1.2)
Chronological age (yr) 6.0 (1.6) 5.9 (1.5) 5.2 (1.4)
Bone age (RUS) (yr) 4.9 (1.6) 4.8 (1.7) 4.2 (1.9)
Height SDSCA -3.0 (0.6) -3.2 (0.5) -3.4 (0.8)
TH SDS -0.5 (0.8) -0.6 (0.7) -0.5 (0.7)
Silver Russell syndrome (n) 6 5 2
All values are expressed as mean (SD) or number
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Table 2 
Mean serum IGF-I and IGFBP-3 levels at start and during the 3-year study period
SGA
Randomized controlled trial GHD group
GH group Control group
n=61 n=26 n=12
IGF-I SDS
Baseline -0.3 (1.1)2 -0.3 (1.0) -1.7 (0.9)1†
3 years 1.2 (1.4)1 -0.9 (1.3)1* 1.4 (1.3)2
IGFBP-3 SDS
Baseline -1.4 (1.1)1 -1.2 (1.1)1 -3.3 (1.3)1†
3 years 0.3 (0.7)1 -1.0 (1.0)1* 0.3 (0.6)
All values are expressed as mean (SD)
1 = significantly different compared to 0 SDS (p<0.005)
2 = significantly different compared to 0 SDS (p<0.05)
* = significantly different compared to the GH and the GHD group (p ≤ 0.001)
† = significantly different compared to the control and the GH group (p ≤ 0.001)
Figure 1
Changes in H SDS of the GH- (black circles), the GHD- (grey circles) and the untreated control group (open squares).
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Changes in levels of growth factors
Serum IGF-I and IGFBP-3 levels at start and during the study are shown in Table 2.At
baseline serum IGF-I and IGFBP-3 levels of the GHD group were significantly lower
compared to the non-GHD children (both p<0.001). During GH treatment both
serum IGF-I and IGFBP-3 levels increased significantly in the GH treated groups. In
the total group, the 3-year change in both IGF-I SDS and IGFBP-3 SDS correlated sig-
nificantly with the 3-year change in H SDS (both r=0.6 and p<0.001). In the GH-
treated groups, this correlation was weaker but still significant (both r=0.3 and p=0.02).
Changes in BA
At start of the study the mean BA delay of 1.0 (0.9) year was comparable between
the 3 groups. During the 3-year study period the delay in bone maturation of the
control group remained unchanged. In contrast, the GH- and GHD-group showed a
significant increase in bone maturation. Figure 2 shows ∆BA/∆CA ratio per year for
the 3 groups.The highest ∆BA/∆CA ratio for the GH-group was observed during the
second year of GH treatment (1.6 (0.70) yrs/yr) and for the GHD-group during the
first year of GH treatment (1.6 (0.6) yrs/yr). During the third year, however, the
∆BA/∆CA ratio was comparable for the 3 groups. During the entire 3-year period
the mean ∆BA/∆CA ratio was 4.3 (0.8 ) yrs / 3.0 (0.0) yr in the GH-group and 3.2
(0.8) yrs / 3.0 (0.0) yr in the control group (p<0.001).
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Figure 2
Changes in bone maturation (∆BA/∆CA ratio) during the first, second and third study year of the GH- (black bars), the GHD- (grey
bars) and the untreated control group (open bars).
* = significantly different compared to the control group (p<0.001)
# = significantly different compared to the control group (p<0.05)
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No significant correlation was found between age and the 3-year ∆BA/∆CA
ratio. In the total group the 3-year ∆BA/∆CA ratio correlated significantly with the 
3-year change in H SDS (r=0.6, p<0.001) and with serum IGF-I levels after 1, 2 and 3
years.Also, within each subgroup the 3-year ∆BA/∆CA ratio correlated significantly
with the 3-year change in H SDS (GH- and GHD group: r=0.3, p=0.006; control group
r=0.5, p=0.007). However, within each subgroup, the 3-year ∆BA/∆CA ratio did not
correlate with changes in serum IGF-I levels.
Changes in BMD
No difference was found in mean BMDTB, BMDLS, and BMAD SDS at start and
during GH treatment between the GH- and the GHD-group (data not shown).
Therefore, BMD of these 2 groups are presented together.At baseline mean BMDTB,
BMDLS, and BMAD SDS in both the GH-treated group (GH- and GHD group) and
the control group were significantly lower than zero (Table 3).At start of the study
10 out of 38 children (26 %) had a BMD SDS below –2.00 SDS and 3 out of 38 
children (8 %) had a BMAD SDS below –2.00 SDS. During 3 years of GH treatment
mean BMDTB, BMDLS, and BMAD SDS showed an impressive increase (all p<0.001).
In contrast, the control group showed only a slight increase in parameters of bone
density.After 2 and 3 years of GH treatment, respectively, all children had a BMDTB
SDS, BMDLS SDS and BMAD SDS in the normal range (above -2.00 SDS).The 3 year
change in BMDTB SDS did neither correlate with changes in H SDS nor with changes
in IGF-I SDS. However, changes in BMDLS SDS and BMAD SDS correlated significantly
with changes in H SDS (r=0.8, p<0.001; r=0.5, p=0.003) and with changes in IGF-I SDS
(r=0.6, p<0.001; r=0.3, p=0.05).
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Table 3 
Changes in BMDTB SDS, BMDLS SDS and BMAD SDS during the 3-year study period in 
the GH-treated and the control group
BMDTB SDS BMDLS SDS BMAD SDS
GH- and GHD group (n=28)
Baseline -0.9 (1.1)1 -1.7 (1.0)1 -0.6 (1.1)2
1 year -0.6 (0.8)1 -0.9 (0.9)1 -0.3 (1.1)
2 years 0.1 (0.6)* -0.4 (0.8)2,# -0.1 (1.0)
3 years 0.2 (0.7)* 0.1 (0.6)* 0.3 (0.9)
Control group (n=10)
Baseline -0.9 (1.2)1 -1.6 (0.8)1 -0.7 (0.6)2
1 year -1.0 (1.2)2 -1.4 (1.0)1 -0.6 (0.8)2
2 years -0.8 (1.0)2 -1.3 (0.9)1 -0.3 (1.0)
3 years -1.0 (0.8)2 -1.3 ( 0.6)1 -0.3 (0.7)
All values are expressed as mean (SD)
1 = significantly different compared to 0 SDS (p<0.005)
2 = significantly different compared to 0 SDS (p<0.05)
* = significantly different compared to the control group (p ≤ 0.005)
# = significantly different compared to the control group (p ≤ 0.05)
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Multiple regression analysis
Using multiple regression, we found age at start of the study (β=-0.1, p=0.001), 1 year
∆BA/∆CA ratio (β=0.2, p=0.01) and the 1-year change in IGF-I SDS (β=0.1, p=0.04)
to be the best predictors of the 3-year increase in H SDS during GH treatment.
These three variables explained 31 % of the variation in the 3-year change in H SDS.
TH SDS, the maximum GH peak during stimulation tests and baseline IGF-I levels did
not significantly contribute to this model.
Growth response in relation to height at start and GH dose
An analysis was performed investigating the effect of GH dose in children with either
a H SDS at start between –2.00 and –3.00 or a H SDS at start ≤ -3.00. For this analy-
sis we used data of the present randomized, controlled GH trial (33 µg/kg/day vs 
control) and data of our previously performed randomized GH-dose-response trial
(33 vs 66 µg/kg/day).Analysis was performed in prepubertal children only.TH SDS of
children receiving either 33 or 66 µg/kg/day did not differ (-0.5 (0.8) and –0.5 (0.9),
respectively).Also, age at start of the study was not significantly different between the
groups. Figure 3 shows that in children with a H SDS at start between –2.00 and
–3.00, the mean H SDS had normalised ( > –2.00 SDS) after 1 year of treatment with
either a normal or a double GH dose.After 2 years, all of these children (100 %) had
a H SDS in the normal range (above –2.00).The 3-year change in H SDS was signifi-
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Figure 3
Changes in H SDS in A) children with a baseline H SDS between –2.00 and –3.00 receiving a GH dose of either 33 (n=33, open
circles) or 66 µg/kg/day (n=8, open squares) and B) children with a baseline H SDS ≤ –3.00 receiving a GH dose of either 33
(n=34, black circles) or 66 µg/kg/day (n=16, black squares).
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cantly higher in children treated with a double dose versus children treated with a
normal dose (2.3 (0.6) versus 1.8 (0.4); p=0.003).
In children with a baseline H SDS ≤ -3.00, mean H SDS showed a normalisation
after 2 years in the double dose group and after 3 years in normal dose group.
However, after 3 years of GH treatment, still 31 % of the double dose group and 41
% of the normal dose group had a H SDS below –2.00 (difference between the
groups not significant). Remarkably, in these very short children the 3-year change in
H SDS did not significantly differ between the two GH-dosage groups.
Safety
GH injections were well tolerated and no adverse events were reported during 
treatment that could be attributed to GH.Thyroid function and hemoglobin A1c
levels remained normal during the study period.
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Discussion
This study reports the effects of GH treatment in a randomized, 3-year controlled
study design with a separate group of GHD children born SGA, treated parallel to
the randomized trial. GH treatment with a dose of 33 µg/kg/day in short SGA child-
ren either with or without GHD resulted in normalisation of their height during
childhood.After two years of GH treatment, the mean H SDS of both GH treated
groups had normalised (i.e. above –2.00), while the H SDS of the untreated control
group remained far below –2.00.These results are comparable to those reported pre-
viously by us and others (6-8).
Serum IGF-I and IGFBP-3 levels, expressed as SDS, were significantly lower
than zero in short non-GHD children born SGA. In short SGA children with GHD
serum IGF-I and IGFBP-3 levels were even more severely reduced. Remarkably, during
GH treatment a similar increase in both IGF-I and IGFBP-3 levels was found in 
children with and without GHD. It has been suggested that disturbances in the
GH/IGF-I axis play a role in the mechanisms underlying poor catch-up growth of
short children born SGA (4,25).The 3-year increment in IGF-I and IGFBP-3 SDS 
correlated well with the 3-year gain in H SDS suggesting that the good response to
GH treatment was mediated through increased serum IGF-I levels.
At start of the study all children had a 1-year delay in bone age, regardless of
their GH-status. During the 3-year study period, bone maturation in untreated short
children born SGA did neither accelerate nor decelerate. So, after the 3-year study
period they still had a bone age delay of one year. In contrast, bone maturation 
accelerated significantly in the GH-treated groups. In the GHD group this accelera-
tion was most obvious during the first year of treatment while in the GH group the
maximum acceleration was observed during the second year of treatment.After the
first two years of treatment this acceleration slowed-down and during the third year
no significant difference was found compared with the untreated control group. Data
describing bone maturation during GH treatment of short SGA children are rather
confusing. It has been reported that bone maturation accelerated spontaneously in
untreated short SGA children (26-28). De Zegher et al., however, found a slower
bone maturation in both untreated and GH-treated SGA children with a relatively
young age at start of the study compared to SGA children with a relatively old age at
start of the study (29). In contrast, during a 3-year follow-up period, we did not
observe any difference in bone maturation between younger and older (until the age
of 8 years) SGA children, either untreated or GH-treated (data not shown).
Interestingly, our study showed that the acceleration in bone maturation is associated
with a strong catch-up growth during the first 3 years of GH treatment.
The 1-year ∆BA/∆CA ratio appeared a very good predictor of the 3-year gain
in height.As has been previously reported by us in another trial also, age at start of
the study showed a significant inverse correlation with the 3 year growth response
during GH treatment (7). Neither target height nor baseline parameters of GH status
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did significantly contribute to the prediction model.
Our study evaluated bone mineral density (BMD) in short prepubertal SGA
children.We found that before GH treatment the mean BMD level was significantly
lower compared to normal children. However, since DXA measures an areal density
(g/cm2), BMD is underestimated in short children (30). For that reason we calculated
bone mineral apparent density (BMAD) which is a widely used validated method to
correct for short stature (19).At baseline, mean BMAD SDS was reduced to a lesser
degree than mean BMDTB and mean BMDLS SDS levels. However, mean BMAD SDS
differed significantly from zero, suggesting bone mineral density in these children is
not only reduced because of their short stature. During GH treatment BMAD and
BMDTB normalised after 1 and 2 years, respectively, whereas BMDLS normalised
after 3 years of GH treatment.These results are comparable to results observed in
GHD children (31,32).
It has been questioned if SGA children with a H SDS below –3.00 should be
treated with a higher dose of GH in order to achieve a more rapid normalisation of
their height.To answer this question we compared the results of the present rando-
mized, controlled GH trial with the results of our first randomized GH-dose-
response trial, in which comparable SGA children received GH treatment at a higher
dose of 66 µg/kg/day (double dose) (7).All SGA children with a H SDS at start
between –2.00 and –3.00, who received either a double or normal dose of GH,
showed a normalisation of H SDS (i.e. > -2.00) within 2 years of treatment. None of
these children had a H SDS below –2.00 after 2 years of treatment. In SGA children
with severe short stature at start of the study (≤ –3.00), mean H SDS normalised
after 2 years of GH treatment in children receiving the double GH dose and after 3
years in children receiving a normal dose.We did, however, not find a significant effect
of GH dose on the 3-year gain in H SDS in children with a H SDS at start ≤ –3.00.
After three years of GH treatment 31 % of the double dose group and 41 % of the
normal dose group still had a H SDS below the normal range.The difference in H
SDS at start between the two height groups was 1 SD.Therefore, it is not surprising
that children with a very low baseline H SDS need more time to catch-up in height
into the normal range. Our results, however, show that treatment with a higher GH
dose does not result in a more rapid catch-up growth. Since it is important to achieve
a height within the normal range before a child enters puberty, we suggest that in
children with a very low H SDS, GH treatment should start at a relatively young age.
So, if a child born SGA is still very growth-retarded (H SDS ≤ -3.00) at the age of 3
years without showing any signs of spontaneous catch-up growth, we suggest to start
treatment with a normal dose of GH at that young age. Obviously, other causes for
short stature (e.g.Turner syndrome, coeliac disease) should be excluded before 
starting GH treatment.
In conclusion, three years of GH treatment results in normalisation of height
during childhood. During GH treatment, bone maturation increased proportionately
to the gain in height.The mean level of bone mineral density in short SGA children is
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significantly reduced compared to normal children but normalises during GH treat-
ment.The height gain of children with severe short stature at start of the study 
(≤-3.00 SDS) does not differ between those receiving a normal versus those receiving
a double GH dose.We therefore conclude that there is no indication to treat these
very short SGA children with a higher GH dose.We want to emphasize, however,
that severely growth retarded SGA children should start GH treatment at a young
age to enable sufficient catch-up growth before onset of puberty.
Acknowledgements
Mrs. E. Lems and mrs. I. van Slobbe, research nurses, are greatly acknowledged for their assi-
stance.We also thank W.J. de Waal,T.C.J. Sas and Y.K. van Pareren and J. van Nieuwkasteele
for using data of the first SGA study.
This study was supported by Novo Nordisk Farma B.V.,The Netherlands.
nic_7.qxd  13-10-2003  13:38  Pagina 89
90
References
1. Albertsson-Wikland K, Karlberg J 1994 Natural growth in children born small for gestational age with
and without catch-up growth.Acta Paediatr Suppl 399:64-70; discussion 71.
2. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop
SL 1995 Children born small for gestational age: do they catch up? Pediatr Res 38:267-71.
3. Chaussain JL, Colle M, Ducret JP 1994 Adult height in children with prepubertal short stature seconda-
ry to intrauterine growth retardation.Acta Paediatr Suppl 399:72-3.
4. de Waal WJ, Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Drop SL 1994 Endogenous
and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children
with short stature after intrauterine growth retardation.The Dutch Working Group on Growth Hormone. Clin
Endocrinol (Oxf) 41:621-30.
5. Boguszewski M, Rosberg S,Albertsson-Wikland K 1995 Spontaneous 24-hour growth hormone profiles
in prepubertal small for gestational age children. J Clin Endocrinol Metab 80:2599-606.
6. Boguszewski M,Albertsson-Wikland K,Aronsson S, Gustafsson J, Hagenas L,Westgren U,Westphal O,
Lipsanen-Nyman M, Sipila I, Gellert P, Muller J, Madsen B 1998 Growth hormone treatment of short children
born small-for-gestational- age: the Nordic Multicentre Trial.Acta Paediatr 87:257-63.
7. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 1999 Growth hormone
treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-
blind, dose- response trial. J Clin Endocrinol Metab 84:3064-70.
8. de Zegher F, Du Caju MV, Heinrichs C, Maes M, De Schepper J, Craen M,Vanweser K, Malvaux P,
Rosenfeld RG 1999 Early, discontinuous, high dose growth hormone treatment to normalize height and weight
of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 84:1558-61.
9. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J,
Vogt TM 1993 Bone density at various sites for prediction of hip fractures.The Study of Osteoporotic Fractures
Research Group. Lancet 341:72-5.
10. Goulding A, Jones IE,Taylor RW, Manning PJ,Williams SM 2000 More broken bones: a 4-year double
cohort study of young girls with and without distal forearm fractures. J Bone Miner Res 15:2011-8.
11. Hansen MA, Overgaard K, Riis BJ, Christiansen C 1991 Role of peak bone mass and bone loss in post-
menopausal osteoporosis: 12 year study. Bmj 303:961-4.
12. Ribot C,Tremollieres F, Pouilles JM 1995 Late consequences of a low peak bone mass.Acta Paediatr
Suppl 411:31-5; discussion 36.
13. Usher R, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea level: standards 
obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr
74:901-10.
14. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ,Verloove-
Vanhorick SP,Wit JM 2000 Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr
Res 47:316-23.
15. Tanner JM,Whitehouse RH 1976 Clinical longitudinal standards for height, weight, height velocity, weight
velocity, and stages of puberty.Arch Dis Child 51:170-9.
16. Wollmann HA, Kirchner T, Enders H, Preece MA, Ranke MB 1995 Growth and symptoms in Silver-
Russell syndrome: review on the basis of 386 patients. European Journal of Pediatrics 154:958-968.
17. Tanner JM,Whitehouse RH, Cameron N, Marshall WA, Healy MJR, Goldstein H 1983 Assessment of 
skeletal maturity and prediction of adult height (TW2-method), 2nd ed.Academic Press, London.
18. Johnson J, Dawson-Hughes B 1991 Precision and stability of dual-energy X-ray absorptiometry 
measurements. Calcif Tissue Int 49:174-8.
19. Kroger H,Vainio P, Nieminen J, Kotaniemi A 1995 Comparison of different models for interpreting bone
mineral density measurements using DXA and MRI technology. Bone 17:157-9.
20. Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM 1997 Bone mineral 
density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol
Metab 82:57-62.
21. Boot AM, Bouquet J, de Ridder MA, Krenning EP, de Muinck Keizer-Schrama SM 1997 Determinants of
body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents.Am J Clin
Nutr 66:232-8.
22. Hokken-Koelega AC, Hackeng WH, Stijnen T,Wit JM, de Muinck Keizer-Schrama SM, Drop SL 1990
Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth
factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. J
Clin Endocrinol Metab 71:688-95.
C
h
ap
ter 5  G
H
 treatm
ent (I)
nic_7.qxd  13-10-2003  13:38  Pagina 90
C
h
ap
ter 5  G
H
 treatm
ent (I)
91
23. Martin JL, Baxter RC 1986 Insulin-like growth factor-binding protein from human plasma. Purification
and characterization. J Biol Chem 261:8754-60.
24. Rikken B, van Doorn J, Ringeling A,Van den Brande JL, Massa G,Wit JM 1998 Plasma levels of insulin-like
growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone 
deficiency. Horm Res 50:166-76.
25. Boguszewski M, Jansson C, Rosberg S,Albertsson-Wikland K 1996 Changes in serum insulin-like growth
factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children
born small for gestational age. J Clin Endocrinol Metab 81:3902-8.
26. Job JC, Rolland A 1986 [Natural history of intrauterine growth retardation: pubertal growth and adult
height].Arch Fr Pediatr 43:301-6.
27. Davies PS,Valley R, Preece MA 1988 Adolescent growth and pubertal progression in the Silver-Russell
syndrome.Arch Dis Child 63:130-5.
28. Ranke MB, Lindberg A 1996 Growth hormone treatment of short children born small for gestational
age or with Silver-Russell syndrome: results from KIGS (Kabi International Growth Study), including the first
report on final height.Acta Paediatr Suppl 417:18-26.
29. de Zegher F, Butenandt O, Chatelain P,Albertsson-Wikland K, Jonsson B, Lofstrom A, Chaussain JL 1997
Growth hormone treatment of short children born small for gestational age: reappraisal of the rate of bone
maturation over 2 years and metanalysis of height gain over 4 years.Acta Paediatr Suppl 423:207-12.
30. Mazess RB, Barden H, Mautalen C,Vega E 1994 Normalization of spine densitometry. J Bone Miner Res
9:541-8.
31. Saggese G, Baroncelli GI, Bertelloni S, Barsanti S 1996 The effect of long-term growth hormone (GH)
treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone
mass. J Clin Endocrinol Metab 81:3077-83.
32. Boot AM, Engels MA, Boerma GJ, Krenning EP, De Muinck Keizer-Schrama SM 1997 Changes in bone
mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children
with GH deficiency. J Clin Endocrinol Metab 82:2423-8.
nic_7.qxd  13-10-2003  13:38  Pagina 91
92
C
h
ap
ter 5  G
H
 treatm
ent (I)
nic_7.qxd  13-10-2003  13:38  Pagina 92
SA
G
C
h
ap
ter x  Introduction
93
Body composition by Dual Energy X-ray Absorptiometry (DXA) in short
children born small for gestational age (SGA) before and during growth
hormone (GH) treatment: Results of a randomized, controlled GH 
treatment study.
Nicolette J.T.Arends1,Theo Stijnen2,Anita C.S. Hokken-Koelega1
1 Department of Pediatrics, Division of Endocrinology, Erasmus MC/Sophia 
Children’s Hospital, Rotterdam, the Netherlands
2 Institute of Epidemiology and Biostatistics, Erasmus MC, Rotterdam,The 
Netherlands
Submitted
C
h
ap
ter 6  G
H
 treatm
en
t (II)
nic_7.qxd  13-10-2003  13:38  Pagina 93
94
Abstract
The aim of this randomized, controlled GH treatment study is to investigate lean
body mass (LBM), fat mass and bone mineral density (BMD) using Dual Energy X-ray
Absorptiometry (DXA), skinfold thickness and BMI in a group of short children born
SGA before and during GH treatment.
All children participated in a 3-year randomized, controlled GH treatment
study. Non-GHD SGA children (n=87) were randomized to receive GH (GH-group,
n=61) or remained untreated (control group, n=26).Twelve SGA children with GH-
deficiency served as a comparison cohort (GHD-group, n=12).All GH treated 
children were treated with 33 µg GH/kg/day. In a subgroup BMD, LBM and fat mass
were measured using DXA.The sum of 4 skinfolds (skinfolds), BMI, and serum IGF-I
levels were measured in all children. Measurements were expressed as standard
deviation scores (SDS), adjusting for sex and age.
At start of the study, SGA children showed a significant reduction of LBM, fat
mass and BMD measured by DXA.Also, skinfolds and BMI were significantly reduced.
Skinfolds correlated strongly with fat mass measured by DXA (r=0.8, p<0.001),
whereas BMI correlated with both fat mass and LBM (r=0.6, p<0.001; r=0.5, p=0.008).
During 3 years of GH treatment, both LBM and BMD increased impressively
(p<0.001), in contrast to the control group. Fat mass decreased significantly during
the first year of GH treatment (p<0.001) followed by an increase to levels com-
parable to baseline. Changes in fat mass correlated with changes in skinfolds (r=0.4,
p=0.05). Changes in BMI did not correlate with either changes in fat mass or LBM.
In short children born SGA, leanness is the result of a significant reduction in
LBM and to a lesser extent of a reduction in total body fat. In addition, BMD is signifi-
cantly reduced in these children. During GH treatment LBM and BMD normalised.
Also, our study indicates that the sum of 4 skinfolds is a better tool than BMI for 
estimating total body fat in short SGA children before and during GH treatment.
C
h
ap
ter 6  G
H
 treatm
ent (II)
nic_7.qxd  13-10-2003  13:38  Pagina 94
C
h
ap
ter 6  G
H
 treatm
ent (II)
95
Introduction
Children who were born small for gestational age (SGA) have a higher risk of being
short in adult life. During the first 2 years of life, ten to fifteen percent of all children
born SGA fail to show catch-up growth in height above the third percentile (1,2).
Disturbances in the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis,
which have been reported in 25 % of the short SGA children during a GH provo-
cative test and in 60 % during a GH profile test, might be involved (3,4).
GH is known to influence linear growth, bone density and body composition.
Children with untreated classical GH deficiency (GHD) have reduced bone mineral
content, reduced muscle mass and increased percentage body fat (5). Not much is
known about the body composition in short children born SGA without GHD (6).
Since disturbances in the GH/IGF-I axis are present in SGA children, it can be hypo-
thesised that their body composition is also altered. In contrast to classical GHD
children who have truncal obesity, short children born SGA either with or without
GHD have a lean appearance.This finding is supported by calculations of body mass
index (BMI) as well as measurements of skinfold thickness (7). However, Dual Energy
X-ray Absorptiometry (DXA) is a more precise method to investigate body composi-
tion. DXA uses a low radiation dose, is very accurate and can easily be performed in
children (8,9).
This is the first controlled GH treatment study investigating fat mass, lean body
mass (LBM) and bone mineral density (BMD) using DXA in a group of short children
born SGA without GHD.All children participated in a 3-year randomized, controlled
GH treatment study. DXA was performed at start of the study and subsequently
every year in both GH-treated and untreated SGA children. DXA results were com-
pared to two commonly used estimates of body composition, i.e. BMI and skinfold
thickness. Results of a non-randomized group of SGA children with GHD served as a
comparison cohort.
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Patients and methods
Subjects
The study comprised 104 Dutch children (48 boys and 56 girls) with short stature
born SGA.All children fulfilled the same inclusion criteria: 1) birth length standard
deviation score (SDS) below – 2.00 for gestational age (10); 2) an uncomplicated neo-
natal period, without signs of severe asphyxia (defined as Apgar score below 3 after 5
minutes), sepsis or long-term complications of respiratory ventilation such as bron-
chopulmonary dysplasia; 3) chronological age (CA) between 3.00 and 7.99 years at
start of the study; 4) height SDS for age below –2.00 according to Dutch standards
(11); 5) height velocity SDS for age below zero to exclude children with spontaneous
catch-up growth (11); 6) prepubertal, defined as Tanner stage 1 or a testicular volume
< 4 (12); 7) normal liver, kidney and thyroid functions. Children with endocrine or
metabolic disorders, chromosomal defects and growth failure caused by other syn-
dromes (e.g. emotional deprivation,Turner syndrome, severe chronic illness, chondro-
dysplasia), with the exception of Silver-Russell syndrome, were excluded.
The study was approved by the Ethics Committees of all nine participating centers.
Written informed consent was obtained from the parents or custodians of each child.
Study design
The study design was an open-labelled multicenter study with a randomized control
group. Before entering the study the GH status was evaluated in all children using GH
stimulation tests (arginine and/or clonidine). Children with GH deficiency (GHD)
which was defined as a GH peak < 10 µg/l during two GH stimulation tests, were not
randomized but started GH treatment at dose of 1 mg/m2 body surface area/day
(~33 µg/kg/day) (GHD-group).The non-GHD children were stratified according to
age (3.00-5.50 versus 5.50-7.99) and height of the parents (height of both parents
above –2.00 SDS versus height of at least one parent below –2.00 SDS).After stratifi-
cation the patients were randomly assigned to either the GH-group (2/3 of children)
or the control group (1/3 of children).The GH-group started immediately with GH
treatment at a dose of 33 µg/kg/day (~1 mg/m2 body surface area/day).The control
group remained untreated for 3 years and received subsequently the same GH treat-
ment as the GH-group.
Biosynthetic GH (r-hGH NorditropinR, Novo Nordisk A/S, Denmark) was given sub-
cutaneously once daily at bedtime.Three-monthly, the GH dose was adjusted to the
calculated body surface area.
Anthropometric measurements
Every 3 months height (H) and weight (W) were measured by two trained investiga-
tors (N.Arends and later on V. Boonstra).The mean of 4 measurements was used for
analysis. Both height and weight were expressed as SD-score for sex and chronologi-
cal age (HSDSCA and WSDSCA) using Dutch references (11). Body mass index (BMI)
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was calculated as weight (in kilogram) divided by square of height (in meters) and was
expressed as SD-score for sex and age (11). Skinfold measurements (SF) of biceps, tri-
ceps, subscapular and suprailiacal were measured in all children using a Holtain skin-
fold calliper by the same two investigators (NA and VB) (13).The mean value of two
measurements was calculated. For analysis we used the sum of the four measure-
ments, expressed as SD-score using references for healthy Dutch children (14).To cal-
culate SD-scores, data of the reference population were transformed using the LMS
method (15).This method transforms the reference data at each age to a normal 
distribution.
Body composition by DXA
In a subgroup of 38 SGA children living near Rotterdam (20 of the GH group, 8 of
the GHD group and 10 of the control group), bone mineral content (BMC in gram),
fat mass (in gram), % body fat and lean body mass (LBM in gram) were measured by
DXA type Lunar DPX-L PED using the pediatric medium scan mode.The coefficients
of variation for BMC, fat mass and LBM has been reported to be 1.8 %, 4.1 % and 1.0
% respectively (9). Bone mineral density (BMD in g/cm2) measured by DXA is an area
density obtained by dividing BMC (in gram) by the projected bone image (area, cm2).
This method adjust for smaller body sizes since the total bone area is less in shorter
individuals.The coefficient of variation for BMD has been reported to be 0.64 % (16).
Since all parameters of LBM, fat mass, % body fat and BMD were dependent on age
and sex, the values were transformed into SD-scores using Dutch reference values
for children older than 4 years (17,18). Reference values were obtained using the
same instrumentation and software.
Biochemical measurements
Blood samples from all children were taken at the start of the study and subsequently
every 12 months for determination of serum IGF-I levels.After centrifugation, all
samples were frozen (-20 C) until assayed.
Hormone assays
A specific RIA measured IGF-I after acid chromatography as described previously
(19,20). Serum IGF-I levels were expressed as SD-scores using reference data from
healthy Dutch children (19,21).
Statistics
Of 104 children 5 children dropped out of the study for the following reasons: one
child was very disappointed she was randomized into the control group, 3 children
had psychological problems with the daily GH injections and in 1 child coeliac disease
was diagnosed. Since these children dropped out either at start or during the first
year of the study, these children were excluded from baseline and 3-year analysis.
Therefore, 99 children (46 boys and 53 girls) were eligible for statistical analysis. Data
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are expressed as the mean plus or minus the standard deviation (SD). SD-scores
were compared with zero using Student's one sample t-test. Differences between
groups were tested using independent Student's t-tests. Differences in 1-year changes
between the groups were tested using analysis of covariance and differences between
points in time within the groups were tested by paired Student's t-tests. Pearson’s
correlation coefficient was used for correlations. Multiple regression analysis was used
to assess multivariate relationships. Statistical significance was defined as p < 0.05.
Statistical tests were performed with use of SPSS package (version 10.0).
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Results
At baseline
Table 1 shows the baseline characteristics of all children in the GH-, control and
GHD-group. Since DXA’s were performed in a subgroup of children, their baseline
characteristics are shown as well.At the start of the study no significant differences
were found between the 3 groups in either the total or the subgroup.Also, the DXA
subgroup did not differ significantly from the total group. Results of children with SRS
did not differ from results of children without signs of SRS (data not shown).
During the 3-year study period, puberty started in 4 children of the GH-group, in 2
children of the control group and in 2 children of the GHD group.Analyses were per-
formed in prepubertal children only.
Height, height velocity and weight 
GH treatment resulted in a normalisation of height in both the GH- and the GHD-
group. In the GH-group height SDS increased from –3.0 SDS at start to –1.3 SDS
after 3 years (p<0.001) and in the GHD-group height SDS increased from –3.4 SDS
to –1.2 SDS (p<0.001). Changes in height SDS did not differ between the GH- and
the GHD-group.The untreated control group showed only a slight increase in height
SDS during the 3 year study period (–3.2 at start to –2.9 SDS; p<0.001).
Height velocity (HV), expressed as cm/year, during the first study year, was significant-
ly higher in the GH- and the GHD-group compared to the control group (10.3, 11.6
and 5.9 cm/yr respectively; both p<0.001). During the third year, HV decreased to 6.9
in the GH-group, 7.4 in GHD-group and 5.0 in the untreated control group. However,
HV was still significantly higher in the GH-treated groups versus the control group
(both p<0.001).
Table 1 
Baseline characteristics
Randomized study Comparison cohort
GH group Control group GHD group
Total group Subgroup Total group Subgroup Total group Subgroup  
DXA DXA DXA
n=61 n=20 n=26 n=10 n=12 n=8
Boys / girls 25 / 36 7 / 13 16 / 10 6 / 4 5 / 7 4 / 4
Gestational age (wks) 36.1 (3.9) 35.4 (3.2) 36.0 (3.6) 36.3 (2.7) 35.9 (3.6) 36.5 (2.6)
Birth length SDS -3.4 (1.5) -3.3 (1.6) -3.1 (1.3) -3.2 (1.4) -3.5 (2.0) -4.0 (2.5)
Birth weight SDS -2.3 (1.2) -2.3 (1.4) -2.7 (1.0) -2.7 (1.0) -2.5 (1.2) -2.8 (1.0)
Chronological age (yr) 6.0 (1.6) 6.0 (1.4) 5.9 (1.5) 6.0 (1.7) 5.2 (1.4) 5.6 (1.5)
Height SDSCA -3.0 (0.6) -3.0 (0.6) -3.2 (0.5) -3.2 (0.5) -3.4 (0.8) -3.4 (0.8)
Weight SDSCA -3.1 (0.9) -2.9 (0.7) -3.0 (0.8) -3.1 (0.8) -3.1 (1.3) -3.2 (1.5)
TH SDS -0.5 (0.8) -0.5 (0.7) -0.6 (0.7) -0.7 (0.6) -0.5 (0.7) -0.5 (0.7)
Silver Russell syndrome (n) 6 2 5 2 2 2
All values are expressed as mean (SD) or number
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In the GH- and the GHD-group weight SDS increased significantly during 3 years of
GH treatment, from –3.1 SDS to –1.4 SDS (p<0.001) and from –3.1 SDS to –1.1 SDS
(p<0.001), respectively.Weight SDS in the control group increased only slightly from
–3.0 SDS at start to –2.8 SDS after 3 years (p=0.04).
Fat mass and lean body  mass (LBM) by DXA
We compared the GH-group versus the untreated control group and used the non-
randomized GHD-group as a comparison-cohort only. Remarkably, at start of the
study no differences in LBM and fat mass were observed between SGA children with
and without GHD.
At start of the study, the SD-scores of lean body mass (LBM), fat mass and %
body fat were significantly lower than zero in all 3 groups (Table 2). LBM was most
severely reduced, with a mean level being significantly lower than –2.0 SDS (p<0.001).
Table 2 
Three year changes in LBM SDS, fat mass SDS, % body fat SDS and BMD SDS of the GH-, the control and the GHD group.
Randomized study Comparison cohort
GH-group Control group GHD-group
n=20 n=10 n=8
LBM SDS
At start -2.7 (0.5)1 -2.7 (0.5)1 -3.0 (1.2)1
1 year -1.8 (0.5)1 -2.6 (0.4)1,* -2.0 (1.0)1
2 years -1.3 (0.5)1 -2.8 (0.4)1,* -1.4 (0.9)2
3 years -1.1 (0.6)1 -3.0 (0.3)1,* -1.1 (0.9)2
Fat mass SDS
At start -1.4 (0.5)1 -1.3 (0.7)1 -1.5 (0.6)1
1 year -1.6 (0.5)1 -1.2 (0.5)1,# -1.6 (0.2)1
2 years -1.3 (0.5)1 -1.0 (0.8)1 -1.4 (0.6)1
3 years -1.2 (0.4)1 -1.1 (0.8)1 -1.4 (0.7)2
% Body fat SDS
At start -1.1 (0.8)1 -1.1 (1.0)2 -1.2 (0.9)2
1 year -1.7 (0.7)1 -0.9 (0.9)2,# -1.8 (0.3)1
2 years -1.3 (0.7)1 -0.6 (1.3) -1.6 (0.8)1
3 years -1.2 (0.6)1 -0.6 (1.4) -1.5 (0.8)2
BMD SDS
At start -0.8 (1.0)1 -0.9 (1.1)1 -1.3 (1.2)2
1 year -0.5 (0.9)2 -1.0 (1.2)2 -0.8 (0.6)2
2 years 0.2 (0.7) -0.8 (1.0)2,* -0.2 (0.3)
3 years 0.2 (0.8) -0.9 (0.8)2,* 0.1 (0.5)
IGF-I SDS
At start -0.3 (1.0) -0.2 (1.1) -1.3 (1.7)*
3 year 1.7 (1.2)1 -0.3 (1.3)* 0.5 (1.0)
All values are expressed as mean (SD)
1 = significantly different compared to zero (p<0.005)
2 = significantly different compared to zero (p<0.05)
* = significantly different compared to the GH-group (p ≤ 0.005)
# = significantly different compared to the GH-group (p ≤ 0.05)
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LBM increased impressively during GH treatment (p<0.001) but remained unchanged
in the control group (Figure 1). Before GH treatment 19 of 20 children (95 %)
showed a LBM SDS below –2.0, whereas after 3 year of treatment only 1 of the 20
children (5 %) had a LBM SDS lower than –2.0.
Both fat mass and % body fat showed a decrease after 1 year of GH treatment
(p=0.09 and p=0.002 respectively) followed by an increase to levels which were not
different from baseline levels. Before GH treatment fat mass SDS was in 1 of the 20
children (5 %) lower than –2.0 SDS and % body fat SDS was also in only 1 child (5 %)
below –2.0.After 3 years of GH treatment none of the children had a fat mass below
–2.0 SDS, whereas two out of 20 children (20) had a % body fat SDS of –2.0 SDS.The
control group showed a moderate increase in % body fat during 3 year (p=0.04),
whereas the amount of fat mass remained the same.
Bone mineral density (BMD ) by DXA
For DXA analysis we compared the GH-group versus the untreated control group.
Since the GHD-group was not randomized and rather small, this group was used as a
comparison-cohort only. However, at start of the study no differences in BMD SDS
were found between the SGA children with and without GHD.
Mean BMD SDS at start of the study was significantly lower compared to zero
in all 3 groups (Table 2). GH-treatment resulted in a significant increase in BMD SDS
(p=0.001).After 2 years of GH treatment mean BMD had normalized in both the
GH- and the GHD- group. Mean BMD SDS of the control group remained un-
changed.At baseline, 3 out of 20 children (15%) had a BMD SDS below –2 SDS 
whereas after 3 years all children had a BMD SDS in the normal range.
Body composition by skinfold thickness and BMI
At start of the study, the sum of 4 skinfolds expressed as SD-score (‘skinfolds’), was
significantly lower compared to zero in all groups (Table 3). Skinfolds showed a signifi-
cant decrease during the first year of GH treatment (p<0.001) which stabilised during
the second and third year of treatment.After 3 years of GH treatment skinfolds of
the GH-group and the GHD-group were lower compared to the skinfolds at start
(p=0.04 and p=0.07 respectively). Skinfolds of the control group did not change
during the 3 year study period.
BMI SD-score at start of the study was also significantly lower compared to
zero in all 3 groups. BMI of both the GH-group and the GHD group showed a signifi-
cant increase after 3 years (p<0.001 and p=0.04 respectively) whereas BMI of the un-
treated control group remained unchanged.
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Figure 1.
Changes in LBM (a), Fat mass (b), % body fat (c), BMD (d), skinfolds (e) and BMI (f) of 
the GH-group (black bars), the untreated control group (open bars) and the GHD-group (grey bars).
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Correlations
For investigating relationships between different parameters of body composition and
serum IGF-I levels, all correlations were corrected for sex and age.
At start of the study fat mass and LBM correlated positively with serum IGF-I levels
(r=0.4, p=0.04 and r=0.3, p=0.05, respectively). No correlation was found between
BMD and IGF-I.
In order to investigate if skinfolds and BMI are accurate estimates of body
composition in these children, we investigated their relation to DXA which is consi-
dered to be the ‘gold standard’. Skinfolds correlated strongly with fat mass (p=0.8;
p<0.001) but not with LBM. BMI, however, correlated with both fat mass and LBM
(r=0.6, p<0.001; r=0.5, p=0.008). Neither skinfolds nor BMI correlated with serum
IGF-I levels.
The increase in LBM correlated strongly with changes in IGF-I (r=0.6, p=0.002)
but not with changes in skinfolds or BMI.The 3-year change in fat mass correlated
moderately with changes in skinfolds (r=0.4, p=0.05) but not with changes in BMI.The 
3-year change in BMD SDS did not correlate with the change in IGF-I SDS.
Table 3 
Three year changes in skinfold thickness and BMI of the GH-, the GHD and the control group.
Randomized study Comparison cohort
GH-group Control group GHD-group
Total group Subgroup Total group Subgroup Total group Subgroup 
DXA DXA DXA
n=56 n=20 n=24 n=10 n=10 n=8
Skinfolds SDS
At start -1.2 (0.6)1 -1.3 (0.6) -1.0 (1.1)1 -1.4 (1.1) -1.1 (0.7)1 -0.6 (1.5)
1 year -1.9 (0.5)1 -2.0 (0.6) -1.0 (1.1)1,* -1.4 (0.8) -1.7 (0.6)1 -1.5 (1.0)
2 years -1.6 (0.5)1 -1.7 (0.5) -0.9 (1.2)1,* -1.1 (1.0) -1.6 (0.7)1 -1.4 (1.2)
3 years -1.5 (0.7)1 -1.4 (0.6) -1.0 (1.3)1 -1.3 (0.9) -1.5 (0.7)1 -1.0 (1.3)
BMI SDS
At start -1.4 (0.9)1 -1.1 (0.9) -1.0 (0.9)1 -1.1 (0.9) -1.0 (1.1)2 -1.0 (1.3)
1 year -1.2 (0.9)1 -0.9 (0.7) -0.9 (0.8)1 -1.0 (0.8) -0.8 (0.9)2 -0.9 (1.1)
2 years -1.0 (0.8)1 -0.8 (0.7) -1.2 (1.1)1 -1.5 (1.1) -0.6 (0.8)2 -0.7 (1.0)
3 years -0.8 (0.9)1 -0.7 (0.7) -1.2 (1.1)1 -1.3 (1.3) -0.5 (0.7) -0.3 (0.9)
All values are expressed as mean (SD)
1 = significantly different compared to zero (p<0.005)
2 = significantly different compared to zero (p<0.05)
* = significantly different compared to the GH-group (p ≤ 0.005)
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Discussion
This is the first controlled GH treatment study investigating body composition
by DXA in a group of short children born SGA before and during GH treatment.We
demonstrated that at start of the study lean body mass (LBM), total body fat and
bone mineral density (BMD) of short SGA children were significantly lower compared
to normal children.
‘Leanness’ is a very broad term often used in short SGA children indicating
they are very thin. However, until now, this characteristic was mainly based on either
a low BMI or a reduction in skinfold thickness (7). Leger et al investigated body com-
position of these children measuring fat and muscle mass on a cross-sectional area of
the thigh by Magnetic Resonance Imaging (MRI) and found a reduction in both fat and
muscle mass (6). However, this method does not measure total body muscle and total
body fat. DXA has been described as a very precise method to investigate lean body
mass (LBM), fat mass and bone mineral density (BMD) of the whole body using a low
radiation dose (22).The present study, therefore, enables us to better specify the
leanness of these children.
We found that at start of the study both LBM and total body fat were signifi-
cantly lower compared to children of the same age and sex. Surprisingly, we did not
detect any differences in either total body fat or LBM between short SGA children
with or without GHD.This confirms the clinical observation that short SGA children
with GHD do not show the typical GHD appearance of truncal obesity which is a
well known feature of children with GHD.Apparently, in short SGA children who are
GHD, SGA related leanness dominates their typical GHD appearance.These data also
demonstrate that in SGA children the diagnosis of GHD based on GH provocative
tests alone is not reliable to predict body composition typical for GHD.
Another interesting finding was the fact that at start of the study all short SGA
children either with or without GHD, showed a more severe reduction in LBM than
in total body fat. So, leanness in these short SGA children can be specified into a 
marked reduction in muscle mass and to a lesser extent a reduction in total body fat.
Since our results were compared to healthy age- and sex matched children with a
normal height, part of the reduction in LBM and fat mass in these short SGA children
can be explained by their short stature.
Epidemiological studies have found that adults, who were born with a low birth
weight, have an increased risk of developing type 2 diabetes mellitus, hypertension and
cardiovascular diseases later in life (23-25).Although the precise mechanism under-
lying this association is not known, it is thought that hyperinsulinism and insulin 
resistance play an important role in the pathogenesis of type 2 diabetes mellitus and
cardiovascular disease (26,27).The fetal program hypothesis supposes insulin resistance
occurs as a result of undernutrition during a critical period in fetal life (28). During
fetal malnutrition glucose is only available for growth of vital organs, such as the brain
and the heart, at the expense of muscle mass.This could be an explanation for the
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reduction in muscle mass, observed in short SGA children. In turn, the severely 
reduced muscle mass may play a role in the reduced insulin sensitivity which was
found in a comparable group of short prepubertal children born SGA (29,30).
By calculating BMD an area density is obtained by dividing BMC (in gram) by
the projected bone image (area, cm2).This adjust for smaller body sizes and therefore
partly corrects for the short stature of these children.At baseline we found a signifi-
cant reduction in mean bone mineral density.This suggests that other factors besides
height might also play an important role. It is well known that muscles form a large
part of the load on bone and therefore have a stimulatory effect on bone mass.
Indeed, we found a severe reduction in LBM at start of the study.We suggest that
part of the reduction in BMD in short SGA children may be explained by a reduced
muscle mass. Other possible causes may comprise low serum IGF-I levels and a low
nutritional intake since most parents report a poor dietary intake.
GH treatment resulted in an impressive increase of LBM. In contrast, total
body fat reduced during the first year of GH treatment and remained stable there-
after.These findings are comparable to the effects of GH treatment in GHD children
and adults (5,31,32).
During GH treatment BMD increased significantly.This observed increment in
BMD could be either a result of the increase in muscle mass, taller stature or a more
direct effect of GH on bone. Furthermore, a better nutritional intake and increased
physical activity during GH treatment, as was reported by parents, might also have
played a role in the increase of BMD.
Both skinfold thickness and BMI are generally used tools for estimating body
composition. In our study, we compared these methods to results obtained by DXA,
which is considered as the ‘gold standard’. Skinfold measurements assess subcutane-
ous fat only, in contrast to BMI, which estimates both total body fat and LBM.At start
of the study the sum of 4 skinfolds correlated strongly with total body fat measured
by DXA whereas BMI did not differentiate as it correlated both with total body fat
and LBM. During GH treatment changes in skinfolds did correlate with changes in
total body fat measured by DXA but changes in BMI neither correlated with changes
in LBM nor with changes in total body fat. Our findings implicate that measuring skin-
fold thickness before and during GH treatment gives a good estimate of total body
fat in short SGA children. Moreover, measuring skinfolds is cheap and easy to per-
form. Conversely, BMI can not distinguish between total body fat and LBM. For that
reason BMI is not an accurate estimate of body composition, at least in short SGA
children. In addition, BMI is not a useful tool to investigate changes in body composi-
tion during GH treatment.
In conclusion, leanness in short children born SGA can now be specified as a
reduction in LBM and to a lesser extent in a reduction of total body fat. BMD was
significantly reduced in these children. During GH treatment LBM and BMD increased
significantly, whereas total body fat decreased during the first year and remained 
stable thereafter. Our study also indicates that, in contrast to BMI, measuring skinfold
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thickness gives a reliable estimate of total body fat in short SGA children both before
and during GH treatment.
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Abstract
Although short SGA children appear to have normal body proportions, objective data
both before and during GH treatment are very limited.Therefore we investigated in a
large group of short children born small for gestational age (SGA), the effects of GH
treatment versus no treatment on head circumference and body proportions.
Furthermore, we studied differences in linear growth and head circumference
between SGA children born with a low birth length and birth weight (SGAL+W) and
SGA children born with a low birth length only (SGAL).
The present study is an  open-labelled, GH-controlled, multicenter study for 3
years. Non-growth hormone deficient short SGA children (n=87), with a mean (SD)
age of 5.9 (1.5) years, were randomised to either a GH-group (n=61), receiving GH in
a dose of 33 µg/kg/day, or an untreated control group (n=26). Height, weight, HC,
sitting height, armspan and hand, tibial and foot size were measured and expressed as
SDS adjusting for sex and age.
At baseline all anthropometric measurements, except HC SDS, were significant-
ly lower than –2 SDS. During GH treatment all anthropometric measurements nor-
malised in accordance to the normalisation of height SDS.At start of the study, mean
HC SDS was significantly lower in SGAL+W children compared to SGAL children
(p=0.006). Interestingly, most children (14 out of 16) with a HC SDS below –2.00 had
been born SGAL+W. During GH treatment, the 3-year increase in height, HC and
other anthropometric measurements was comparable between SGAL+W and SGAL
children. In both SGAL+W and SGAL controls, no changes in SD-scores of height, HC
and other anthropometric measurements were found during the 3-year follow-up
period.
Untreated short SGA children have normal body proportions with the exception of
HC which is relatively large in many of these children. SGAL+W children still had a
smaller HC at the age of 5.9 years compared to SGAL children.Three years of GH
treatment induced a proportionate growth resulting in a normalization of height and
other anthropometric measurements, including HC, in contrast to untreated SGA
controls.
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Introduction
Short stature occurs in 10-15 % of the children who were born small for gestational
age (SGA) (1,2).The pathophysiology underlying this insufficient catch-up growth is
still unknown but disturbances in the growth hormone (GH)/insulin-like growth 
factor-I (IGF-I) axis may play a role (3,4).
Several studies have shown beneficial effects of growth hormone (GH) treat-
ment on height in these short children (5-7). GH treatment resulted in a significant
increase in height to values within the normal range followed by growth along the
target height (TH) percentile.
Although short children born SGA appear to have normal body proportions,
objective data are limited. Sas et al reported in a group of short SGA children a nor-
malisation of body proportions during GH treatment with either a dose of 1 or 2
mg/m2 body surface area/day (8). Since this study did not comprise an untreated 
control group, a causal effect of GH treatment on the normalisation of body propor-
tions could not be proven.There are no data on longitudinal changes of body propor-
tions in short untreated SGA children.
In most GH-trials in short SGA children SGA is defined on either birth length
and birth weight alone or both. None of the GH trials have investigated differential
effects of GH on growth and hormonal changes in those SGA children who have
been either born with both a low birth length and a low birth weight (SGAL+W) or
those born with a low birth length only (SGAL). It is generally thought that in those
born SGAL+W growth restriction occurred early in gestation while in SGAL new-
borns this occurred later in gestation. It has been reported that during childhood
SGA children have, in general, a smaller head circumference compared to AGA 
children (9,10). No data are available on head circumference in short SGA children
before and during GH treatment.
We present the results of a randomised, 3-year controlled GH-trial studying
head circumference and body proportions in short SGA children at baseline and
during 3 years of GH treatment in comparison with results of untreated short SGA
children. Furthermore, we studied linear growth and head circumference in SGAL+W
versus SGAL children. Our study is the first one differentiating between SGA children
who had been proportionately (SGAL+W) or disproportionately (SGAL) small at
birth.
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Patients and methods
Subjects
The study comprised 91 Dutch children (43 boys and 48 girls) with short stature
born SGA.All children fulfilled the same inclusion criteria: 1) birth length standard
deviation score (SDS) below – 2.00 for gestational age (11); 2) an uncomplicated neo-
natal period, without signs of severe asphyxia (defined as Apgar score below 3 after 5
minutes), sepsis or long-term complications of respiratory ventilation such as 
bronchopulmonary dysplasia; 3) chronological age (CA) between 3.00 and 7.99 years
at start of the study; 4) height SDS for age below –2.00 according to Dutch standards
(12); 5) height velocity SDS for age below zero to exclude children with spontaneous
catch-up growth; 6) prepubertal, defined as Tanner stage 1 or a testicular volume < 4
(13); 7) sufficient GH response to a GH-stimulation test with either clonidine or 
arginine, which was defined as a GH peak above 10 µg/l; 8) normal liver, kidney and
thyroid functions. Children with endocrine or metabolic disorders, chromosomal
defects and growth failure caused by other syndromes (e.g. emotional deprivation,
Turner syndrome, severe chronic illness, chondrodysplasia), with the exception of
Silver-Russell syndrome were excluded.
The study was approved by the Ethics Committees of all nine participating centers.
Written informed consent was obtained from the parents or custodians of each child.
Study design
The study design is an open-labelled multicenter study with a randomised control
group.All children (n=91) were stratified according to age (3.00-5.50 versus 5.50-
7.99) and height of the parents (height of both parents above –2.00 SDS versus height
of at least one parent below –2.00 SDS).After stratification the patients were rand-
omly assigned to either the GH-group (2/3 of children) or the control group (1/3 of
children).The GH-group (n=64; 27 boys and 37 girls) started immediately with GH
treatment at a dose of 1 mg/m2 body surface area/day (~33 µg/kg/day).The control
group (n=27; 16 boys and 11 girls) remained untreated for 3 years and subsequently
received the same GH treatment as the GH-group. Biosynthetic GH (r-hGH
NorditropinR, Novo Nordisk A/S, Denmark) was given subcutaneously once daily at
bedtime.Three-monthly, the GH dose was adjusted to the calculated body surface
area.
Anthropometric measurements
Standing height was measured 3-monthly by two trained investigators (NA, later VB)
using a Harpenden stadiometer and values were expressed as SD-score for sex and
chronological age (height SDS) using Dutch references (12).Target height (TH) was
calculated using Dutch reference data according to the formula:1/2 * (Hfather +
Hmother + 13) + 4.5 for boys and 1/2 * (Hfather + Hmother - 13) + 4.5 for girls,
where the addition of 4.5 cm represents the secular trend.TH was expressed as SD-
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score using Dutch references (12).Weight for height was used as a measure of body
composition since body mass index (BMI) is not an accurate estimate of body com-
position during GH treatment in short SGA children (Arends et al, submitted).WH
was expressed as SD-score for sex and age (12). Head circumference (HC) was
measured 3-monthly and expressed as SD-score for sex and age (12).
Sitting height (SH) was measured every 6 months using a Harpenden sitting height
table. Every 6 months armspan (armspan), the length of the left hand (hand), left foot
(foot) and left tibia (tibia) were measured by the same investigators using a
Harpenden anthropometer.All measurements were expressed as SD-score (SDS)
adjusting for sex and age. Reference data were available from the Dutch Oosterwolde
study which consisted of 1240 healthy boys and 1093 healthy girls (14).
Definition of SGAL+W and SGAL
SGAL+W was defined as a birth length and a birth weight ≤ -2.00 SDS for gestational
age (1,11). SGAL was defined as a birth length ≤ -2.00 and a birth weight > -2.00 SDS
for gestational age.
Statistics
Of 91 children 4 children dropped out of the study for the following reasons: one
child was very disappointed she was randomized into the control group, 2 children
had psychological problems with the daily GH injections and in 1 child coeliac disease
was diagnosed. Since these children dropped out either at start or during the first
year of the study, these children were excluded from baseline and 3-year analysis.
Therefore, 87 children were included for statistical analysis.
During the 3-year study period, puberty started in 4 children of the GH-group and in
2 children of the control group.Analysis was performed in prepubertal children only.
As soon as a child entered puberty he or she was excluded from further analysis.
Data were expressed as the mean plus or minus the standard deviation (SD). SD-
scores were compared with zero using Student's one sample t-test. Differences
between groups were tested using independent Student's t-tests. Differences in 1-year
changes between the groups were tested using analysis of covariance and differences
between points in time within the groups were tested by paired Student's t-tests.
Spearman’s correlation coefficient was used for correlations. Statistical significance
was defined as p < 0.05. Statistical tests were performed with use of SPSS package
(version 10.0).
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Results
Table 1 shows the baseline characteristics of the total, the GH- and the control
group.At baseline no significant differences were found between the 2 groups.
Thirteen children had Silver-Russell syndrome. Results of children with SRS did not
differ from results of children without signs of SRS (data not shown).
At baseline no significant differences in anthropometric measurements were
found between the 2 groups (Table 2).All anthropometric measurements, except HC
SDS, were significantly lower compared to –2 SDS. Remarkably, HC SDS was the least
affected part of the body and was not significantly lower than –2.00 SDS. Sixteen of
87 children (18 %) had a HC SDS ≤ -2.00. Height SDS, SH SDS and foot SDS were
most severely reduced. Height SDS correlated significantly with SH (r=0.6; p<0.001),
foot (r=0.6; p<0.001), tibia (r=0.7; p<0.001) and armspan (r=0.5; p<0.001). However,
height SDS did neither correlate with hand nor with HC SDS.
During GH treatment the size of the measured body parts expressed as SDS showed
an increment towards zero (Figure 1).After 2 years of GH treatment, the mean
height, SH and foot SDS had normalised (i.e. >-2.00 SDS), whereas the mean hand,
tibial and armspan had normalised after 1 year of GH treatment. In contrast, anthro-
pometric measurements of the untreated control group remained unchanged or
showed only a slight increase during the study period. In the GH-group, 3-year 
changes in height correlated significantly with changes in SH (r=0.5; p<0.001), foot
(r=0.5; p<0.001), tibia (r=0.5; p<0.001), armspan (r=0.3; p<0.03) and HC (r=0.5;
p<0.001), but not with changes in hand SDS.
SGAL+W versus SGAL
SGAL+W children had significantly lower values for gestational age, birth length SDS,
birth weight SDS and birth HC SDS compared to SGAL children (Table 3).
Interestingly, at baseline, at a mean (SD) age of 5.9 (1.5) years, mean height SDS had
become comparable for SGAL+W and SGAL children but the mean HC SDS was still
significantly lower in SGAL+W children compared to SGAL children (-1.3 (0.8) versus
–0.8 (0.9), p=0.006).At baseline, 14 out of 55 SGAL+W children had a HC SDS ≤ -2.0
in contrast to 2 out of 32 SGAL children (25 % versus 6 %; p<0.001).Also,WH SDS
was significantly lower in SGAL+W children (-1.8 (1.0) versus –0.8 (0.9), p<0.001).
Three years of GH treatment induced a significant increase in height, weight and HC
SDS which was similar for SGAL+W and SGAL children. HC SDS, however, remained
still lower in SGAL+W children compared to SGAL children after 3 years of GH 
treatment, albeit the difference did not reach level of significance.The 3-year change
in HC SDS correlated negatively with age at start of GH treatment in both SGAL+W
and SGAL children (r=0.4; p=0.01 and r=0.7; p<0.001).Thus, the younger they started
GH treatment the greater the increase in HC SDS.After 3 years of GH treatment
WH SDS was still significantly lower in the SGAL+W group compared to the SGAL
group.
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In SGAL+W and SGAL controls no changes in height, weight and HC SDS were
found during the 3-year follow-up period.
The SD-scores for SH, hand, tibia, foot and armspan did not differ between SGAL+W
and SGAL children, neither at start of the study nor after 3 years of GH treatment
(data not shown).
Table 1 
Clinical data of the total group (n=87)
Total group GH group Control group
n=87 n=61 n=26
Boys / girls 41 / 46 25 / 36 16 / 10
Gestational age (wks) 36.1 (3.7) 36.1 (3.9) 36.0 (3.6)
Birth length SDS -3.5 (1.4)# -3.4 (1.5)# -3.1 (1.3)#
Birth weight SDS -2.4 (1.2)# -2.3 (1.2)† -2.7 (1.0)†
Birth HC SDS -1.8 (1.4)* -1.7 (1.5)* -1.9 (1.4)*
Chronological age (yr) 5.9 (1.5) 6.0 (1.6) 5.9 (1.5)
TH SDS -0.5 (0.8)* -0.5 (0.8)* -0.6 (0.7)*
Silver Russell syndrome (n) 11 6 5
All values are expressed as mean (SD) or number
* = significantly lower than zero (p<0.001)
# = significantly lower than –2.00 SDS (p<0.001)
† = significantly lower than –2.00 SDS (p<0.05)
Table 2 
Baseline anthropometric measurements of the total group (n=87).
Total group GH group Control group
n=87 n=61 n=26
Height SDS -3.1 (0.6)# -3.0 (0.6)# -3.2 (0.5)#
SH SDS -3.0 (0.7)# -3.0 (0.8)# -3.0 (0.6)#
Foot SDS -3.0 (0.7)# -3.0 (0.7)# -3.1 (0.8)#
Armspan SDS -2.5 (0.7)# -2.4 (0.7)# -2.6 (0.7)#
Tibia SDS -2.3 (0.6)# -2.2 (0.6)† -2.3 (0.6)†
Hand SDS -2.2 (0.7)† -2.2 (0.7)* -2.2 (0.7)*
HC SDS -1.0 (0.8)* -0.9 (0.9)* -1.1 (0.8)*
All values are expressed as mean (SD)
* = significantly lower than zero (p<0.001)
# = significantly lower than –2.00 SDS (p<0.001)
† = significantly lower than –2.00 SDS (p<0.05)
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Figure 1.
Changes in height (a), SH (b), armspan (c), hand (d), tibia (e) foot (f) and HC (g) of the GH- (black bars) and the untreated control
group (open bars).
1 = significantly different from zero (p<0.001)
a = significantly different towards baseline value (p<0.001)
b = significantly different towards baseline value (p<0.01)
* = significantly different between the GH- and the control group (p<0.001)
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Table 3 
Gestational age and anthropometric measurements in SGAL+W and SGAL children who were either treated with GH (GH-group)
or untreated (controls).
SGAL+W SGAL 
GH-group Controls GH-group Controls
n = 35 n = 20 n = 26 n = 6
At birth
Gestational age (wks) 34.7 (4.1)* 35.3 (3.5) 37.9 (2.5) 38.5 (2.6)
Birth length SDS -4.3 (1.4)* -3.5 (1.3)† -2.2 (0.6) -1.9 (0.6)
Birth weight SDS -3.2 (0.7)* -3.0 (0.7)* -1.2 (0.8) -1.4 (0.6)
Birth HC SDS -2.4 (1.5)* -2.2 (1.1) -0.9 (1.0) -0.9 (1.9)
At start of study
Age 5.7 (1.7) 5.7 (1.6) 6.3 (1.3) 6.7 (0.9)
Height SDS -3.0 (0.7) -3.2 (0.6) -3.0 (0.6) -3.1 (0.4)
Weight SDS -3.4 (1.0)† -3.2 (0.9)# -2.7 (0.6) -2.5 (0.5)
HC SDS -1.3 (0.8)# -1.3 (0.9) -0.8 (1.0) -0.9 (0.6)
WH SDS -2.0 (1.0)* -1.5 (1.1)# -0.9 (0.8) -0.4 (0.8)
After 3 yrs
Height SDS -1.2 (0.7)1 -2.9 (0.6) -1.4 (0.8)1 -2.9 (0.4)
Weight SDS -1.5 (1.0)1 -3.0 (1.1) -1.1 (0.6)2 -2.1 (0.7)
HC SDS -0.7 (0.9)3 -1.3 (0.8) -0.3 (1.0)3 -1.2 (0.5)
WH SDS -0.9 (1.1)† -1.1 (1.1)# -0.2 (0.8) 0.2 (1.2)
3-year changes in
Height SDS 1.8 (0.4)1 0.3 (0.3) 1.6 (0.4) 1 0.2 (0.3)
Weight SDS 1.9 (0.8)#1 0.2 (0.4) 1.6 (0.4) 1 0.4 (0.7)
HC SDS 0.6 (0.5)1 0.0 (0.3) 0.5 (0.5) 1 -0.3 (0.2)
WH SDS 1.0 (1.0)3 0.4 (0.5) 0.7 (0.5) 0.6 (0.8)
SGAL+W: birth length and birth weight ≤-2.00
SGAL: birth length ≤ -2.00 and birth weight > -2.00
Differences between SGAL+W and SGAL children (in the GH- and control group) 
(* = p ≤ 0.001; † = p ≤ 0.01; # = p<0.05)
Differences between the GH- and control group (in SGAL+W and SGAL children) 
(1 = p ≤ 0.001; 2 = p ≤ 0.01; 3 = p<0.05)
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Discussion
Short children born SGA show a reduced size of their sitting height (SH), armspan,
tibial-, foot- and hand size, which is in proportion to their reduced height. Children
who were treated with GH for 3 years had a normalisation of their height in contrast
to children who remained untreated for 3 years. In the GH-treated children sitting
height, armspan, tibial, foot and hand SDS increased in concordance with their increase
in height SDS indicating that body proportions remained normal during 3 years of
GH treatment. Conversely, height and other anthropometric measurements remained
unchanged in the untreated control group.Therefore, the present study now demon-
strates that the observed changes in various body parts of GH-treated children are
the result of GH treatment. Our results agree with previous findings in a comparable
group of short SGA children (8). In that study, however, all children received GH 
treatment and therefore no conclusions could be drawn concerning a causal effect of
GH treatment on changes in body proportions.
Interestingly, head circumference (HC) of the total group of short SGA 
children was less affected.While height and all other anthropometric measurements
showed a mean value which was significantly less than –2.0 SDS, the mean HC SDS
was the only parameter showing a value above –2.0 SDS. Of a total of 87 short SGA
children, only sixteen (18 %) had a HC SDS below the normal range, i.e. below –2.0
SDS at a mean (SD) age of 5.9 (1.5) years. Interestingly, most children (14 out of 16)
with a HC SDS below –2.00 had been proportionately small at birth (SGAL+W).
Although the magnitude of spontaneous catch-up growth after birth in HC had been
greater in SGAL+W children compared to SGAL children (+1.0 (1.2) vs 0.0 (1.1);
p<0.001), HC SDS was still significantly lower in SGAL+W children at a mean age of
5.9 years.This finding strongly suggests that short SGA children who have been 
proportionately small at birth have a greater risk for a relatively small HC during
childhood.
During GH treatment HC SDS increased similarly in both SGAL+W and SGAL
children. Since at start of the study HC SDS was significantly smaller in SGAL+W
children, these children still had a smaller HC after 3 years of GH treatment.
Apparently, GH treatment has a similar effect on HC in both SGAL+W and SGAL
children. In contrast, those remaining untreated for 3 years either being born as
SGAL+W or SGAL, had no gain in HC SDS during the 3-year study period.Thus, GH
treatment induces a significant increase in HC SDS in both SGAL+W and SGAL
children.
There has been some debate about the effects of being born SGA on intelli-
gence and behaviour (15). Recently 2 large population-based studies showed lower
school performances in 16- and 20 year olds who were born SGA (10,16). It has also
been reported that a lower intelligence was associated with a smaller HC in SGA
children at various ages (9,17). Lundgren et al found an important association
between both birth length and persistent short stature and subnormal intellectual
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performances (17).The first Dutch SGA study investigated psychological functioning
in a group of short SGA children who had similar inclusion criteria as the present
study (18).This study showed a significant reduction in intelligence and attention and
an increase in behavioural and emotional problems. Both intelligence and attention
were significantly associated with HC during childhood. Our present study shows that
at a mean age of 5.9 years, short SGAL+W children have smaller head circumferences
than SGAL children.These findings suggest that SGAL+W children might have a 
higher risk for lower school achievements and psychological problems. Unfortunately,
our present study did not include intelligence tests.
Since GH treatment results in an increase in HC and HC is associated with
intelligence, we may speculate that GH treatment could have a positive influence on
intellectual performances of short SGA children.Van der Reijden et al did perform
intelligence tests in short SGA children before and after 2 years of GH treatment and
did find a significant increase in Intelligence Quotient (IQ) after 2 years (18).
Unfortunately this study did not include an untreated control group. Our study shows
that the gain in height HC SDS during GH treatment correlated negatively with age at
start.Thus, if GH treatment would stimulate intellectual and psychological develop-
ment of short SGA children, it may be important to start treatment at a young age.
This would especially apply for SGA children who have been proportionately small at
birth since they are particularly at risk for a small HC during childhood.
Gestational age of SGAL+W children was significantly shorter than that of
SGAL children. Despite their shorter gestational age, their birth length, birth weight
and birth HC were more severely reduced suggesting that growth retardation was
more severe or occurred rather early during pregnancy. Possibly, in these SGAL+W
children genetic causes could play a role. Recently, we investigated whether the IGF-I
gene was involved in the phenotype of short children born SGA (19). In a large group
of SGAL+W children allele 191 of the IGF1.PC1 marker, located between exon 2 and
3 of the IGF-I gene, was transmitted more often from parent to child than one would
expect based on Mendelian frequencies. Children carrying this allele had significantly
lower serum IGF-I levels and had a smaller HC at the age of 1.3 years compared to
children not carrying this allele.Thus, this functional IGF-I polymorphism might play a
role in short SGA children who have been born proportionately small.Woods et al
described severe pre- and postnatal growth failure as well as mental retardation in a
child with a partial deletion of the IGF-I gene (20).These studies suggest that IGF-I
plays not only an important role in somatic growth but might also be involved in the
development of neuropsychological functioning. Further research is required to inves-
tigate the role of GH treatment on the increase in HC and its effect on neuropsycho-
logical functioning in SGA children.
In conclusion, untreated short SGA children have generally normal body pro-
portions. Besides height, the sizes of sitting height, armspan, tibial, foot and hand are
all significantly lower than –2.0 SDS. In contrast, head circumference is less severely
affected and therefore relatively large in these children (-1.1 SDS).Those who had
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been born SGAL+W, still had a smaller HC at the age of 5.9 years compared to
those who had been born SGAL.Three years of GH treatment induced a propor-
tionate growth resulting into normalization of both height and other anthropometric
measurements, including HC.
Acknowledgements.
Mrs. E. Lems and mrs. I. van Slobbe, research nurses, are greatly acknowledged for their assi-
stance.The participating centers were: E.C.A.M. Houdijk, Free University Hospital Amsterdam;
J.C. Mulder, Rijnstate Hospital, Arnhem; J.J.J.Waelkens, Catharina Hospital, Eindhoven; R.J.H.
Odink, Beatrix Children's Hospital, Groningen;W.H. Stokvis, Medical University Center Leiden;
C. Rongen-Westerlaken, Canisius-Wilhelmina Hospital, Nijmegen;A.C.S. Hokken-Koelega,
Sophia Children's Hospital, Rotterdam; H.M. Reeser, Juliana Children's Hospital,The Hague;
M. Jansen,Wilhelmina Children's Hospital, Utrecht,The Netherlands.This study was suppor-
ted by Novo Nordisk Farma B.V.,The Netherlands.
nic_7.qxd  13-10-2003  13:39  Pagina 123
124
References
1. Albertsson-Wikland K, Karlberg J 1994 Natural growth in children born small for gestational age with
and without catch-up growth.Acta Paediatr Suppl 399:64-70; discussion 71.
2. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop
SL 1995 Children born small for gestational age: do they catch up? Pediatr Res 38:267-71.
3. de Waal WJ, Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Drop SL 1994 Endogenous
and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children
with short stature after intrauterine growth retardation.The Dutch Working Group on Growth Hormone. Clin
Endocrinol (Oxf) 41:621-30.
4. Boguszewski M, Rosberg S,Albertsson-Wikland K 1995 Spontaneous 24-hour growth hormone profiles
in prepubertal small for gestational age children. J Clin Endocrinol Metab 80:2599-606.
5. Boguszewski M,Albertsson-Wikland K,Aronsson S, Gustafsson J, Hagenas L,Westgren U,Westphal O,
Lipsanen-Nyman M, Sipila I, Gellert P, Muller J, Madsen B 1998 Growth hormone treatment of short children
born small-for-gestational- age: the Nordic Multicentre Trial.Acta Paediatr 87:257-63.
6. de Zegher F, Du Caju MV, Heinrichs C, Maes M, De Schepper J, Craen M,Vanweser K, Malvaux P,
Rosenfeld RG 1999 Early, discontinuous, high dose growth hormone treatment to normalize height and weight
of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 84:1558-61.
7. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 1999 Growth hormone
treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-
blind, dose- response trial. J Clin Endocrinol Metab 84:3064-70.
8. Sas TC, Gerver WJ, De Bruin R, Mulder PG, Cole TJ, De Waal W, Hokken-Koelega AC 2000 Body 
proportions during 6 years of GH treatment in children with short stature born small for gestational age 
participating in a randomised, double-blind, dose-response trial. Clin Endocrinol (Oxf) 53:675-81.
9. Ounsted M, Moar VA, Scott A 1988 Head circumference and developmental ability at the age of seven
years.Acta Paediatr Scand 77:374-9.
10. Strauss RS, Dietz WH 1998 Growth and development of term children born with low birth weight:
effects of genetic and environmental factors. J Pediatr 133:67-72.
11. Usher R, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea level: standards 
obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr
74:901-10.
12. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ,Verloove-
Vanhorick SP,Wit JM 2000 Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr
Res 47:316-23.
13. Tanner JM,Whitehouse RH 1976 Clinical longitudinal standards for height, weight, height velocity, weight
velocity, and stages of puberty.Arch Dis Child 51:170-9.
14. Gerver WJM, De Bruin R 1996 Paediatric Morphometrics:A reference manual. Bunge, Utrecht.
15. Grantham-McGregor SM 1998 Small for gestational age, term babies, in the first six years of life. Eur J
Clin Nutr 52 Suppl 1:S59-64.
16. Larroque B, Bertrais S, Czernichow P, Leger J 2001 School difficulties in 20-year-olds who were born
small for gestational age at term in a regional cohort study. Pediatrics 108:111-5.
17. Lundgren EM, Cnattingius S, Jonsson B,Tuvemo T 2001 Intellectual and psychological performance in
males born small for gestational age with and without catch-up growth. Pediatr Res 50:91-6.
18. van der Reijden-Lakeman I 1996 Growing pains Thesis. Erasmus University Rotterdam, Rotterdam.
19. Arends N, Johnston L, Hokken-Koelega A, Duijn Cv C, Ridder Md M, Savage M, Clark A 2002
Polymorphism in the IGF-I Gene: Clinical Relevance for Short Children Born Small for Gestational Age (SGA).
J Clin Endocrinol Metab 87:2720.
20. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ 1996 Intrauterine growth retardation and post-
natal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335:1363-7.
C
h
ap
ter 7  G
H
 treatm
ent (III)
nic_7.qxd  13-10-2003  13:39  Pagina 124
C
h
ap
ter x  Introduction
125
C
h
ap
ter 8  D
iscu
ssio
nS
A
G
General Discussion
nic_7.qxd  13-10-2003  13:39  Pagina 125
126
General Discussion
The present thesis describes several aspects of a large cohort of short children born
small for gestational age (SGA).The first part of this thesis tried to unravel some of
the late consequences (insulin insensitivity) as well as etiological aspects of being born
SGA.The latter consisting of genetical aspects and morphological details of the 
pituitary region.
The second part of this thesis contains the 3-year results of the randomised,
open-labelled, controlled GH study.This study was started in October 1996 and
patients were included during the following 2 years. Nine different centers partici-
pated in the study and 99 children were included.The effects of GH treatment versus
no treatment on growth, bone maturation, bone mineral density, body composition
and body proportions were investigated.
In this chapter our findings are discussed regarding our present knowledge in
view of the current literature.
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Late consequences of being born SGA
Insulin sensitivity
We found that in short SGA children insulin sensitivity (Si) was reduced to only 38 %
of the levels found in the short AGA controls.As expected the acute insulin response
(AIR) was nearly three times higher in short SGA children compared to the AGA
controls, as compensation for this reduction in Si. In normal subjects a reciprocal 
relationship exists between insulin action and insulin secretion by the pancreatic β-
cell (1). If insulin sensitivity decreases, β-cells will secrete larger amounts of insulin in
order to maintain a normal glucose metabolism. If the β-cells fail to adapt or fail to
maintain the secretion of large amounts of insulin, the risk of developing type 2 
diabetes mellitus increases. Our results show that short prepubertal SGA children
maintained a normal glucose tolerance due to a compensatory increase in insulin
secretion. Since these abnormalities are found in young children it can be questioned
how long it will take before type 2 diabetes will become overt.This important
question can only be answered during long-term follow-up. Glucose effectiveness, the
ability of glucose to enhance its own peripheral uptake and reduce its endogenous
production in the liver independent of insulin, was not significantly different between
the short SGA and AGA children. Our findings agree with results described by
Hofman et al., who also found a reduced insulin sensitivity in a group of 15 short pre-
pubertal SGA children (2). Our results are also comparable to those found in a group
of young adults who were born SGA.(3). In the present study, glucose intolerance was
already subclinically present in one SGA child (4 %).This finding is comparable to the
results described by Sas et al, who found impaired glucose tolerance during an OGTT
in 8 % of another group of 79 short prepubertal SGA children (4).
Leanness is a typical feature of short prepubertal SGA children (5). It is well known
that increasing leanness is associated with a dramatic increase in insulin sensitivity (6).
In contrast to what is to be expected in lean individuals, insulin sensitivity in pre-
pubertal SGA children was significantly reduced. Johnson et al investigated longitudinal
(annual) changes in fat mass, measured by Dual Energy X-ray Absorptiometry
(DEXA), and insulin sensitivity in a cohort of healthy children.They found that a low
insulin sensitivity at a young age was followed by a higher increase in fat mass over
years, independent of sex and pubertal stage (7).This might implicate that lean and
short SGA children with a low Si are at an increased risk of becoming obese in early
or later adulthood. Since a high BMI is one of the features of the metabolic syn-
drome, the observed reduction in insulin sensitivity in SGA children may precede the
changes in body composition occurring in later life.When these children would 
develop overweight, it would worsen their underlying reduced Si, thereby strongly
increasing the risk of type 2 diabetes mellitus.
Short prepubertal children born SGA have asymptomatically a severe reduction in 
insulin sensitivity despite a lean appearance.
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Blood pressure
Our data showed a significantly higher systolic BP in short SGA children compared to
age- and height-matched children (8). In contrast, diastolic BP was not significantly 
different from age- and height-matched children.These data are consistent with pre-
vious data in another group of short SGA children reported by Sas et al., in which
systolic blood pressure was also elevated to levels in the high-normal range (9).
Hypertension in adult life has been associated with a low birth weight (10,11).Also,
studies investigating blood pressure during childhood and early adulthood  have
shown a significant inverse relationship between systolic blood pressure and birth
weight (12,13). Not much is known about the etiology of this relationship. Barker et
al postulated that changes in hemodynamic load during fetal life may alter arterial
structure leading to related to hypertension later in life (10). Brenner et al. hypo-
thesized that poor nephron development could be a link between low birth weight
and hypertension later in life (14). Fetal growth retardation in rats will lead to smaller
kidneys and a reduced number of nephrons (15). Impaired renal development would
result in a reduction of the glomerular filtration surface area.This in turn leads to sys-
temic and glomerular hypertension later in life.As a result glomerular sclerosis could
occur and even worsen the situation by further reducing glomerular filtration surface
area leading to a vicious circle. Since there is evidence that blood pressure is tracking
from childhood to adulthood (16), our results might indicate that short children born
SGA are at increased risk of becoming hypertensive in later life. It has been reported
that a high systolic BP is more important in the pathogenesis of cardiovascular 
disease than a high diastolic BP (17).Therefore, short children born SGA need regular
evaluation of their blood pressure during childhood and adulthood.
During childhood short SGA children have a significantly increased systolic blood 
pressure.
Serum lipids
Fasting serum levels of total cholesterol, triglycerides, LDL and HDL-cholesterol were
all within the normal range.These findings are in agreement with previous reports
(9,18). Our study is the first one investigating fasting serum FFA levels in SGA 
children.We found that the mean fasting serum FFA level was in the high-normal
range, with 6 children (21 %) having levels above the normal range. Recently, an
important role was attributed to FFA in the pathogenesis of type 2 diabetes (19).Two
peptides play an important role in the FFA metabolism.Acylation stimulating protein
(ASP) stimulates FFA uptake by peripheral cells and esterification into TG (20). If ASP
activity is low, serum FFA level will increase. Sniderman et al. found a defect in the
ASP pathway leading to an ineffective FFA storage which in turn will result in insulin
resistance and obesity (21).Thus, a reduction in ASP activity might play a role in the
increased serum FFA levels in these children.Another possibility is an increased activi-
ty of hormone sensitive lipase (HSL). HSL is responsible for hydrolysis of TG, the rate
limiting step in the breakdown of TG in adipocytes (22).A raised activity of HSL will
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result in an increased breakdown of TG followed by an increase in serum FFA levels.
In normal subjects HSL is deactivated by insulin when energy supply is sufficient (23).
If suppression by insulin fails, HSL activity increases which in turn may result in a rise
in serum FFA levels. Several studies postulated that the HSL gene is involved in type 2
diabetes (24-26). Further research is therefore required to study FFA metabolism in
larger groups of SGA children.
Serum lipids, i.e. total cholesterol, triglycerides, LDL and HDL-cholesterol were all 
within the normal range. However, 6 children (21%) had serum FFA levels above the 
normal range.We hypothesize that FFA in short SGA children might play a role in the
development of type 2 diabetes later in life.
Clustering
The present study investigates insulin sensitivity in relation to cardiovascular risk fac-
tors in a group of young children born SGA with short stature. Studies in healthy
children have revealed that insulin sensitivity and fasting insulin levels were related to
blood pressure, serum lipids and obesity (27-29). Epidemiological studies have also
shown that clustering of fasting insulin and risk factors for cardiovascular disease was
already present during childhood and early adulthood (30,31). Since insulin sensitivity,
BMI, blood pressure and serum lipids are known to correlate with one another it is
not correct to investigate correlation coefficients between only two variables. In
order to investigate the underlying relationship between all variables we performed a
cluster analysis.We found two important clusters.The first cluster clearly showed
that insulin insensitivity (1/Si) was related to higher systolic and diastolic blood 
pressure and higher serum FFA levels.This is in concordance with previous epidemio-
logical studies in children and adults reporting an association between low insulin 
sensitivity and cardiovascular risk factors (30,32-34). In contrast to previous reports,
we found a second cluster, consisting of BMI, total cholesterol, LDL-cholesterol and
triglycerides.This second cluster comprised parameters which are known to be 
closely related to obesity. Since our study group was far from obese it is not 
surprising that we did not find clustering of BMI with insulin insensitivity (1/Si). Our
findings may imply that a reduction in insulin sensitivity together with a slight increase
in serum FFA levels and systolic blood pressure are the first abnormalities in the
development of the metabolic syndrome. Our study shows that short SGA children
who are generally lean show signs of pre-diabetes mellitus type 2 which may become
overt when they become overweighed. For that reason it seems particularly 
important to prevent overweight in children born SGA.
Although the metabolic syndrome is an adult disease, our study shows that risk 
factors for the development of type 2 diabetes mellitus and cardiovascular diseases 
are already present during childhood in short children born SGA who are far from 
obese.
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The metabolic syndrome in SGA infants with spontaneous catch-up growth
Since a lot of data regarding the association between diabetes mellitus type 2, cardio-
vascular risk factors and low birth weight are based on epidemiological studies we
have to be careful when extrapolating these results to our study population.A lot of
these studies did not differentiate between individuals with and without postnatal
catch-up growth.The present study comprises SGA children without postnatal catch-
up growth during childhood. Results of studies investigating risk factors for type 2 
diabetes mellitus and cardiovascular disease in SGA individuals with catch-up growth
are rather conflicting.A Swedish study found an increased risk of high systolic blood
pressure in men born SGA, especially if they remained short (35). Postnatal catch-up
growth in height did not further increase this risk in those were born short only
(SGAL). In those who were born both light and short (SGAL+W), postnatal catch-up
growth in height reduced the risk of high systolic blood pressure.Also, linear catch-up
growth in height reduced the risk of overweight in these men born SGA.The effects
of fetal and childhood growth on type 2 diabetes and hypertension in adult life were
also investigated in a Finnish population study.They found that type 2 diabetes was
associated with a low birth weight, a short birth length and thinness at birth, followed
by catch-up growth after birth and accelerated growth in both height and weight to
above average after the age of 7 years (36).Also, they found an association between
hypertension and low birth weight, short body length and thinness at birth followed
by catch-up growth from birth until the age of 7 years in both height and weight up
to average levels (37).The disadvantage of this study is that patients were selected by
disease, i.e. by having either hypertension or type 2 diabetes mellitus.Also, no growth
data were shown from birth until adulthood but only from 7 until 15 years of age, a
growth period were puberty plays a major role.
Thus, it seems that spontaneous catch-up growth in height only, does not increase 
the risk for the development of hypertension and type 2 diabetes mellitus.
Catch-up growth in weight for height, however, may increase the risk for these adult 
diseases.
Further research is needed to investigate the effects of postnatal catch-up growth 
on the development of type 2 diabetes mellitus and cardiovascular disease in 
individuals born SGA.
Genetic research in short SGA children
IGF-I gene in relation to growth
Several causes of being born SGA are summarized in the Introduction (Table 1, page
13). However, in most cases the cause remains unclear. GH deficiency (GHD) does
not seem to play a major role as in the present study only 12 out of 99 short SGA 
children had GHD. In addition, classical GHD usually does not result in birth weights
below –2 SDS. Since IGF-I seems to play an important role in both pre- and postnatal
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growth we hypothesized that IGF-I could play an important role in these short SGA
children. From studies in knock-out mice we know that the IGF-I gene plays an
important role in both pre-and postnatal growth (38,39).Also in humans IGF-I is an
important factor for normal prenatal and postnatal growth, development and metabo-
lism. Several studies have shown a positive relationship between serum IGF-I levels
and size at birth (40-43). It is highly remarkable that in humans only one case has
been reported describing a homozygous deletion of exon 4 and 5 of the IGF-I gene in
a 15-year old boy (44).This child was severely growth retarded both pre- and post-
natally.We investigated whether the IGF-I gene was involved in the phenotype of
short children born SGA (45). Since homogeneity is an important factor in associa-
tion studies, we decided to include only those children who both had a birth length
and birth weight below –2 SDS for gestational age (SGAL+W).Allele 191 of the
IGF1.PC1 marker, located between exon 2 and 3 of the IGF-I gene, was transmitted
more often from parent to child than one would expect based on Mendelian frequen-
cies. SGA children carrying this allele had significantly lower serum IGF-I levels com-
pared to SGA children not carrying this allele suggesting a ‘causal allele’. Our results
are supported by those of Vaessen et al (46).They investigated a polymorphism in the
promotor region of the IGF-I gene in a population-based study.They found that
absence of the wildtype allele was associated with a reduction in birth weight of 213
gram. In contrast, Johnston et al, at first, did not find an association of the allelic varia-
tion of the IGF-I gene and birth size in a French cohort of adults who were born
SGA and AGA (controls) (47).A possible explanation for their negative results can be
the heterogeneity of this SGA cohort.Although the mean adult height of the SGA
cohort was significantly lower compared to the AGA cohort, no distinction was made
between the SGA adults who had attained normal height and those who remained
short.Also, the definition of SGA differed between the two studies. However, after
changing the definition of SGA into a birth weight and a birth length below –2 SD for
gestational age, they could confirm our results in both this French as well as a
Swedish cohort of short SGA children (48).
Another interesting finding was that children carrying the 191 allele of the
IGF1.PCR marker had significantly smaller head circumference (HC) at the age of 1.3
years compared to children not carrying this allele (45).Thus, genetically determined
low serum IGF-I  levels may lead not only to a reduction in length, weight and head
circumference at birth but also to persistent short stature and small head circum-
ference during childhood and adulthood. IGF-I plays an important role in brain growth
and development (49). Brains of IGF-I knock-out mice are significantly smaller com-
pared to control mice (50). It has been reported that during childhood SGA children
have, in general, a smaller head circumference compared to AGA children, irrespective
of their height (51,52).Also, a smaller HC has been associated with lower intelligence
in SGA children at various ages (51,53).A human homozygous partial deletion of the
IGF-I gene resulted in severe growth retardation, sensorineural deafness and mental
retardation (44). In the first Dutch SGA trial psychological tests were performed.A
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significant reduction in both intelligence and attention were found, which in turn were
significantly associated with a smaller HC (54).We found that SGA children who were
both short and light at birth (SGAL+W) have a higher risk for a smaller HC at the
age of 5.9 years. Unfortunately, our present study did not include intelligence tests
but we hypothesize that SGAL+W children might have an increased risk for lower
school achievements and psychological problems. Possibly, the IGF-I gene is not only
involved in somatic growth but also plays a role in head size and neuropsychological
functioning.
This study shows an association between a polymorphism of the IGF-I gene and low 
serum IGF-I levels in a group of short children born SGA. Genetically determined low 
serum IGF-I levels may lead not only to a reduction in birth length, weight and head 
circumference but also to persistent short stature and small head circumference during
childhood and adulthood (proportionate small).
IGF-I gene in relation to the metabolic syndrome
The IGF-I gene also plays an important role in the pathogenesis of diabetes. Besides
being an important contributor to pre-and postnatal growth, IGF-I has a stimulatory
effect on growth and development of pancreatic beta-cells.A lifetime exposure to
low-normal serum IGF-I levels has been reported as a risk factor for developing 
cardiovascular disease and type 2 diabetes (55-57). Until now there has been descri-
bed only one human partial deletion of the IGF-I gene (58). Besides a very low birth
weight, severe postnatal growth retardation and sensorineural deafness this boy had a
severe insulin resistance (58).Vaessen et al investigated in a population-based study a
polymorphism located in the promotor region of the IGF-I gene (57).They found that
absence of the wildtype allele was significantly associated with lower serum IGF-I
levels and lower body height.Also, they found an increased relative risk for the deve-
lopment of type 2 diabetes and myocardial infarction in non-carriers of the wildtype
allele.We also found an association between a polymorphism of the IGF-I gene, loca-
ted between exon 2 and 3, and low serum IGF-I levels in a specific group of short
children born SGA who remained proportionate small (Chapter 3). Unfortunately we
do not have data on insulin sensitivity in all children participating in the genetic part
of the study.The subgroup of children who underwent an FSIGT was too small to
investigate any influence of the IGF-I polymorphism.
These studies indicate the importance of the IGF-I gene in the development of adult
diseases. Regarding the two hypothesis, our data support the fetal insulin hypothesis.
The IGF-I gene may be one of the links between a low birth weight and the increased
risk for adult diseases. Certainly, the IGF-I is not the only gene involved.The relation
between birth weight and adult disease is probably multifactorial whereby several
genes may play a role. In addition, environmental factors may have an additive effect
especially in those individuals with a certain genetic susceptibility.
We suggest that the IGF-I gene may be one of the links between low birth weight 
and an increased risk of adult disease.
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Pituitary region in short SGA children
This is the first study investigating the pituitary region in short children born SGA.
Disturbances in the growth hormone (GH)-insulin-like growth factor-I (IGF-I)-axis
might play a role in the lack of catch-up growth of these children. Studies in patients
with hypopituitarism, i.e. multiple pituitary hormone deficiency (MPHD) and isolated
GH deficiency (IGHD), revealed abnormalities in the pituitary region using magnetic
resonance imaging (MRI) (59-61).These abnormalities included ectopia of the neuro-
hypophysis (NH), hypoplasia or interruption of the pituitary stalk (PS) and hypoplasia
of the adenohypophysis (AH).We hypothesized that disturbances in the GH/IGF-I
axis, as had been reported in these children, might be related to abnormalities in the
pituitary region.Therefore MRI’s were performed in short SGA children without
IGHD (SGA group), short SGA children with IGHD (SGA+IGHD group), non-SGA
children with IGHD (IGHD group), non-SGA children with multiple pituitary hormone
deficiencies (MPHD group) and in children with normal stature (control group).
However, we found no major abnormalities in the pituitary region of the SGA
group. None of the SGA children had an ectopic NH or a disrupted or an absent PS.
Concordantly, Nagel et al. found no abnormalities in the pituitary gland of 3 children
with short stature after intrauterine growth retardation (IUGR) (62).Also no major
abnormalities were found in the pituitary region of the SGA+IGHD group. Only one
out of the ten showed a hypoplastic AH (10 %).As previously reported by others, 40
% of the non-SGA children with IGHD (IGHD group) showed a hypoplastic AH and
an ectopic NH (38 % and 42 %, respectively) and 4 out of 24 (17 %) showed PS
abnormalities (62,63). In non-SGA children with multiple pituitary hormone deficien-
cies (MPHD group) 87 % showed a hypoplastic AH and an ectopic NH and 67 %
showed PS abnormalities. Children with MPHD showed the lowest maximum GH
peaks and serum IGF-I and IGFBP-3 levels.Thus, children with the most severe form
of GHD showed the most severe pituitary abnormalities.These findings agree with
observations described in previous reports (62-66).
Pituitary height (PH) was measured in all patient groups. Since PH is dependent
on age and sex, values are expressed in SD scores (67). Evaluating all children we
found a significant positive correlation between PH SDS and the severity of GHD
(maximum GH peak, IGF-I and IGFBP-3 levels).This indicates that a child with a low
maximum GH peak, low serum IGF-I and low IGFBP-3 levels has a greater risk of
having a small pituitary gland.These findings agree with the findings of Nagel et al who
investigated 91 children with different causes of short stature (62). PH SDS in the
SGA group was comparable to the PH SDS of the control group. PH SDS in the
SGA+IGHD group, however, was significantly lower compared to the SGA group and
the control group. So, even a moderate decrease in PH (with PH remaining within the
normal range) was associated with significantly lower maximum GH peaks during
provocation tests and to significantly lower serum IGF-I and IGFBP-3 levels.
Therefore, assessment of PH in children with partial IGHD without MRI abnor-
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malities in the pituitary region, may support the diagnosis of GHD. Since our data
indicate that it is unlikely to find pituitary abnormalities in short non-IGHD children
born SGA, we conclude that in these children there is no need to perform MRI’s as
part of a diagnostic process.
We did not find evidence in favour of our hypothesis that disturbances in the
GH/IGF-I axis in short children born SGA, might be related to abnormalities in the
pituitary region.Thus, subnormal GH secretion and subnormal serum IGF-I and
IGFBP-3 levels in short SGA children can not be explained by anatomic abnormalities
in the pituitary region. However, in the SGA+IGHD group PH was significantly lower
compared to the SGA group and controls suggesting that the size of the pituitary
may play a role in the GH secretion in SGA children with IGHD. It is not known
whether a reduced number or a reduced volume of somatotrophic cells may lead to
a smaller pituitary causing a reduction in GH secretion. Schechter et al showed that
the somatotrophic cells of a patient with IGHD were morphologically identical to
normal somatotrophic cells (68).The IGF system may play a role in the development
and functioning of the anterior pituitary gland (69). However, further research is
required to investigate this area.
Several genes are involved in the development of the pituitary gland.
Abnormalities in these genes are related to both morphological and functional abnor-
malities (70).As short SGA do not show abnormalities in the pituitary region it is
unlikely that these genes are involved in the etiology of being born SGA.
Short SGA children either with or without IGHD did not show major anatomic
abnormalities in the hypothalamic-pituitary region.There is no indication to per-
form an MRI as part of a diagnostic process in short children born SGA without 
GHD.
Effects of 3 years of GH treatment: Results of the randomized,
controlled GH trial.
Growth
This is the first study reporting the effects of GH treatment versus no treatment in
short non-GHD children born SGA in a randomized, 3-year study design with an
additional group of GHD children born SGA who were treated parallel to the rando-
mized trial. GH treatment with a dose of 33 µg/kg/day in short SGA children either
with or without GHD resulted in normalisation of their height during childhood.
After two years of GH treatment, the mean H SDS of both the GH- and the GHD-
group had normalised, i.e. above –2.00 (-1.6 (0.7) and -1.6 (0.6) respectively), while
the H SDS of the untreated control group remained –3.0 (0.5) SDS.After 3 years of
GH treatment 21.1 % of the GH-group and 20 % of the GHD-group still had a height
below –2.0 SDS.All children of the untreated control group remained a height below
–2.0 SDS during the 3-years study period. Our results are comparable to those
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reported previously by us and others (71-73). Since GH treatment studies in short
SGA children are longitudinal studies it takes on average ten years before the effects
of GH treatment on adult height can be analysed. Recently, adult height data of the
first Dutch randomized GH-dose-response trial treating short SGA children with 
either a low or a high dose of GH (33 or 66 µg/kg/day) were analysed (74).After a
mean duration of 7.8 years, height SDS in children receiving the low GH dose in-
creased from –2.9 (0.8) at start of the study to an adult height SDS of –1.1(0.8) at
the end of the study. Height SDS in children receiving the high dose increased from
–3.0 (0.8) at start of the study to an adult height of –0.9 (0.8). Neither adult height
SDS nor gain in height during GH treatment differed significantly between the two
dosage groups. GH treatment resulted in a normalisation of height, i.e. an adult height
above –2.0 SDS, in 85 % of all children.Also, 98 % had an adult height within their tar-
get height range. Carel et al showed final height data of a controlled GH trial in short
SGA adolescents (75).They found an increment in adult height of 0.6 SDS in those
receiving GH in a dose of 66 µg/kg/day compared to an untreated control group.
After a mean duration of 2.7 (0.6) years of GH treatment adult height was obtained
in most children. In 50 % of the GH-treated children and in 27 % of the control group
adult height appeared to be in the normal range for the general population, i.e. above
–2 SDS.Two other studies reported adult height data in only small numbers of 
children. In one study 16 children with a mean age of 12.7 years at start of the study,
were treated with a dose of 0.7 IU/kg/day (76). H SDS had increased from –2.0 SDS
at start to –1.0 SDS at the end of treatment.Another study present 12 short children
born SGA with a mean age of 7.6 at start of the study who were treated with a low
dose of GH (77).They found an increment in H SDS from –2.9 SDS at start to –1.5
SDS at the end of treatment.
Based on combined results of randomised long-term GH trials (50 % Dutch data) it
was recently decided by the US and European registration committees that short
children who were born SGA form an indication for GH treatment.
From data of our randomized, controlled GH study, we can conclude that, in contrast 
to no treatment, 3 years of GH treatment results in a normalisation of height during 
childhood.
Bone maturation
Bone maturation is important because it relates to the closure of the epiphyseal
growth plates and therefore has an important impact on adult height.We found that
before GH treatment all children had a 1-year delay in bone age, regardless of their
GH-status. During the 3-year study period, bone maturation accelerated significantly
in the GH-treated groups. In the GHD group this acceleration was most obvious
during the first year of treatment (mean ∆BA/∆CA 1.6 (0.6) yrs/yr) while in the GH
group the maximum acceleration was observed during the second year of treatment
(mean ∆BA/∆CA 1.6 (0.7) yrs/yr).After the first two years of treatment this accele-
ration slowed-down and during the third year no significant difference was found
nic_7 14-10 cor..qxd  15-10-2003  17:04  Pagina 135 - Optima Grafische Communicatie
136
compared with the untreated control group. Bone maturation in untreated short
children born SGA did neither accelerate nor decelerate. So, after the 3-year study
period they still had a bone age delay of one year in contrast to the GH-treated
groups who had a bone age similar to their calendar age. Data describing bone matu-
ration during GH treatment of short SGA children are rather confusing. It has been
reported that bone maturation accelerated spontaneously in untreated short SGA
children (76,78,79). Our data, however, could not confirm these findings.Also, a 
slower bone maturation was found in both untreated and GH-treated SGA children
with a relatively young age at start of the study compared to SGA children with a
relatively old age at start of the study (80). In contrast, during a 3-year follow-up
period, we did not observe any difference in bone maturation between younger (age
3.0 to 5.5 years) and older (age 5.5 to 8 years) SGA children, either untreated or
GH-treated. Our results, however, showed that the acceleration in bone maturation is
associated with a strong catch-up growth during the first 2 years of GH treatment.
Sas et al showed a similar acceleration of bone maturation during the first 2 years of
treatment with either a low or a high dose of GH treatment (71). Despite this accele-
ration of bone age during the first 2 years of GH treatment 89 % of all children 
attained an adult height above –2.0 SDS (74).We did neither find any differences in
bone maturation between SGA children with or without SRS nor between SGA
children with or without GHD.
There is no evidence to assume that the observed acceleration in bone maturation 
during the first 2 years of GH treatment would have a negative effect on final 
height.
Differential effects of GH dose
Although the present study was not designed to study a dose dependent effect of
GH treatment on height, we tried to answer the following question: Should short
SGA children with a H SDS below –3.00 be treated with a higher dose of GH in
order to achieve a more rapid normalisation of their height? To answer this question
we compared the results of the present randomized, controlled GH trial with the
results of our first randomized GH-dose-response trial, in which a part of the short
SGA children who met the same in- and exclusion criteria, received GH treatment at
a higher dose of 66 µg/kg/day (double dose) (71).All SGA children with a H SDS at
start between –2.00 and –3.00, who received either a normal or a double dose of
GH, showed a normalisation of H SDS (i.e. > -2.00) within 2 years of treatment. None
of these children had a H SDS below –2.00 after 2 years of treatment indicating that
all children had normalized their height. In SGA children with severe short stature at
start of the study (≤ –3.00), mean H SDS normalised after 3 years of GH treatment
in children receiving a normal GH dose and after 2 years in children receiving the
double dose.We did, however, not find a significant effect of GH dose on the 3-year
gain in H SDS in children with a H SDS at start ≤ –3.00.After three years of GH 
treatment 31 % of the double dose group and 41 % of the normal dose group still
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had a H SDS below the normal range.This difference was not significant. Since the 
difference in H SDS at start between the two height groups was 1 SD, it is not surpri-
sing that children with a very low baseline H SDS need more time to catch-up in
height into the normal range. Our results, however, show that treatment with a higher
GH dose does not result in a more rapid catch-up growth.Thus, there is no indica-
tion to treat short SGA children with severe short stature (H SDS at start ≤ –3.00)
with a double GH dose. It is however important to achieve a height within the nor-
mal range before a child enters puberty.Therefore we suggest that in children with a
very low H SDS, GH treatment should start at a relatively young age.Thus, if a child
born SGA is still very growth-retarded (H SDS ≤ -3.00) at the age of 3 years without
showing any signs of spontaneous catch-up growth, we suggest to start treatment
with a GH dose of 33 µg/kg/day (normal dose) at that young age.
We did not find an indication to treat very short SGA children (H SDS ≤ -3.00) with 
a higher GH dose.We rather suggest to start GH treatment at an early age in order 
to achieve a normal height before puberty starts.
Insulin-like growth factor–I (IGF-I) and IGF binding protein-3 (IGFBP-3)
Disturbances in the GH/IGF-I axis have been described in short SGA children (81,82).
Also, it has been suggested that these disturbances might play a role in the insufficient
postnatal catch-up growth in these children (81,83).At start of the present study all
children underwent a GH-stimulation test in order to assess GH-deficiency (GHD).
Twelve of a total of 99 children (12 %) were diagnosed as GHD. In short non-GHD
children born SGA baseline serum IGF-I and IGFBP-3 levels, expressed as SDS, were
significantly lower compared to normal age and sex related children. In the 12 short
SGA children with GHD serum IGF-I and IGFBP-3 levels were even more severely
reduced. Remarkably, during GH treatment a similar increase in both IGF-I and
IGFBP-3 levels was found in children with and without GHD.The 3-year increment in
IGF-I and IGFBP-3 SDS correlated well with the 3-year gain in H SDS suggesting that
the good response to GH treatment was mediated through increased serum IGF-I
levels. In a previous Dutch study, five-year results of GH treatment with either a 
normal or a double dose showed an increase in both IGF-I and IGFBP-3 levels during
the first years (71). Levels did not further increase after 3 years of GH treatment.
During the first 3 years of that study children receiving the double dose had signifi-
cantly higher IGF-I levels compared to children receiving the normal dose. However,
after 5 years no differences in IGF-I and IGFBP-3 levels were observed between the 2
dosage groups.The clinical impact of these high serum IGF-I and IGFBP-3 levels is not
known. Based on the initially higher IGF-I levels in children who were treated with
the double dose we prefer to treat children with the normal dose rather than the
double dose. For safety reasons serum IGF-I and IGFBP-3 levels need to be checked
annually until adult height is attained.
Three years of GH treatment results in a significant increase in serum IGF-I and 
IGFBP-3 levels which correlates well with the 3-year gain in H SDS.These data 
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suggest that the good response to GH treatment was mediated through increased 
serum IGF-I levels.
Body composition and bone mineral density (BMD)
This is the first GH-controlled study investigating body composition by Dual Energy
X-ray Absorptiometry (DXA) in a group of short children born SGA before and
during GH treatment. DXA is a precise method to investigate fat mass, lean body
mass (LBM) and bone mineral density (BMD). It uses a low radiation dose, is very
accurate and can easily be performed in children (84,85).
Bone mineral density (BMD)
In short SGA children BMD at start of the study was significantly lower compared to
normal children. However, part of this reduction can be explained by the fact that
these children are all short. DXA measures an areal density (g/cm2) and therefore
BMD is underestimated in short children (86). For that reason we calculated bone
mineral apparent density (BMAD) which is a widely used validated method to correct
for short stature (87).At baseline, mean BMAD SDS was reduced to a lesser degree
than mean BMDTB and mean BMDLS SDS levels. However, mean BMAD SDS still
differed significantly from zero, suggesting bone mineral density in these children is
not only reduced because of their short stature. Other factors, besides height, might
also play an important role. It is well known that muscles form a large part of the
load on bone and therefore have a stimulatory effect on bone mass. Indeed, we found
a severe reduction in LBM at start of the study. So, a part of the reduction in BMD in
short SGA children may be explained by a reduced muscle mass. Other possible cau-
ses may comprise low serum IGF-I levels and a low nutritional intake since most
parents report a poor dietary intake.
During GH treatment BMAD and BMDTB normalised after 1 and 2 years,
respectively, whereas BMDLS normalised after 3 years of GH treatment.These results
are comparable to results observed in GHD children (88,89).The observed incre-
ment in BMD could be either a result of the increase in muscle mass, taller stature or
a more direct effect of GH on bone. Furthermore, a better nutritional intake and
increased physical activity during GH treatment, as was reported by parents, might
also have played a role in the increase of BMD.
Short children born SGA show a significant reduction in BMAD which normalises 
during GH treatment.
Lean body mass (LBM) and fat mass
‘Leanness’ is a very broad term often used in short SGA children indicating they are
very thin. However, until now, this characteristic was mainly based on either a low
BMI or a reduction in skinfold thickness (9). Leger et al investigated body composi-
tion of these children measuring fat and muscle mass on a cross-sectional area of the
thigh by Magnetic Resonance Imaging (MRI) and found a reduction in both fat and
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muscle mass in the thigh (5). However, this method does not measure total body
muscle and total body fat. Measuring body composition using DXA enables us to 
better specify the leanness of these children.
We found that at start of the study both LBM and total body fat were signifi-
cantly lower compared to children of the same age and sex. Surprisingly, we did not
detect any differences in either total body fat or LBM between short SGA children
with or without partial GHD.This confirms the clinical observation that short SGA
children with partial GHD do not show the typical GHD appearance of truncal 
obesity which is a well known feature of children with partial GHD.Apparently, in
short SGA children who are GHD, SGA related leanness dominates their typical
GHD appearance.
Another interesting finding was the fact that at start of the study all short SGA
children either with or without partial GHD, showed a more severe reduction in LBM
than in total body fat. So, leanness in these short SGA children can be specified into a
reduction in muscle mass and to a lesser extent a reduction in total body fat. Since
our results were compared to healthy age- and sex matched children with a normal
height, part of the reduction in LBM and fat mass in these short SGA children can be
explained by their short stature. Other possible causes for the reduction in muscle
mass include low IGF-I levels and poor nutritional intake.
The fetal program hypothesis postulates that during fetal malnutrition glucose
is only available for growth of vital organs, such as the brain and the heart, at the
expense of muscle mass (90).This could also be one of the explanations for the
observed reduction in muscle mass in short SGA children.
GH treatment resulted in an impressive increase of LBM. In contrast, total
body fat reduced only during the first year of GH treatment and remained stable the-
reafter.Thus GH treatment has both a lypolitic effect on fat mass and an anabolic
effect on LBM.These findings are comparable to the reported effects of GH treat-
ment in GHD children and adults (89,91,92).
In short children born SGA, leanness is the result of a reduction in LBM and to a 
lesser extent of a reduction in total body fat. GH treatment results in a significant 
increase of LBM and a slight reduction of fat mass.
Skinfold thickness and body mass index (BMI)
Both BMI and skinfold thickness are generally used tools for estimating body compo-
sition.The lean appearance of short SGA children has previously been supported by
calculating BMI and by measuring skinfold thickness (9,93). Skinfold measurements
assess subcutaneous fat only, in contrast to BMI, which estimates total body fat and
LBM together. In our study, we compared these methods to results obtained by DXA,
which is considered as the ‘gold standard’ for these measures.At start of the study
skinfolds correlated strongly with total body fat measured by DXA whereas BMI 
correlated both with total body fat and LBM. During GH treatment changes in skin-
folds did correlate with changes in total body fat measured by DXA but changes in
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BMI neither correlated with changes in LBM nor with changes in total body fat.This
implicates that measuring skinfold thickness before and during GH treatment gives a
reliable estimate of total body fat in short SGA children. Furthermore, measuring 
skinfolds is cheap and easy to perform. Conversely, BMI can not distinguish between
total body fat and LBM. For that reason BMI is not an accurate estimate of body
composition, at least in short SGA children. In contrast to skinfold thickness, BMI is
also not a useful tool to study changes in body composition during GH treatment.
Our study indicates that the sum of 4 skinfolds is a better tool than BMI for 
estimating total body fat in short SGA children both before and during GH 
treatment.
Body proportions
Although short children born SGA clinically appear to have normal body proportions,
objective data are limited. Sas et al reported in a group of short SGA children normal
body proportions which remained normal during GH treatment with either a dose of
1 or 2 mg/m2 body surface area/day (94). However, that study did not comprise an
untreated control group.The present study showed that short SGA children have a
reduced size of their sitting height (SH), armspan, tibial-, foot- and hand size, which is
in proportion to their reduced height. In the GH-treated children sitting height, arm-
span, tibial, foot and hand SDS increased in concordance with their increase in height
SDS indicating that body proportions remained normal during 3 years of GH treat-
ment. Conversely, height and other anthropometric measurements remained un-
changed in the untreated control group.Therefore, we were now able to demonstrate
that the observed changes in various body parts of GH-treated children are the
result of GH treatment.These results agree with our previous findings in a com-
parable group of short SGA children (94).
Untreated short SGA children have generally normal body proportions.Three years 
of GH treatment results in a proportionate growth of height, sitting height, armspan,
tibial, foot and hand.
Head circumference
Head circumference (HC) of the total group of short SGA children was less affected
compared to other parts of the body.While height and all other anthropometric
measurements showed a mean value which was significantly less than –2.0 SDS, the
mean HC SDS was the only parameter showing a value above –2.0 SDS. Possibly a
brain sparing effect during fetal life might have played a role. Only 18 % of all SGA
children had a HC SDS below the normal range, i.e. below –2.0 SDS. Interestingly,
most of the short SGA children (14 out of 16) had been proportionately small at
birth (SGAL+W).Although the magnitude of spontaneous catch-up growth in HC
after birth had been greater in SGAL+W children compared to SGAL children, HC
SDS was still significantly lower in SGAL+W children at a mean age of 5.9 years.This
finding strongly suggests that short SGA children who have been proportionately
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small at birth have a greater risk for a relatively small HC during childhood. During
GH treatment HC SDS increased similarly in both SGAL+W and SGAL children.
Since at start of the study HC SDS was significantly smaller in SGAL+W children,
these children still had a smaller HC after 3 years of GH treatment.
In individuals born SGA a smaller HC has been associated with a lower intelli-
gence (51,53). Lundgren et al found an important association between both birth
length and persistent short stature and subnormal intellectual performances (53).
During the first Dutch randomized GH-dose-response trial psychological functioning
was investigated by a psychologist. Results showed a significant reduction in intelli-
gence and attention and an increase in behavioural and emotional problems com-
pared to healthy peers (54). Both intelligence and attention were significantly 
associated with HC during childhood. Since short SGAL+W children have smaller
head circumferences than SGAL children at a mean age of 5.9 years, we hypothesize
that SGAL+W children have a higher risk for lower school achievements and psycho-
logical problems. Unfortunately, our present study did not include intelligence tests.
Compared to their height, head circumference is less severely affected and the refore 
relatively large in most short SGA children.Those who had been born SGAL+W, still 
had a smaller HC at the age of 5.9 years compared to those who had been born 
SGAL and therefore they may have an increased risk for lower school achievements 
and psychological problems. GH treatment induced a similar increase in HC for 
SGAL+W and SGAL children.
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Conclusions
Our study shows that risk factors for the development of type 2 diabetes mellitus
and cardiovascular disease do already exist during childhood in short and lean pre-
pubertal children born SGA. Since low IGF-I levels are associated with type 2 diabetes
and cardiovascular risk factors, we hypothesize that the IGF-I gene may be one of the
genes involved in both a low birth length and weight and these diseases in later life.
Our data also show that genetically determined low IGF-I levels may lead to a reduc-
tion in birth weight, length and head circumference and to persistent short stature
and small head circumference in later life (proportionate small). No major abnormali-
ties were found in the pituitary region of short children born SGA indicating that
there is no need to perform MRI as part of a diagnostic process.Three years of GH
treatment results in a normalisation of height during childhood and an increase in
bone maturation proportionately to the gain in height.There is no indication to treat
very short SGA children (H SDS ≤ -3.00) with a higher GH dose. It is however
important to start GH treatment at an early age in order to achieve a normal height
before puberty starts. Leanness in short SGA children proves to be the result of a
significant reduction in LBM and to a lesser extent of a reduction in total body fat. In
addition, BMAD is reduced in these children. Both LBM and BMAD normalized during
GH treatment. Our study shows that the sum of 4 skinfolds is a better tool than BMI
for estimating total body fat in short SGA children both before as well as during GH
treatment. Short SGA children are proportionately short. Interestingly HC is relatively
large in many of these children. However, at the age of 5.9 years children born
SGAL+W still had a smaller HC compared to children born SGAL.As a smaller HC is
associated with an increased risk for lower intellectual performance and psychological
problems, children born SGAL+W may be at risk for lower school achievements.
Three years of GH treatment induced a proportionate growth resulting in a normali-
zation of height and other anthropometric measurements, including HC, in contrast
to untreated SGA controls.
Hypothesis
The results of this thesis may be summarized in Figure 1.Although I am aware of the
fact that not all effects can be attributed to the IGF-I gene, most probable other
genes may have similar effects, the following hypothesis may arise. Genetically deter-
mined low IGF-I levels may play a central role in the etiology and consequences of
short children born with both a small birth weight and birth length (SGAL+W). Low
IGF-I levels in these short SGA children may be responsible for being born SGA in
the first place. Subsequently these low IGF-I levels may be responsible for the lack of
catch-up growth, their typical appearance (leanness, small head circumference), their
increased risk for adult diseases (type 2 diabetes mellitus, hypertension, cardiovascular
disease) and their good response to GH treatment.
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Future research and recommendations
Future research
Epidemiological studies demonstrated that spontaneous postnatal catch-up growth in
weight and height during childhood has been associated with an increased for develo-
ping risk type 2 diabetes in adult life (36). Our results show a reduction in insulin sen-
sitivity in short children born SGA. It might be relevant, however, to investigate risk
factors for type 2 diabetes during childhood in a group of  prepubertal SGA children
who did show catch-up growth during the first years of life. In the first Dutch study
an oral glucose tolerance test (OGTT) was used to investigate glucose metabolism.
The disadvantage of an OGTT is that glucose needs to be absorbed in the gastroin-
testinal tract.Therefore the exact amount of intravascular glucose is not known.
During an FSIGT test glucose is administered intravenously, which makes the test very
accurate for research of insulin metabolism. Body composition seems to play an
important role in the development of type 2 diabetes mellitus. However, in short SGA
children BMI is not a valuable estimate of body composition neither before nor
during GH treatment (95). In order to investigate the relation between body compo-
sition (i.e. body fat and muscle mass) and glucose and insulin metabolism we recom-
mend to perform FSIGT tests and DXA’s (at the same day).
Our results showed that serum lipids in short prepubertal SGA children were in the
normal range. However, we did find an elevation of mean serum FFA levels in the
high-normal range with 21 % of the children having serum FFA levels above the nor-
mal range.These findings have not been previously described. In order to confirm
these findings it is necessary to measure fasting FFA levels in larger cohort of short
Figure 1.
Consequences of genetically determined low IGF-I levels in short children born SGAL+W
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SGA children. Moreover, it might be very interesting to evaluate these findings in SGA
children with spontaneous catch-up growth after birth.As both acylation stimulating
protein (ASP) and hormone sensitive lipase (HSL) play a role in  FFA metabolism 
further research is needed to investigate their role in SGA children.
Also, hypertension has been associated with being born SGA and catch-up growth in
height and weight during childhood (37).Therefore, it would also be interesting to
investigate blood pressure and serum lipids in a large cohort of short SGA children
and investigate these parameters in relation to FSIGT tests to see whether clustering
occurs. In order to evaluate the presence of clustering in a cohort of SGA children
with spontaneous catch-up growth the results of the FSIGT tests in combination with
the DXA results should be analysed together with the results of blood pressure and
serum lipids.
Our results suggest the existence of a functional variant of the IGF-I gene located
between the promoter region and exon 3 which results in significantly lower serum
IGF-I levels.We do not know whether this polymorphism itself is involved in regu-
lating serum IGF-I levels or that this polymorphism influences other polymorphisms
regulating IGF-I production. In order to unravel the role of this IGF-I polymorphism
sequencing of the coding regions of the IGF-I gene is needed. Since IGF-I is not the
only gene involved in fetal and postnatal growth it is important to further investigate
other genes. Possible candidate genes may include the insulin and the IGF-II gene and
their receptor genes.
Recommendations during GH treatment
Long-term continuous GH treatment in short SGA children results in a normalization
of height and proportionate growth of other body parts. GH treatment seems a safe
treatment since no adverse events occurred during either the present or the rando-
mised dose-response trial. However, long-term follow-up is required to reassure that
GH treatment during childhood does not induce adverse events in adulthood.
We evaluated the influence of the severity of growth retardation at start and the GH
dose on the gain in height. Our results showed that treatment with a double GH
dose did not result in a more rapid catch-up growth. Since it is important to achieve
a height within the normal range before a child enters puberty, we suggest to start
GH treatment with a normal dose at a relatively young age (e.g. 3 years of age).
Obviously, other causes for short stature (e.g.Turner syndrome, coeliac disease)
should be excluded before starting GH treatment.
Since short stature after being born SGA increases the risk of overweight in adult life
it is interesting to further evaluate how GH treatment interferes with this weight
gain. GH treatment also results in an increase in weight. However, this increase in
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weight is not due to an increase in body fat but due to an increase in muscle mass. It
is not yet known if body composition further changes after discontinuation of GH
treatment and if the risk on overweight is changed after GH treatment.Therefore
long term follow-up of these children/adults is necessary.Also, it is important to 
educate these children about the risks of obesity and measures to prevent obesity.
GH induces relative insulin resistance with an increase in fasting insulin levels.
Although a recent report showed that these changes were reversible after discontinu-
ation of GH treatment, it is important to regularly evaluate glucose metabolism
during and after discontinuation of GH treatment (96).This can be performed by
measuring serum HbA1c levels and fasting glucose and insulin levels. If these values
are abnormal an FSIGT test can be performed. It is however not necessary to per-
form FSIGT tests on a regular base in all short SGA children receiving GH treatment.
Blood pressure and serum lipids need to be monitored during and after GH treat-
ment. Since epidemiological studies show an increased risk of systolic blood pressure
which do not further increase in those SGA children showing postnatal catch-up
growth it is relevant to evaluate the effect of GH treatment during and after disconti-
nuation of GH treatment.Although it has been reported that serum lipids, i.e. total
cholesterol, LDL cholesterol, HDL cholesterol and triglycerides remained within the
normal range during 5 years of GH treatment it still is important to monitor these
lipids during and after discontinuation of GH treatment (9).Also, it might be interes-
ting to investigate FFA levels during GH treatment.
Lower intellectual performance and problems with psychological functioning have
been described in those born SGA. Both were associated with a smaller HC. GH 
treatment appears to improve the growth of the head.The effect of GH treatment on
intellect and beviour has only been evaluated in one study.Although a beneficial effect
on the long term was reported, these findings need confirmation. Unfortunately, no
psychologist was involved in the present study to evaluate these parameters in com-
parison to an untreated control group. It is however important to study in the
coming years the psychological effects before, during and after GH treatment.
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Summary
The present thesis describes several aspects of short children who were born small
for gestational age (SGA). In the first part (Chapter 2, 3 and 4) we studied possible
consequences of being born SGA (i.e. insulin sensitivity, serum lipids and blood 
pressure) as well as etiological factors that might have played a role in the develop-
ment of SGA (i.e. genetical causes and anatomical abnormalities in the pituitary
region). In the second part of the thesis (Chapter 5, 6 and 7) results are presented of
the second Dutch randomised, controlled GH trial.This study investigates the effects
of GH treatment versus no treatment on growth, bone maturation, bone mineral
density (BMD), body composition, i.e. fat mass, lean body mass (LBM), BMI and 
skinfold thickness, and body proportions.
Chapter 1
An overview is given of the literature regarding the definition of SGA, the prevalence
and etiology of SGA, Silver-Russell syndrome, growth factors playing a role in fetal
growth, postnatal effects during childhood and late consequences of being born SGA.
Also, an overview of the literature until 1997 (the start of the present study) is given
of the most important trials investigating the effects of GH treatment on linear
growth in short children born SGA.At the end of this chapter the aims of the 
present study and the study design of the second Dutch GH trial are described.
Chapter 2
Epidemiological studies have shown that the metabolic syndrome, a combination of
type 2 diabetes mellitus, hypertension, dyslipidemia and a high body mass index (BMI),
occurs more frequently among adults who were born with a low birth weight. Since
insulin is thought to play a key role in the pathogenesis of this syndrome we investiga-
ted insulin sensitivity and possible risk factors for cardiovascular disease in a group of
short prepubertal children born small for gestational age (SGA).
Frequently sampled intravenous glucose tolerance tests (FSIGT) were perfor-
med in order to investigate insulin sensitivity (Si) in 28 short prepubertal children
born SGA.Twelve short children born appropriate for gestational age (AGA) were
used as controls for the FSIGT’s results. In short SGA children, blood pressure (BP)
and fasting levels of serum free fatty acids (FFA), triglycerides (TG), total cholesterol
(TC), high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL)
cholesterol were measured. In order to study the interrelationship between insulin
insensitivity (1/Si), BMI, blood pressure and serum lipids a cluster analysis was perfor-
med in short SGA children.
Insulin sensitivity (Si) in short SGA children was significantly reduced to 38 %
of the mean Si level measured in short AGA controls.As a result the mean acute
insulin response (AIR) was significantly higher in SGA children compared to short
AGA controls. Differences in Si and AIR between the 2 groups remained significant
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after adjusting for age and BMI.The mean systolic BP SDS was 1.3 (1.1), being signifi-
cantly higher than zero. Mean fasting serum levels of FFA,TC,TG, HDL and LDL were
all within the normal range. However, 6 of the 28 SGA children (21 %) had serum FFA
levels above the normal range.Two important clusters emerged from cluster analysis.
The first cluster clearly showed that insulin insensitivity (1/Si) was related to higher
systolic and diastolic blood pressure and higher serum FFA levels.A second cluster
showed a relation between BMI, total cholesterol, LDL-cholesterol and triglycerides.
In conclusion, although the metabolic syndrome has been described as an adult
disease, our study showed that risk factors for the development of type 2 diabetes
mellitus and cardiovascular disease are already present during childhood in short pre-
pubertal children born SGA, suggesting a pre-type 2 diabetes mellitus phenotype.
Chapter 3
Low birth weight is associated with an increased risk in adult life of type 2 diabetes,
hypertension and cardiovascular disease.The fetal insulin hypothesis postulates that
genes involving insulin resistance could effect birth weight and disease in later life.
Besides insulin, there is extensive evidence that insulin-like growth factor-I (IGF-I)
plays an important role in fetal growth.We hypothesized that minor genetic variations
in the IGF-I gene could influence pre- and postnatal growth.
Three microsatellite markers located in the IGF-I gene in 124 short children
(height <-1.88 SDS) who were born small for gestational age (SGA) and their parents
were studied. SGA was defined as both a birth weight and birth length below –1.88
SDS for gestational age.
Two polymorphic markers showed transmission disequilibrium.Allele 191 of
the IGF1.PCR1 marker was transmitted more frequently from parent to child and
allele 198 of the 737/738 marker was transmitted less frequently from parent to
child. Children carrying the 191-allele had significantly lower IGF-I levels than children
not carrying this allele (-1.1 SDS vs. –0.50 SDS; p=0.03).Also, head circumference SDS
remained smaller in children with allele 191 compared to children without allele 191
(-2.1 SDS vs. –0.9 SDS; p=0.003).
Our results show that genetically determined low IGF-I levels may lead to a
reduction in birth weight, length and head circumference and to persistent short sta-
ture and small head circumference in later life. Since low IGF-I levels are associated
with type 2 diabetes and cardiovascular disease, we propose that the IGF-I gene may
also provide a link between low birth weight and such diseases in later life.
Chapter 4
Disturbances in the GH / IGF-I axis are reported in 25 – 60 % of short children born
small for gestational age (SGA). Pituitary abnormalities, i.e. ectopia of the neurohypo-
physis (NH), hypoplasia or interruption of the pituitary stalk (PS) and hypoplasia of
the adenohypophysis (AH) have been described in patients with either isolated GH
deficiency (IGHD) or multiple pituitary hormone deficiencies (MPHD).We hypo-
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thesized that in short SGA children abnormalities in the IGF-I / GH axis might be
related to abnormalities in the pituitary region. MRI was performed in four groups of
short children: SGA children without GH deficiency (SGA group; n=17), SGA children
with isolated GH deficiency (SGA + IGHD group; n=10), non-SGA children with iso-
lated GH deficiency (IGHD group; n=24) and non-SGA children with multiple pituita-
ry hormone deficiencies (MPHD group; n=15). MRI was also performed in children
with normal stature (control group; n=13). Pituitary height (PH) and thickness of the
pituitary stalk (PS) were measured and the relationship with the maximum GH peak
during a GH stimulation test, serum IGF-I and IGFBP-3 levels was evaluated.
Short SGA children either with or without IGHD did not show major anato-
mic abnormalities in the hypothalamic-pituitary region in contrast to 58 % of the non-
SGA IGHD children and 87 % of the MPHD children who had anatomic abnormali-
ties. PH in SGA children without GHD was normal whereas it was significantly lower
in SGA children with IGHD.The lowest PHs were measured in non-SGA children
with MPHD. Evaluating all children we found a significant positive correlation between
pituitary height SDS (PH SDS) and the severity of GHD (maximum GH peak, IGF-I
and IGFBP-3 levels). Even a moderate decrease in PH was associated with significantly
lower maximum serum GH peaks and lower serum IGF-I and IGFBP-3 levels.
We concluded that PH measurements in children with less severe GHD, who
underwent MRI as part of the diagnostic process, might support the diagnosis of
GHD even in the absence of anatomical abnormalities. Our study demonstrates that
there is no indication to perform MRI of the pituitary region in short children born
SGA without GHD.
Chapter 5
The effects of 3 years of GH treatment versus no treatment on height, bone matura-
tion and bone mineral density (BMD) in a large cohort of short children born SGA
were presented.Also, the influence of the severity of growth retardation at start and
the GH dose on the gain in height was evaluated.
The study design was an open-labelled, controlled multicenter GH study for 3
years. Non-growth hormone deficient (GHD) children (n=87) were randomized to
either a GH-group (n=61) or an untreated control group (n=26). In addition, 12 SGA
children had GHD (GHD-group) and were treated in parallel. Both the GH- and the
GHD-group were treated with a GH dose of 33 µg/kg/day (normal dose). Height,
bone age (BA) and bone mineral density (BMD) were evaluated. BMD was investiga-
ted using Dual Energy X-ray Absorptiometry (DXA). Since height is an important
determinator of BMD, bone mineral apparent density (BMAD) was calculated in order
to adjust for short stature. Data of our first GH trial in which short SGA children
were treated with a GH dose of 66 µg/kg/day (double dose) were used to study the
effect of a double GH dose versus a normal dose on the gain in height.
Both the GH-group and the parallel treated GHD-group showed a significant
increase in height, in contrast to the untreated control group (p<0.001). Bone matu-
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ration (∆ bone age (BA)/∆ calendar age(CA)) increased significantly during the first
two years of GH treatment but slowed-down thereafter.The 3-year ∆BA/∆CA ratio
correlated significantly with the gain in height (r=0.6, p<0.001).At baseline, mean
BMD SDS and BMAD SDS were significantly lower than zero. Both BMD and BMAD
SDS increased significantly during GH treatment (p<0.001).An analysis was perfor-
med investigating the effect of GH dose (33 µg/kg/day versus 66 µg/kg/day) on height
gain in children with either a H SDS at start between –2.00 and –3.00 or a H SDS at
start ≤ -3.00.The gain in height of children with severe short stature at start (≤ -3.00
SDS), did not differ between those receiving either a normal or double dose.
In conclusion, 3 years of GH treatment in short children born SGA results in a
normalisation of height during childhood. During GH treatment, bone maturation
increased proportionately to the gain in height. BMAD in short SGA children is signi-
ficantly reduced compared to normal children but normalises during GH treatment.
Since the height gain of children with severe short stature at start of the study 
(≤-3.00 SDS) does not differ between those receiving 33 µg GH /kg/day versus those
receiving 66 µg GH /kg/day, we conclude that there is no indication to treat very
short SGA children with the higher GH dose.We want to emphasize, however, that
severely growth-retarded SGA children should start GH treatment at a young age to
enable sufficient catch-up growth before onset of puberty.
Chapter 6
Short children born SGA have a lean appearance.Therefore, body composition was
investigated before and during GH treatment by Dual Energy X-ray Absorptiometry
(DXA) measuring fat mass, lean body mass (LBM) and bone mineral density (BMD).
Results were compared to estimates of body composition, i.e. measurement of skin-
fold thickness and calculation of BMI.
All children participated in a 3-year randomized, controlled GH treatment
study. Non-GHD SGA children (n=87) were randomized to receive GH (GH-group,
n=61) or remain untreated (control group, n=26).Twelve SGA children with GH-
deficiency served as a comparison cohort (GHD-group, n=12).All GH treated child-
ren were treated with 33 µg GH/kg/day. In a subgroup BMD, LBM and fat mass were
measured using DXA.The sum of 4 skinfolds (skinfolds), BMI, and serum IGF-I levels
were measured in all children.
At start of the study, SGA children showed a significant reduction of LBM, fat
mass and BMD measured by DXA.Also, skinfolds and BMI were significantly reduced.
Skinfolds correlated strongly with fat mass measured by DXA, whereas BMI correla-
ted with both fat mass and LBM. During 3 years of GH treatment, both LBM and
BMD increased significantly in contrast to the control group. Fat mass decreased sig-
nificantly during the first year of GH treatment followed by an increase to levels com-
parable to baseline. Changes in fat mass correlated with changes in skinfolds whereas
changes in BMI did neither correlate with changes in fat mass nor LBM.
Thus, leanness in short children born SGA can now be specified as a reduction
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in LBM and to a lesser extent in a reduction of total body fat. Our study also indica-
tes that, in contrast to BMI, measuring skinfold thickness gives a reliable estimate of
total body fat in short SGA children both before and during GH treatment.
Chapter 7
Short SGA children appear to have normal body proportions, however, objective data
before and during GH treatment were very sparse.The effects of GH treatment ver-
sus no treatment on height, weight, head circumference (HC), sitting height, armspan
and hand, tibial and foot size were evaluated. Furthermore, differences in linear
growth and head circumference between SGA children born with a low birth length
and birth weight (SGAL+W) and SGA children born with a low birth length only
(SGAL) were investigated.
The study was an open-labelled, GH-controlled, multicenter study for 3 years.
Non-growth hormone deficient short SGA children (n=87) were randomised to 
either a GH-group (n=61), receiving GH in a dose of 33 µg/kg/day, or an untreated
control group (n=26). Height, weight, HC, sitting height, armspan and hand, tibial and
foot size were measured 3-monthly before and during GH treatment.
At onset of the study all anthropometric measurements, except HC SDS, were
significantly lower compared to –2 SDS. During GH treatment all anthropometric
measurements normalized in accordance to the normalisation of height SDS.At start
of the study, mean HC SDS was significantly lower in SGAL+W children compared to
SGAL children. Interestingly, most children (14 out of 16) with a HC SDS below –2.00
had been born SGAL+W. During GH treatment, the 3-year increase in height, HC
and other anthropometric measurements was comparable between SGAL+W and
SGAL children. In untreated SGAL+W and SGAL children, however, no changes in
SD-scores of height, HC and other anthropometric measurements were found during
the 3-year follow-up period.
Thus, short SGA children have normal body proportions with the exception of
HC which is relatively large in many of these children. SGAL+W children still had a
smaller HC at the start of GH treatment (mean age of 5.9 years) compared to SGAL
children.Three years of GH treatment induced a proportionate growth resulting in a
normalization of height and other anthropometric measurements, including HC, in
contrast to untreated SGA controls.
Chapter 8
In the general discussion our findings are discussed in relation to the current 
literature.Also suggestions for future research are given.
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Samenvatting
Dit proefschrift beschrijft verschillende aspecten van kinderen met een te kleine leng-
te die bij de geboorte reeds te klein waren voor de zwangerschapsduur (small for
gestational age, SGA). In Deel 1 (Hoofdstuk 2, 3 en 4) worden mogelijke late gevolgen
beschreven van SGA zoals veranderingen in insuline gevoeligheid, serum lipiden en
bloeddruk.Tevens worden etiologische aspecten beschreven die een rol zouden kun-
nen spelen bij het ontstaan van SGA zoals genetische oorzaken en anatomische afwij-
kingen in het hypofyse gebied. In Deel 2 van dit proefschrift (Hoofdstuk 5, 6 en 7)
worden de resultaten beschreven van de tweede Nederlandse gerandomiseerde,
gecontroleerde groeihormoon (GH) studie. Deze studie onderzocht de effecten van
GH behandeling versus geen behandeling op groei, botrijping, botdichtheid, lichaams-
samenstelling (vetmassa, spiermassa) en lichaamsverhoudingen.
Hoofdstuk 1
Hier wordt een overzicht gegeven van de literatuur betreffende de definitie van SGA,
de prevalentie en etiologie van SGA, Silver-Russell syndroom (SRS), groeifactoren die
een rol spelen bij de foetale groei, postnatale effecten van SGA op de kinderleeftijd
en late gevolgen van SGA op de volwassen leeftijd.Tevens wordt een literatuur over-
zicht tot 1997 (start van de huidige studie) gegeven van de meest belangrijke GH stu-
dies bij SGA kinderen met een te kleine lengte.Tenslotte worden de doelen van de
huidige studie en de opzet van de gerandomiseerde, gecontroleerde GH trial
beschreven.
Hoofdstuk 2
Epidemiologische studies laten zien dat type 2 diabetes mellitus (DM), hypertensie en
cardiovasculaire ziekten vaker optreden bij personen die geboren zijn met een laag
geboortegewicht. De combinatie van type 2 DM, hypertensie, dyslipidemie en een
hoge body mass index (BMI) wordt ook wel “metabolic syndrome” genoemd en is
eveneens geassocieerd met een laag geboortegewicht. De onderliggende mechanis-
men zijn echter niet goed bekend maar aangenomen wordt dat insuline resistentie en
hyperinsulinisme een belangrijke rol spelen in de pathogenese van zowel diabetes als
cardiovasculaire ziekten. Om te bestuderen of deze afwijkingen reeds op de kinder-
leeftijd aanwezig zijn, werden insuline gevoeligheid en risicofactoren voor cardio
vasculaire ziekten onderzocht bij een groep prepubertaire SGA kinderen met een te
kleine lengte.
Bij 28 te kleine SGA kinderen werd een Frequently Sampled Intravenous
Glucose Tolerance test (FSIGT test) verricht om de insuline gevoeligheid (Si) te 
bepalen. De resultaten werden vergeleken met de resultaten van FSIGT tests bij 12 te
kleine kinderen die geboren waren met een normaal geboortegewicht. Bloeddruk en
serum lipiden (free fatty acids (FFA), triglycerides (TG), totaal cholesterol (TC), high-
density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol)
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werden gemeten bij de SGA kinderen en vergeleken met normaal waarden. Om de
relatie te bestuderen tussen insuline ongevoeligheid, BMI, bloeddruk en serum lipiden
werd een cluster analyse verricht.
Insuline gevoeligheid (SI) was significant lager in de SGA groep vergeleken met
de controle groep (p=0.004). Gemiddelde Si waardes in SGA kinderen bedroeg 38 %
van de gemiddelde Si waardes gemeten in de controle groep. Een verminderde 
insuline gevoeligheid kan worden gecompenseerd door een verhoogde uitscheiding
van insuline, gemeten als de acute insuline respons (AIR). Zoals verwacht was de AIR
bij de SGA kinderen significant hoger dan bij de kinderen uit de controle groep 
(p< 0.001). Deze verschillen bleven significant na correctie voor leeftijd en body mass
index (BMI). Bloeddruk en serum lipiden werden vergeleken met referentie waarden
die gelden voor ‘normale’ kinderen. De gemiddelde systolische bloeddruk was signi-
ficant hoger dan de gemiddelde bloeddruk voor kinderen met dezelfde lengte, leeftijd
en geslacht. Nuchtere gemiddelde FFA,TC,TG, HDL en LDL waardes lagen allen 
binnen het normale gebied. Echter, 6 van de 21 kinderen (21%) hadden verhoogde
nuchtere FFA waardes die buiten het normale gebied lagen. Cluster analyse werd 
verricht om het onderlinge verband tussen insuline ongevoeligheid, bloeddruk, BMI en
serum lipiden te bestuderen. Uit deze analyse kwamen 2 belangrijke ‘clusters ’ naar
voren. De eerste cluster laat zien dat insuline ongevoeligheid gerelateerd was aan een
hogere diastolische en systolische bloeddruk en hogere nuchtere FFA’s. De tweede
cluster omvatte een relatie tussen TC, LDL,TG and BMI.
Concluderend, kinderen met een te kleine lengte die bij de geboorte reeds te
klein waren, hebben op de kinderleeftijd al een verminderde insuline gevoeligheid die
asymptomatisch aanwezig is.Tevens hebben ze reeds een verhoogde systolische
bloeddruk en heeft 21 % verhoogde FFA spiegels. Dus, alhoewel het “metabolic 
syndrome” een volwassen ziekte is, laat deze studie zien dat risico factoren voor het
ontwikkelen van type 2 diabetes mellitus en cardiovasculaire ziekten reeds aanwezig
zijn op de kinderleeftijd in deze (nu nog) tengere en te kleine SGA kinderen.
Hoofdstuk 3
Een laag geboortegewicht is geassocieerd met een verhoogd risico op het ontstaan
van type 2 diabetes mellitus, hypertensie en cardiovasculaire ziekten tijdens de 
volwassen leeftijd. De “fetal insulin hypothesis” veronderstelt dat erfelijke factoren
(genen) die betrokken bij het ontstaan van insuline resistentie, mogelijk een effect
kunnen hebben op zowel het geboortegewicht als op volwassen ziekten. Behalve 
insuline, is er overtuigend bewijs dat insulin-like growth factor-I (IGF-I) een belangrijke
rol speelt bij foetale groei.Wij veronderstelden dat geringe genetische variatie in het
IGF-I gen van invloed zou kunnen zijn op zowel pre- als postnatale groei.
Drie microsateliet markers gelokaliseerd op het IGF-I gen werden onderzocht
in een groep van 124 te kleine SGA kinderen en hun ouders. SGA werd gedefinieerd
als zowel een geboortelengte als een geboortegewicht kleiner dan –2.00 SDS voor de
zwangerschapsduur. De resultaten werden geanalyseerd middels een Transmission 
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disequilibrium test (TDT test). De test onderzoekt het transmissie disequilibrium
oftewel de overerving van een allel.Twee markers lieten “”transmission dise-
quilibrium” zien.Allel 191 van de IGF1.PCR1 marker werd vaker doorgegeven van
ouder naar kind en allel 198 van de 737/738 marker werd minder vaak doorgegeven
van ouder naar kind. Kinderen die drager zijn van het 191-allel hadden significant 
lagere serum IGF-I waarden dan kinderen die dit allel niet hadden (-1.1 SDS vs. –0.50
SDS; p=0.03).Tevens bleken dragers van het 191-allel op de leeftijd van 1,5 jaar een
kleinere hoofdomtrek te hebben in vergelijking met niet-dragers van dit allel (-2.1
SDS vs. –0.9 SDS; p=0.003).
Deze resultaten laten zien dat genetische bepaalde lage IGF-I spiegels kunnen
niet alleen leiden tot een lager geboortegewicht, een kleinere geboortelengte en een
kleinere hoofdomtrek bij de geboorte maar ook tot een persisterende kleine lengte
en kleine hoofdomtrek op latere leeftijd.Aangezien lage serum IGF-I spiegels geasso-
cieerd zijn met type 2 diabetes mellitus en cardiovasculaire ziekten veronderstellen
wij dat het IGF-I gen mogelijk een link kan zijn tussen een laag geboortegewicht en
ziekten op de volwassen leeftijd.
Hoofdstuk 4
Afwijkingen in de groeihormoon (GH) / insulin-like growth factor-I (IGF-I) as zijn
beschreven in 25 – 60 % van de kinderen met een te kleine lengte die bij de geboorte
reeds te klein waren. Hypofysaire afwijkingen zoals een ectopische neurohypofyse
(NH), hypoplasie of een onderbroken hypofysesteel en hypoplasie van de adenohypo-
fyse (AH) zijn beschreven bij patiënten met zowel een geïsoleerde GH-deficiëntie
(IGHD) als met multipele hypofysaire hormoon deficiënties (MPHD).Wij onder-
zochten of de afwijkingen in de GH/IGF-I as bij te kleine SGA kinderen gerelateerd 
zouden kunnen zijn aan eventuele afwijkingen in het hypofyse gebied.
MRI scans werden verricht bij 4 groepen kinderen met een te kleine lengte:
SGA kinderen zonder IGHD (SGA groep; n=17), SGA kinderen met een IGHD (SGA
+ IGHD groep; n=10), niet-SGA kinderen met IGHD (IGHD groep; n=24) en niet-
SGA kinderen met multipele hypofysaire hormoon deficiënties (MPHD groep; n=15).
MRI scans werden eveneens verricht bij kinderen met een normale lengte (controle
groep; n=13). Hypofyse lengte (PH) en dikte van de hypofysesteel (PS) werden 
gemeten en de relatie met de GH piek tijdens een GH stimulatie test, serum IGF-I 
en IGFBP-3 spiegels werden bestudeerd.
Te kleine SGA kinderen met of zonder IGHD lieten geen belangrijke anato-
mische afwijkingen zien in het hypothalamus-hypofyse gebied in tegenstelling tot 58 %
van de kinderen uit de niet-SGA IGHD groep en 87 % van de kinderen uit de niet-
SGA MPHD groep die wel anatomische afwijkingen lieten zien. De hypofyse lengte
van SGA kinderen zonder IGHD was normaal maar bij SGA kinderen met IGHD was
deze significant kleiner. De kleinste hypofyse lengte werd gemeten bij niet-SGA 
kinderen met MPHD.Wanneer de hypofyse lengtes van alle kinderen werden geanaly-
seerd, werd een significant positieve correlatie gevonden tussen de hypofyse lengte en
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de ernst van de GHD (maximum GH piek, IGF-I en IGFBP-3 waarden). Zelfs een
geringe afname van de hypofyse lengte was geassocieerd met significant lagere GH
piek en lagere serum IGF-I en IGFBP-3 waarden.
Wij concludeerden dat het meten van de hypofyse lengte bij kinderen met een
minder ernstige GHD, de diagnose GHD kan steunen zelfs bij de afwezigheid van 
anatomische afwijkingen. Bij SGA kinderen met een te kleine lengte zonder GHD is
er geen indicatie om een MRI van de hypofyse te verrichten als onderdeel van een
diagnostisch proces.
Hoofdstuk 5
Hier worden de effecten beschreven van 3 jaar GH behandeling versus geen behande-
ling op lengtegroei, botrijping en botdichtheid (bone mineral density = BMD) bij een
grote groep SGA kinderen met een te kleine lengte.Tevens werd de invloed van
zowel de ernst van de groeiretardatie bij start van de studie, als de GH dosis op de
toename in lengte tijdens de behandeling bestudeerd.
De studie opzet van deze multicenter studie was een open-labelled, gecontro-
leerde GH studie voor een periode van 3 jaar.Voor de start van de studie werd een
GH-stimulatie test verricht om een eventuele GH-deficiëntie (GHD) te diagnos-
tiseren  Niet-GHD kinderen (n=87) werden gerandomiseerd tot een GH-groep
(n=61) of een controle groep (n=26). De GH-groep startte direct met GH behande-
ling terwijl de controlegroep de eerste 3 jaar van het onderzoek onbehandeld bleef.
Kinderen die GHD bleken te zijn werden niet gerandomiseerd maar startten direct
met GH-behandeling (GHD-groep; n=12). Zowel de GH- als de GHD groep werden
behandeld met een GH dosis van 33 µg/kg/dag (normale dosis). Lengte, botleeftijd en
botdichtheid (BMD) werden gemeten. BMD werd bepaald met behulp van de Dual
Energy X-ray Absorptiometry (DXA). Omdat BMD mede bepaald wordt door de
lengte werd de zogenaamde bone mineral apparent density (BMAD) berekend om zo
te corrigeren voor een te kleine lichaamslengte. Data van de eerste Nederlandse GH
trial, waarbij te kleine SGA kinderen werden behandeld met een GH dosis van 66
µg/kg/dag (dubbele dosis), werden gebruikt om het effect te bestuderen van een 
normale versus een dubbele dosis op de toename in lengte.
Zowel de GH- als de GHD-groep lieten een significante toename zien in 
lengte, in tegenstelling tot de onbehandelde controle groep.Tijdens de eerste 2 jaar
met GH behandeling nam de botrijping (∆ botleeftijd (BA)/∆ kalender leeftijd(CA))
significant toe Tijdens het derde jaar vertraagde de botrijping. De 3-jaars ∆BA/∆CA
ratio correleerde positief met de lengte toename. Bij start van de studie waren BMD
en BMAD bij de SGA kinderen significant lager in vergelijking met normale kinderen.
Beide lieten tijdens GH behandeling een duidelijke toename zien.Tenslotte werd het
effect van GH dosis (33 µg/kg/dag versus 66 µg/kg/dag) op de lengte toename be-
studeerd bij kinderen die bij start van de studie of een lengte SDS hadden tussen
–2.00 en –3.00 of een lengte hadden ≤ -3.00.De lengte toename van kinderen met
een lengte SDS ≤ -3.00 verschilde niet tussen kinderen die behandeld werden met
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een normale of een dubbele dosis.
Concluderend, 3 jaar behandeling met GH resulteert bij SGA kinderen met een
te kleine lengte in een normalisatie van de lengte tijdens de kinderjaren.Tijdens GH
behandeling nam de botrijping toe overeenkomstig met de toename in lengte. BMAD
was aanvankelijk verlaagd in vergelijking met normale kinderen maar normaliseerde
tijdens GH behandeling.Aangezien er geen effect van een dubbele dosis GH waar-
neembaar was op de lengte toename van kinderen met een ernstige groeiretardatie
(lengte SDS ≤ -3.00) concluderen wij dat er geen indicatie is om SGA kinderen met
een ernstige groei retardatie te behandelen met een dubbele dosis GH.We willen
echter wel benadrukken dat het van belang is om deze ernstig groei-geretardeerde
SGA kinderen reeds op jonge leeftijd te behandelen om zo voldoende inhaalgroei te
bewerkstelligen alvorens de puberteit begint.
Hoofdstuk 6
SGA kinderen met een te kleine lengte zien er in het algemeen zeer tenger uit. Om
de lichaamsamenstelling van deze kinderen te bestuderen voor en tijdens GH behan-
deling werden vetmassa, vetvrije massa (lean body mass = LBM) en botdichtheid
(BMD) bepaald middels Dual Energy X-ray Absorptiometry (DXA). De resultaten
werden vergeleken met frekwent  gebruikte afgeleiden van de lichaamsamenstelling:
het meten van de huidplooidikte en het berekenen van de body mass index (BMI).
Alle kinderen namen deel aan de 3-jaars open-labelled, gerandomiseerde,
gecontroleerde GH trial. Niet-GHD kinderen (n=87) werden gerandomiseerd tot of
de GH-groep (n=61) of de onbehandelde controle groep (n=26).Twaalf SGA kinderen
met GHD dienden als een vergelijkend cohort (GHD-groep, n=12). Kinderen uit GH-
en GHD-groep werden beide behandeld met een dosis van 33 µg GH/kg/dag. Bij een
subgroep van de kinderen werden DXA’s verricht om vetmassa, LBM en BMD te
bepalen. Huidplooidiktes en BMI werden gemeten bij alle kinderen.
Bij start van de studie hadden te kleine SGA kinderen een verminderde vetmassa,
LBM en BMD.Tevens waren de huiplooidiktes en BMI lager in vergelijking met nor-
male kinderen. Huidplooidikte was goed gecorreleerd met vetmassa gemeten met
behulp van DXA, terwijl BMI correleerde met zowel vetmassa als LBM.Tijdens 3 jaar
GH behandeling nam zowel LBM als BMD significant toe in tegenstelling tot de con-
trole groep.Vetmassa nam tijdens het eerste jaar af om vervolgens weer toe te
nemen tot waardes vergelijkbaar met waardes bij start.Veranderingen in vetmassa
correleerden goed met veranderingen in huidplooidiktes. Echter veranderingen in BMI
correleerden noch met veranderingen in vetmassa noch met veranderingen in LBM.
Dus, het begrip ‘tenger’ bij kleine SGA kinderen kan nu gespecificeerd worden als een
reductie in LBM en in mindere mate een reductie in de totale vetmassa. Deze studie
laat eveneens zien dat het meten van huidplooi diktes, in tegenstelling tot het be-
rekenen van BMI, een betrouwbare schatting geeft van de totale vetmassa bij kleine
SGA kinderen zowel voor als tijdens GH behandeling.
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Hoofdstuk 7
Te kleine SGA kinderen lijken normaal geproportioneerd. Echter objectieve data
betreffende lichaamsproporties voor en tijdens GH behandeling zijn zeer spaarzaam.
Daarom werden de effecten van GH behandeling versus geen behandeling op lengte,
gewicht, hoofdomtrek (HC), zithoogte, spanwijdte en hand, voet en tibia lengte
bepaald.Tevens werden verschillen in lengte groei en toename van HC bestudeerd
tussen SGA kinderen geboren met zowel een te kleine geboortelengte als een te laag
geboortegewicht (SGAL+W) en SGA kinderen met alleen een te kleine geboorte-
lengte (SGAL).
De studie betreft een open-labelled, gecontroleerde GH trial gedurende 3 jaar.
Niet-GHD SGA kinderen (n=87) werden gerandomiseerd tot een GH-groep (n=61)
of een onbehandelde controle groep (n=26). De GH-groep werd behandeld met een
GH dosis van 33 µg/kg/dag. Lengte, gewicht, hoofdomtrek (HC), zithoogte, spanwijdte
en hand, voet en tibia lengte werden voor en tijdens GH behandeling bepaald.
Bij start van de studie waren alle antropometrische metingen, behalve de HC SDS,
significant lager dan –2 SDS.Tijdens GH behandeling normaliseerde alle metingen
overeenkomstig het normaliseren van de lengte. Bij start van de studie bleken
SGAL+W een significant kleinere HC SDS te hebben in vergelijking met SGAL
kinderen. Opmerkelijk, de meeste kinderen (14 van de 16) met een HC SDS kleiner
dan –2.00 SDS, waren geboren met zowel een te kleine lengte als een te laag gewicht
(SGAL+W).Tijdens GH behandeling was er geen verschil in toename van lengte, HC
en de overige antropometrische metingen tussen de SGAL+W kinderen en de SGAL
kinderen. Kinderen uit de onbehandelde controle groep lieten geen toename zien 
van lengte, HC en overige antropometrische metingen tijdens de 3-jarige follow-up
periode.
Kortom, SGA kinderen met een te kleine lengte zijn normaal geproportioneerd
met uitzondering van de hoofdomtrek, welke relatief groot is bij de meeste kinderen.
SGAL+W kinderen hadden bij start van de studie (op een gemiddelde leeftijd van 5.9
jaar) nog steeds een kleinere hoofdomtrek in vergelijking met SGAL kinderen. Drie
jaar GH behandeling induceert een geproportioneerde groei resulterend in een 
normalisatie van lengte en andere antropometrische metingen, inclusief hoofdomtrek,
in tegenstelling tot onbehandelde kleine SGA kinderen.
Hoofdstuk 8
In de algemene discussie worden de bevindingen besproken tegen de achtergrond 
van de huidige kennis en literatuur.Tevens worden suggesties gedaan voor eventueel
toekomstig onderzoek.
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Eindelijk, het is af!
Ik blik met een goed gevoel terug op een paar (!) jaartjes onderzoek. Het waren leer-
zame, uitdagende, vernieuwende, interessante, leuke en vooral ook gezellige jaren.
Deze “mega-klus” was uiteraard niet gelukt zonder de hulp en steun van collega’s,
vrienden en familie. Iedereen heel hartelijk bedankt. Een paar mensen wil ik in het 
bijzonder noemen:
Allereerst bedank ik alle kinderen en ouders voor hun deelname aan deze studie.
Jullie vormden tenslotte de basis van dit proefschrift. Mede door jullie kan ik op mijn
onderzoeksperiode terugkijken als een leerzame maar vooral ook een hele leuke tijd!
Dank jullie wel!
Mijn co-promotor, dr.A.C.S. Hokken-Koelega, beste Anita, jouw enthousiasme en
gedrevenheid vind ik nog steeds heel bijzonder. Het werkt zeer motiverend! Ik heb
veel van je geleerd en ik kijk dan ook terug op een hele plezierige samenwerking!
Ook wil ik je heel hartelijk bedanken voor de kans die je me hebt gegeven om in
Londen onderzoek te doen. Het is zeer de moeite waard geweest!
Mijn promotor, Prof.dr. S.L.S. Drop, beste Sten, hartelijk dank dat ik onderzoek heb
mogen doen bij de subafdeling Endocrinologie. Ook wil ik je bedanken voor je snelle
en kritische blik bij het beoordelen van de manuscripten, de introductie en de 
discussie. O ja, de musicals, opera’s en musea in Londen waren best aardig!!
Prof.dr. M.O. Savage, dear Martin, thank you very much for the opportunity you gave
me to work in your section Pediatric Endocrinology. I felt it was a great honour to
work in your team.Thank you very much for reading this thesis and for participating
in the Committee.
Prof.dr.A.J. Clark, dear Adrian, it has been a great pleasure working in your laborato-
ry! I learned a lot and had a wonderful time! Thank you very much for participating in
the Committee.
Prof.dr. C.M. van Duijn, beste Cock, hartelijk bedankt voor je hulp bij de analyses van
het genetisch onderzoek en voor het beoordelen van dit proefschrift.
Prof.dr. S.W.J. Lamberts, beste professor Lamberts, hartelijk dank voor uw snelle
beoordeling van het proefschrift.
Prof.dr. G.J. Bruining, beste Mu, hartelijk bedankt voor de prettige samenwerking, je
enthousiaste ideeën en natuurlijk voor het plaatsnemen in de grote commissie.
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Alle kinderarts-endocrinologen die hebben meegewerkt aan de studie: Prof.dr. H.
Delemarre-Van de Waal, Dr. E.C.A.M. Houdijk, Dr. M. Jansen, Drs. J.C. Mulder, Dr.
R.J.H. Odink, Dr. H.M. Reeser, Dr. C. Rongen-Westerlaken, Dr.W.H. Stokvis-Brantsma
en Dr. J.J.J.Waelkens.Allemaal hartelijk bedankt voor de prettige samenwerking, de
behulpzaamheid en de gastvrijheid op de polikliniek van jullie ziekenhuis.
Het Ter Meulen Fonds wil ik bedanken voor hun financiële bijdrage die het mogelijk
maakte om genetisch onderzoek in het St. Bartholomew’s Hospital in Londen te gaan
doen.
Novo Nordisk Farma BV Nederland wil ik hartelijk bedanken voor hun de financiële
bijdrage aan zowel de IUGR-2 studie als aan dit proefschrift.
Novo Nordisk A/S Denmark, thank you for your financial support of this thesis.
Voor alle statische hulp gaat mijn dank uit naar Prof.dr.Th. Stijnen, Dr. P. Mulder, Drs.
M de Ridder en Dr. Hugo Duivenvoorden. Statistiek blijft een vak apart!
Dr.W.S. Cutfield and Dr. P.L Hofman, thank you very much for your mail and phone
assistance in the performance and analysis of the FSIGT tests.
Dr. S.G.F. Robben, beste Simon, hartelijk dank voor het aanwijzen van de hypofyses.
Jeanette Vergeer,Wilma Luijten en Ruud Oskamp, hartelijk bedankt voor het isoleren
van het DNA.
De studenten, inmiddels collega’s (!),Wendy van der Lip en Onno Akkermans wil ik
hartelijk bedanken voor hun hulp en vooral ook voor de gezelligheid!
Van de afdeling Endocinologie wil ik allereerst Venje Boonstra bedanken.Venje, dankje-
wel voor de snelle overname van de studie destijds. Onze samenwerking was super-
leuk, ik hoop dat we deze gauw in de kliniek kunnen voortzetten! Je weet, ik wil je
graag helpen bij jouw dankwoord!
Esther Lems, Essie, dankjewel voor al je hulp bij het opzetten en voorbereiden van de
poli’s. Ik wist dat ik altijd op je kon rekenen. Je bent een heerlijk mens! Ik hoop dat
we nog veel kunnen lachen!
Ingrid van Slobbe, Slobbie, steun en toeverlaat in den beginne! In dienst voor bijna alle
“endo studies” behalve voor de IUGR-2 studie. Ondanks dit heb je me heel veel
geholpen. Dankzij jou precisie en ervaring dankt de IUGR-2 studie zijn structuur en
ordelijkheid. Je bent een held!
Natuurlijk ook Janneke, Marianne, Inge,Yvonne, Dick,Theo, Marije, Ellen, Robert, Floor,
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Marieke,Annabelle, Dederieke,Wietske, Danielle en natuurlijk Dini hartelijk bedankt
voor alle hulp, koffie en gezelligheid.
Alle (ex)onderzoekers in het SKZ bedank ik voor de gezellige tijd binnen en buiten
het SKZ, de borrels, de etentjes, de weekenden en, niet onbelangrijk, de nuttige tips.
I had a lovely time working at the Department of Molecular Endocrinology of St.
Bartholomew’s Hospital in London.
Dr. Linda Johnston, dear Linda, thank you so much for teaching me the “art of lab
work”. It was really nice working with you.
Thanks a lot for a wonderful time Lorraine, Peter, Luke, Frankie,Asma, Patricia, Jo K.,
Patsy, Edwin, Fiona and Jo B. My special thanks go to Louise Metherell, dear Lou
thanks a lot for all your help in the lab. I’m sure the “genemachine” wouldn’t have sur-
vived without you!
Evelien Gevers. Beste Evelien, ik vond toch dat ik je hier even persoonlijk moest
bedanken voor onze wetenschappelijke en minder wetenschappelijke discussies in the
pubs van Londen. Het was erg gezellig!
Krista Kolkman. Lieve Kris, onze vriendschap is iets heel speciaals, hij dateert al uit
1969! Ik vind het heel bijzonder dat je me in deze laatste fase van “m’n levenswerk”
bijstaat. Dankjewel voor al je creatieve ideeën en de nauwkeurigheid waarmee je dit
proefschrift hebt vormgegeven. Het is supermooi geworden.
Zowel mijn ouders, schoonouders als Maria Waterreus wil ik hartelijk bedanken voor
hun goede zorgen. Dankzij hen wist ik dat Stijn en Job in goede handen waren waar-
door ik me volledig kon concentreren op het laatste stukje van m’n proefschrift. Dank
jullie wel!
Mijn paranimfen, Martine Verhoeven en Hestien Vreugdenhil. Lieve Tinus en Hestien,
jullie zijn geweldig! Ik ben blij dat jullie naast me staan!
Lieve pap en mam, dank jullie wel voor alles! Jullie onvoorwaardelijke steun, interesse
en liefde geven me nog steeds een intens gelukkig gevoel!
Lieve Vinnie, ik hou van je!
Kom Stijn, kom Job, kom gauw, dan gaan we bruggen bouwen!
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medical student she worked as a nurse in Sophia Children’s Hospital in Rotterdam.At
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List of Abbreviations
BA = bone age
BMAD = Bone mineral apparent density
BMC = Bone mineral content
BMD = Bone mineral density
BMDLS = Bone mineral density of the lumbar spine
BMDTB = Bone mineral density of the total body
BMI = Body mass index
CA = Calendar age
GH = Growth hormone
GHD = GH-deficiency
H = height
HC = Head circumference
IGF-I = Insulin-like growth factor-I
IGFBP-3 = IGF-binding protein-3
LBM = Lean body mass
SDS = Standard deviation score
SGA = Small for gestational age
SGAL+W = SGA children born with a low birth length and birth weight
SGAL = SGA children born with a low birth length only
SH = Sitting height
TH = Target height
WH = Weight for height
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